A Microfluidic Approach to Investigate Changes in Functional Properties of Nociceptive Axons Underlying Inflammatory Pain States by Rangwani, Natasha
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








A Microfluidic Approach to Investigate Changes in Functional Properties of








A Microfluidic Approach to Investigate Changes in 
Functional Properties of Nociceptive Axons 
















Wolfson Centre for Age-Related Diseases 
The Institute of Psychiatry, Psychology, and Neuroscience  
















I declare that the research presented in this thesis is my own work, unless otherwise 
stated in the text.  
 

































The lack of analgesics available for the management of chronic pain is attributed to 
our limited understanding of the molecular mechanisms responsible for this 
debilitating condition. Our current understanding of pain mechanisms is primarily 
based on extrapolation from observations of the dorsal root ganglia (DRG) cell body. 
However, our knowledge of the functional properties of nociceptive nerve terminals 
and axons, where the pain response is initiated, is still lacking.  
 
To address this gap in our understanding, I established an in vitro microfluidic 
(MFC)-based model to investigate functional properties of nociceptive axons in 
isolation from the cell soma. This platform made it possible to model peripheral 
sensitisation in response to a combination of inflammatory mediators (IM) including 
prostaglandin E2 (PGE2), bradykinin, histamine and serotonin. Two types of 
functional sensitisation were identified in isolated IM-treated nociceptive axons using 
this model: 1. enhanced magnitude of axonal responses, and 2. increased number of 
responders were observed in response to chemical stimuli, compared to vehicle-
treated groups. We propose this MFC-based in vitro platform as a novel model to 
study peripheral inflammatory sensitisation, delivering an improved capacity to 
understand the major axonal molecular players of inflammatory pain conditions.  
 
PGE2 is a widely-known pain mediator, and the most abundantly produced 
eicosanoid lipid in inflamed tissue. Despite the pivotal role of PGE2 in the genesis of 
neuropathic and inflammatory pain, the underlying molecular mechanisms are yet 
unclear. The developed MFC-based model was exploited to decipher axonal 
mechanisms responsible for changes in nociceptor function induced by PGE2. PGE2 
directly depolarised the axonal membrane resulting in persistent neuronal activity, 
observed even after removal of the PGE2 stimulus. This points towards the basis of 
clinical ongoing pain patients experience, which persists despite resolution of 
inflammation. Using pharmacological strategies, we identify Nav1.8 channels and the 
cAMP/PKA signalling pathway as important mediators of PGE2-induced persistent 
neuronal activity.  
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To further investigate key players underlying nociceptor sensitisation, we 
hypothesized that axonal HCN2 channels are required for nociceptor sensitisation 
and activation in response to inflammatory mediators. The role of axonal HCN2 was 
explored using both pharmacological tools as well as HCN2 knockout mice. 
However, based on the data presented in this study, it remains inconclusive whether 
axonal HCN2 channels play an important role in inflammation-induced nociceptor 
sensitisation and PGE2-induced persistent axonal activity.  
 
Next, I sought to extend the use of the MFC-based assay to human-induced 
pluripotent stem cells (hIPSC)-derived nociceptive neurons with the aim of 
developing a more clinically relevant in vitro model of peripheral sensitisation. We 
established optimal conditions to culture these cells in MFC devices and 
characterised the different populations of neurons present at 4 weeks in vitro. We 
also reveal preliminary data suggesting the presence of TRPV1-independent 
mechanisms underlying peripheral sensitisation as well as GDNF-dependent 
capsaicin sensitivity in hIPSC-derived sensory neurons.  
 
This study describes the use of MFC platform as a novel and robust tool to study 
axonal mechanisms of pain in both primary rodent and human stem cell-derived 
neurons. Moreover, the work presented expands our knowledge of axonal molecular 
mechanisms contributing towards peripheral sensitisation and particularly, persistent 
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1. GENERAL INTRODUCTION 
 
Inflammatory pain remains to be a significant clinical challenge, with a large number 
of patients receiving inadequate pain relief. Despite significant advances in our 
understanding of mechanisms underlying the pathophysiology of inflammatory pain, 
most findings from preclinical research have failed to translate into successful 
therapies in the clinical setting. Known molecular mechanisms underlying pain 
sensation are based primarily on traditional in vitro preparations which are restricted 
to one component of nociceptors: the cell body. However, our knowledge of the 
pharmacology of peripheral fine nerve terminals, where the nociceptor is exposed to 
the inflammatory insult, is yet primitive. Recent evidence points towards distinct 
mechanisms taking place in the subcellular compartments of nociceptors, underlying 
painful conditions. Thus, the role of axonal molecular mechanisms contributing to 
changes in sensory neuron function during inflammatory pain states will be the main 
focus of this thesis.  
 
This introduction provides an overview of what pain is, the different types of pain and 
its pathophysiology, including both central and peripheral mechanisms. More 
specifically, the available literature on mechanisms associated with known key 
players involved in inflammatory pain mechanisms including inflammatory mediators 
(IM), second messenger pathways and ion channels will be discussed. Finally, this 
chapter will evaluate the translatability of current in vivo and in vitro models, and will 
describe the DRG axon as a better model to study molecular mechanisms of 





1.1. Introduction to Pain  
Pain is defined as “an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage” by the 
International Association for the study of Pain (IASP).  
 
According to Global Burden of Disease (GBD) study 2013, published in the Lancet, a 
number of both acute and chronic pain conditions are major contributors to the 
overall global burden of disease. This study reported that within the category of 
acute conditions, tooth pain was the 5th most common condition contributing to GBD 
and within the category of chronic conditions, six of the most common conditions 
contributing to GBD included migraines, lower back pain, chronic neck pain, pain-
related to musculoskeletal conditions, osteoarthritis and urolithiasis (Rice et al., 
2016). According to a recent meta-analysis, chronic pain conditions affect between 
one-third and one-half of the population in the United Kingdom and this is likely to 
increase over the next decade due to the ageing population (Fayaz et al., 2016). 
These findings highlight the importance of pain conditions in their contribution 
towards the overall global burden of disease and calls upon the recognition of pain 
as a clinical entity as opposed to a symptom of other conditions.  
 
Opioids and non-steroidal anti-inflammatory drugs (NSAIDs) remain as the first-line 
classes of analgesics, since the discovery of morphine and the synthesis of aspirin in 
the 1800s. Opioids are the most potent analgesics that are routinely used for cases 
of acute severe pain, as well as chronic pain in terminal diseases. However, these 
drugs are associated with a number of life-threatening side effects including 
tolerance, addiction and respiratory depression, owing to which the use of opioids for 
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the management of pain has become highly controversial. A meta-analysis of 67 
reports suggested that opioid analgesic therapy in chronic pain patients is associated 
with addiction and illicit substance abuse (Fishbain et al., 2008). Similarly, while 
NSAIDs are effective in a wide range of patients, the use of these drugs is 
associated with serious gastrointestinal side effects. A population study reported that 
NSAIDs cause 3500 hospitalisations for and 400 deaths from ulcer bleeding per year 
in the UK, in patients aged over 60 (Langman, 2001). NSAIDs act via inhibition of 
cyclooxygenase (COX) enzymes, which are responsible for the production of 
inflammatory prostaglandins. Two distinct isoforms of the COX enzyme (COX-1 and 
COX-2) were discovered in the 1990’s (Tazawa et al., 1994). Initially, it was thought 
that the undesirable effects of NSAIDs were associated with inhibition of COX-1, 
which is constitutively present and responsible for homeostatic functions of 
prostaglandins, whereas the therapeutic effect of NSAIDs was owed to COX-2 
inhibition, considered to be induced only during inflammatory conditions. Based on 
this, COX-2 selective inhibitors were developed with the aim of reducing the number 
of side-effects associated with NSAIDs. Although drug companies were successful in 
developing selective COX-2 inhibitors (i.e. rofecoxib, celecoxib) which showed an 
improved gastric safety profile, their long-term use has been associated with 
increased risk of heart attack and stroke (Bresalier et al., 2005). Due to this, 
rofecoxib was withdrawn from the market in 2004 and the cardiovascular risk of 
COX-2 selective inhibitors is currently being reassessed (Varga et al., 2017). It is 
now thought that COX-2 is not strictly inducible and may be involved in physiological 
functions of the body, as it has been found to be expressed constitutively in the 
brain, kidney and reproductive tract (Ferreri et al., 1999; Kniss, 1999; Yamagata et 
al., 1993). Despite decades of research, drug development companies have failed to 
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design pain-killers with the broad range of analgesic efficacy or potency of opioids 
and NSAIDs, without their associated adverse effects.  
 
1.2. Types of Pain 
Pain can be classified into different categories based on its duration and 
pathophysiology. Acute pain is characterized by a sudden onset, with a duration of 
hours to days. In this case, the cause of pain is known (i.e. illness, trauma or 
surgery) and sensation of pain disappears when the underlying cause is treated. By 
contrast, chronic pain is thought to initiate in the same manner as acute pain, but its 
duration is much longer, as the pain persists despite the resolution of the underlying 
cause.  
 
Chronic pain is generally divided into two main categories; inflammatory pain and 
neuropathic pain. Inflammatory pain is associated with tissue damage, which results 
in an ongoing inflammatory response. Neuropathic pain is defined as pain caused by 




Figure 1. Key characteristics of chronic inflammatory and neuropathic pain. 
Common aspect of peripheral sensitisation and hyperexcitability in both major types 
of chronic pain is highlighted.  
 
However, it is important to note that there is significant overlap between these two 
categories. Sensory fibres can be damaged or sensitised as a result of long-term 
inflammation and neuronal damage can result in an ongoing inflammatory reaction 
such as in chronic inflammatory demyelinating neuropathy. Moreover, despite their 
distinct etiologies, both types of pain have a common feature: sensitisation of 
peripheral afferent neurons (Figure 1). The sensitisation of peripheral nociceptive 
neurons involves hyperresponsiveness, reduced activation thresholds and 
spontaneous activity which contribute towards common pain symptoms such as 




1.2.1. Neuropathic pain 
Neuropathic pain is defined as pain arising as a direct consequence of a nerve lesion 
or a disease affecting the somatosensory system. This definition covers a variety of 
painful neuropathic disorders ranging from diabetic neuropathy to lower back pain 
(Treede et al., 2008). Neuropathic pain affects 1 in 5 adults world-wide and the long-
term pain (> 6 months) results in a low quality of life, high morbidity and significant 
costs in healthcare (Andrew et al., 2014). 
 
Both peripheral lesions such as mechanical trauma, metabolic disease or infections 
and nerve damage of the central processes (i.e. spinal cord injury, stroke or multiple 
sclerosis) can lead to chronic neuropathic pain, but its pathophysiology is not well 
understood. However, both peripheral and central nervous systems are thought to be 
involved and this complicates its clinical diagnosis, and as a consequence leads to 
difficulties in choosing appropriate treatment for patients.  
 
Neuropathic pain induced-changes can vary between patients depending on the type 
and extent of the injury. Removal of debris, recruitment of anti-apoptotic survival 
factors, induction of axonal growth and collateral sprouting, synaptic remodelling and 
remyelination are some of the changes that are potentially adaptive and are aimed at 
the rebuilding and growth of the peripheral nerves as well as restoring normal axonal 
target contacts (Cafferty et al., 2008). However, there are a number of alterations 
that may occur in the nervous system after a neural insult which are clearly 
maladaptive and contribute to the development of neuropathic pain. These include 
both central and peripheral changes in the activation threshold of different ion 
channels, spontaneous action potential firing, reduced GABAergic signalling, 
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inadequate connectivity and neuronal loss which contribute to the hyperexcitable 
state of the nervous system (Woolf, 2011). There is evidence of a phenotypic switch 
of large diameter Aβ fibres. Under physiological conditions, these neurons respond 
to low-threshold input and generate innocuous sensation. However, following a 
neural insult, they undergo alterations and produce pain (Witting et al., 2001). For 
instance, a study showed that after an intraplantar injection with an inflammatory 
stimulus, Aβ fibres adopt the capacity to express substance P and enhance dorsal 
horn excitability resulting in an exaggerated response to innocuous stimuli 
(Neumann et al., 1996). Ectopic impulse generation is also an important aspect of 
neuropathic pain, as several patients report experiencing spontaneous pain or 
ongoing pain in absence of a stimulus (Campero et al., 1998). A significant amount 
of evidence points towards the fact that spontaneous activity originates in the 
periphery, from neuromas and cell bodies of injured DRG neurons (Amir et al., 2005; 
Wu et al., 2002). 
1.2.2. Inflammatory pain 
Pain is a common symptom underlying several chronic inflammatory conditions 
including different forms of arthritis, inflammatory bowel diseases and periodontitis to 
name a few. Arthritis alone affects approximately 10 million people in the UK, with a 
cost of 161million on community prescriptions for arthritis conditions in England in 
2015 (According to Arthritis Research UK). These chronic inflammatory diseases are 
extremely debilitating as they deteriorate quality of life significantly and are 
associated with high costs of therapy and care as well as high mortality (Straub and 
Schradin, 2016). Pain is a characterizing symptom of arthritic conditions, as it is 
considered the primary reason patients seek rheumatic care. Moreover, pain 
syndromes such as fibromyalgia are strongly associated with rheumatoid arthritis 
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patients, which complicates disease management significantly (Coury et al., 2009). 
Traditional treatments such as disease modifying anti-rheumatic drugs (DMARD), 
focus on reducing inflammation though there has been a greater emphasis on 
treating the pain itself (Lee, 2013).  
 
 
The cardinal signs of inflammation include rubor (redness), tumor (swelling), dolor 
(pain) and calor (heat) which occur due to vasodilation, oedema and altered neural 
signals (Donaldson, 2014). The inflammatory response is an extremely complex 
phenomenon, involving the simultaneous interplay of a number of different cell types 
including immune, epithelial and neuronal cells. Following tissue or nerve damage, a 
wide variety of mediators are released by damaged tissue, recruited immune cells as 
well as surrounding sensory fibres. These include prostaglandins, bradykinin, 
Substance P, histamine, adenosine triphosphate (ATP) and serotonin, amongst 
others (Dray, 1995). Ongoing inflammation presents a huge challenge for both 
researchers and clinicians as it is a primary cause of chronic painful conditions, 
organ dysfunction, and death. Mechanisms of inflammatory pain will be discussed in 
further detail in sections 1.4 and 1.5.  
 
1.3. Pathophysiology of Pain 
Pain is a protective response of our body, which is crucial for avoiding tissue 
damage, as it alarms the body of potentially damaging stimuli by triggering 
avoidance behaviours. Specialised sensory neurons or nociceptors are the cellular 
components of the painful response. Nociceptors have a number of receptors, 
including ion channels and GPCPRs, that are responsible for transducing 
mechanical, thermal or chemical stimuli leading to depolarized membrane potential 
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(Basbaum et al., 2009; Gold and Gebhart, 2010). An intense enough change in 
membrane potential can result in the generation of electrical signals defined as 
action potentials which are transmitted to central relay stations of the pain pathway 
(Figure 2).  
1.3.1.  Different Components of Nociceptors  
Nociceptors are pseudo-unipolar primary afferent neurons, where a single axon 
protrudes from the cell body of the dorsal root or trigeminal neuron and is split into 
one peripheral branch, sending the axon to innervate the skin and one axon to 
synapse on second order neurons of the dorsal horn of spinal cord. The subcellular 
components of sensory neurons include the nerve terminal, the axon, and the cell 
body which will be described further below in the context of nociception. 
1.3.1.1.  The Nerve Terminal  
 
The peripheral terminals are responsible for the detection and transduction of 
external stimuli into electrical messages or pain signals (i.e. action potentials). These 
peripheral terminals or nerve endings express a variety of ionotropic and 
metabotropic receptors that are finely tuned to respond to specific thermal, 
mechanical or chemical stimuli. Moreover, the differential expression and distribution 
of ion channels defines specific pain modalities (i.e. type of sensation such as heat, 
cold or mechanical stimuli), conferring the rich functional heterogeneity observed 
between subpopulations of sensory neurons (Dubin and Patapoutian, 2010). For 
instance, noxious heat, activates nociceptors which express the transient receptor 
potential (TRP) vanilloid 1 (TRPV1), also known as the receptor for capsaicin, the 
active ingredient of chilli peppers (Caterina et al., 1997). Conversely, noxious cold, 
activates nociceptors expressing TRPM8, also known for its sensitivity to menthol 
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(Bautista et al., 2007). Sensors of mechanical stimuli are less well defined and 
characterized. However, studies have suggested potential candidates including 
some TRPV2 and TRPV4, acid-sensitive ion channels (ASIC1, 2, and 3), potassium 
channels as well as Piezo channels (Delmas et al., 2011; Patapoutian et al., 2009a). 
Finally, chemical stimuli can act on metabotropic receptors such as GPCRs located 
at the nerve endings, and modulate ion channels indirectly through the activation of 
signal transduction mechanisms. Indirect modulation of ion channels also results in 
altered nociceptor excitability.  
1.3.1.2.  The Axon  
 
Supra-threshold stimuli results in activation of nociceptors, resulting in depolarization 
and subsequent generation of action potentials (AP). Axons are responsible for the 
conduction or transmission of these AP to the cell body. Voltage-gated ion channels 
along the axonal membrane are activated by the change in membrane potential and 
play crucial role in nociception: channels selective for sodium and potassium ions 
are critical for the generation of action potentials, whereas calcium channels serve in 
the release of neurotransmitters from central or peripheral terminals as depicted in 
Figure 2 (Basbaum et al., 2009).  
1.3.1.3. The cell body  
 
The cell body, or the nucleus containing component of the neuron, responds to the 
arriving action potentials through transcriptional and post-translational modifications, 
which ultimately modulate gene expression of important molecular players of 
nociception resulting in altered function, localization or structure of a given protein 
(Woolf and Costigan, 1999). For instance, studies have shown that an injection of 
carrageenan, commonly used to induce an inflammatory response in animal models, 
 24 
led to increased transcription and translation of the Nav1.8 ion channel, which 
contributes towards increased excitability of nociceptors (Coggeshall et al., 2004). 
1.3.1.4. Higher central centres  
 
Finally, induced action potentials reaches the central terminals, which synapse on 
second order neurons located in defined areas of the spinal cord dorsal horn (Woolf 
and Ma, 2007). The spinal cord is the first relay station, and is involved in modulation 
of the signals by inhibitory interneurons. These signals then travel supraspinally to 
the thalamus, where further processing of the nociceptive signal occurs. Nociceptive 
signals are interpreted and perceived as pain sensation in somatosensory and 
prefrontal cortices in the brain (Tracey and Mantyh, 2007). Of note, a descending 
feedback pathway modulates ascending information, and thus is responsible for the 
regulation of nociceptor activity (Millan, 2002). The limbic system, specifically the 
amygdala also plays an important role in the emotional evaluation of sensory 
information as well as pain-enhancing and pain-inhibiting functions, serving as an 
important modulator of the experience of pain (Strobel et al., 2014). To conclude, 
nociceptors are the cellular substrate for two pivotal aspects of nociception: the 
transduction and transmission of noxious stimuli from the periphery to the CNS.  
1.3.2.  Classification of nociceptors  
Nociceptors are generally classified into two major categories, thinly myelinated Aδ- 
and slow conducting or unmyelinated C- fibres (Meyer et al., 2006). Both Aδ- and C-
fibres are polymodal, as they are capable of detecting and transducing a variety of 
noxious stimuli, including thermal, mechanical and chemical. However, they differ in 




Aδ fibres are medium-diameter myelinated afferents, responsible for mediating fast 
nociception. These are subdivided in two subpopulations: type I, and type II. Type I 
Aδ- fibres are sensitive to mechanical and chemical stimuli, but have a relatively low 
sensitivity for heat. On the other hand, type II Aδ- fibres are sensitive to heat but 
have a high threshold for mechanical stimuli (Basbaum et al., 2009; Lawson, 2002). 
C-fibres are small-diameter unmyelinated afferents that mediate slow nociception. C-
fibres can be further classified in two subpopulations: peptidergic and non-
peptidergic fibres. Peptidergic neurons express the receptor for nerve growth factor 
(NGF), TrkA, and release neuropeptides such as substance P (SP) and calcitonin 
gene-related peptide (CGRP). Peptidergic neurons project primarily to lamina I and 
outer lamina II.  Non-peptidergic neurons express the receptor for glial-derived 
neurotrophic factor (GDNF), c-RET, and bind the IB4 isolectin. These neurons 




Figure 2. Schematic showing pain pathways of the nervous system. 
Exposure to noxious stimulus in the periphery is detected by nerve terminals of 
primary sensory neurons, such as small diameter Aδ- and C- fibres. Nociceptive 
signal is sent to the dorsal horn of the spinal cord. The signal is modulated at this 
stage, and subsequently sent to higher centres in the brain via secondary neurons, 
where the signal is interpreted and perceived as pain sensation (Adapted from 
(Scholz and Woolf, 2002)).  
 
1.4. Peripheral vs. Central Mechanisms of Sensitisation  
The pain response is essential to protect our body from damaging stimuli, however 
under certain conditions this response is dysregulated and no longer has a beneficial 
function for the body (Dubin and Patapoutian, 2010). In these cases, nociceptors 
undergo a process of sensitisation to the persistent stimuli. Nociceptor sensitisation 
results in altered electrophysiological properties, including a reduction in activation 
threshold as well as higher magnitude of response or higher number of APs are 
triggered in response to noxious stimulation (Bessou and Perl, 1969). From a 
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behavioral point of view, these cellular changes are manifested as hyperalgesia, 
where stimulation of nociceptors causes an exaggerated response. In some cases, 
peripheral nociceptors fire action potentials in the absence of any type of stimulus, 
resulting in spontaneous pain (Djouhri et al., 2006). Although peripheral mechanisms 
of pain are the primary focus of my thesis and will be discussed in further detail, 
central mechanisms underlying pain pathophysiology will be discussed briefly in the 
following section.  
1.4.1. Central Sensitisation  
Central sensitization is an amplification of signaling within the CNS that elicits pain 
hypersensitivity. Evidence for the augmentation of sensory input in the CNS 
associated with pain hypersensitivity was first shown in 1983, when a preclinical 
study showed that injury induced firing in the nerve endings resulted in long-lasting 
increase in the excitability of spinal cord neurons (Woolf, 1983). Central sensitization 
is thought to involve several mechanisms including an increase in synaptic strength 
due to augmented excitatory transmitter release or increased post-synaptic response 
to the transmitter as well as a reduction in inhibitory pathways, which manifests as 
allodynia where pain sensation is evoked to innocuous stimuli (Takazawa and 
MacDermott, 2010; Woolf et al., 1994). Changes in functional properties of dorsal 
horn neurons have also been reported, where increased membrane excitability leads 
to recruitment of subthreshold synaptic input, contributing towards suprathreshold 
action potentials (Rivera-Arconada and Lopez-Garcia, 2010).  As a consequence, an 
increase in synaptic strength develops involving changes in neurotransmitter 
synthesis and calcium channel density (Hendrich et al., 2008). Moreover, astrocytes, 
gap junctions, epigenetic mechanisms and microglia have also been linked to central 
sensitization mechanisms (Chacur et al., 2009; Chiang et al., 2010; Gao et al., 2009; 
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Hathway et al., 2009). Structural changes in the amygdala, and prefrontal cortex 
have been associated with the emotional aspects of pain and conditioned fear 
(Pedersen et al., 2007). Overall, these changes result in innocuous inputs resulting 
in painful sensations due to abnormal sensory processing within the central nervous 
system. 
1.4.2. Peripheral Sensitisation  
Peripheral sensitisation involves alterations in activation threshold, and membrane 
excitability of peripheral ends of nociceptors. Noxious stimuli can cause excitation of 
a nociceptor via activation of receptors such as ion channels, and an influx of cations 
resulting in a localised depolarisation. A large enough depolarisation, results in the 
opening of voltage-gated channels which are responsible for the generation of action 
potentials, or “pain signals” that travel to the DRG cell soma from the site of injury. 
The afferent functions of peripheral nerve fibres involve the transmission of pain 
signals from the skin to the CNS via Aδ- fibres and C-fibres. The efferent functions 
involve the release of neuropeptides such as calcitonin gene-related peptide (CGRP) 
and SP from their nerve endings. Neuropeptides act by triggering a series of pro-
inflammatory mechanisms including vasodilation, plasma extravasation, oedema 
formation, and recruitment of inflammatory cells. The antidromic release of 
neuropeptides in the peripheral tissue causing vasodilation, increased vascular 
permeability and alteration in immune cell biology is also termed neurogenic 
inflammation. Following injury and inflammation, a nociceptor is sensitised due to 
changes in the functional properties of ion channels found along the nociceptor. IMs 
for instance, can act on metabotropic receptors, triggering second messenger 
systems which then modulate ion channel function (Hucho and Levine, 2007; Linley 
et al., 2010b).  Sensitisation can occur within minutes, involving post-translational 
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modification such as phosphorylation of ion channels. However, long term 
sensitization is also thought to involve alteration in the expression of ion channels 
due to transcriptional changes. Addition of phosphate groups can significantly alter 
properties of peripheral ion channels, which may potentially explain changes in 
excitability of neurons in painful conditions. Known mechanisms of peripheral 
sensitisation have been reviewed extensively (Basbaum et al., 2009; Dubin and 
Patapoutian, 2010; Gangadharan and Kuner, 2013; Schaible et al., 2011). The 
known players and mechanisms underlying peripheral sensitization will be discussed 
in further detail in sections 1.5-1.7.  
 
In summary, both peripheral and central mechanisms contribute to the generation of 
pain after nerve injury and/or inflammatory insult. Collectively, these mechanisms 
contribute to rapid modulation in signal transduction pathways and long-term 
alterations in mediator and receptor systems. However, despite the importance of 
central changes taking place at the CNS which contribute to the amplification of the 
pain response during chronic pain conditions, this thesis will focus primarily on 
peripheral mechanisms underlying painful conditions. The following sections will 
discuss the available evidence with regards to key players in the context of 
inflammatory pain.  
 
1.5.  Key players of inflammatory pain states 
Pro-inflammatory agents are responsible for enhancing the excitability of the 
nociceptor and amplifying the inflammatory response via direct or indirect modulation 
of several ion channels. There is evidence demonstrating that the action of IMs 
released during the inflammation response leads to functional modulation of a wide 
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variety of other ion channels such as, TRPV1, voltage-gated ion channels, ASIC and 
HCN channels amongst others, which leads to altered nociceptor excitability (Figure 
3). 
 
Figure 3. Peripheral mechanisms of sensitisation. 
Tissue damage induces the synthesis and release of a cocktail of inflammatory 
mediators (IM). Prostaglandin E2, bradykinin, NGF, ATP and protons bind to their 
receptors on the peripheral terminals of nociceptors. This results in activation of 
signaling cascades including the cyclic-adenosine monophosphate/protein kinase A 
(cAMP/PKA) pathway, mitogen-activated protein kinase (MAPK) pathway, and 
phospholipase C/inositol 1,4,5-triphosphate/diacylglycerol (PLC/IP3/DAG) pathway 
leading to altered ion channel function as well as their expression/distribution at the 




Thus, in the following sections, the key players involved in peripheral sensitisation in 
the context of inflammatory pain will be discussed in detail, including the main IM, 
signalling cascades that are activated as a result of mediator-GPCR receptor 
interactions as well as key ion channels that are modulated as a direct or indirect 
effect of IM.  
1.5.1. IMs associated with pain  
Nociceptor sensitization is a consequence of tissue damage and inflammation, which 
is driven primarily by the recruitment and activation of immune and tissue resident 
cells at the site of injury, and subsequent release of IM. It has been recognized that 
key players involved in the inflammatory response interact with the sensory nervous 
system and contribute to persistent pain states (Ji et al., 2014). IMs that are known 
contributors of pain will be discussed in detail in the following sections.   
 
1.5.1.1. Prostaglandins  
 
Prostaglandins are ubiquitously expressed lipid molecules that play an important role 
in the generation and development of the inflammatory response. They are produced 
when phospholipase A (PLA) releases arachidonic acid (AA), which is in turn 
metabolized by cyclooxygenase 1 and 2 (COX-1 and COX-2) enzymes to produce 
prostaglandin E2 (PGE2), prostacyclin (PGI2), prostaglandin D2 (PGD2), and 
prostaglandin F2 (PGF2) (Figure 4). The production of prostaglandins is 
maintained at low levels under normal conditions. Prostaglandins are responsible for 
housekeeping functions such as regulation of vascular tone, water homeostasis and 
pulmonary vascular remodelling (Lundequist, 2010). However, in inflammation, 
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production of prostaglandins is dramatically increased. The time-dependent increase 
of COX-2 mRNA levels have been demonstrated in both animal models of 
inflammation as well as in human oral mucosa following the onset of inflammation 
(Anderson et al., 1996; Khan et al., 2007). Moreover, a 10 to 80-fold increase in 
COX-2 expression has been observed in immune and non-neuronal cells present at 
the site of injury such as monocytes, macrophages, chondrocytes, fibroblasts and 
epithelial cells, leading to increased levels of prostaglandins (Crofford, 1997). The 
importance of prostaglandins in the context of pain is highlighted by the successful 
clinical use NSAIDS and selective COX-2 inhibitors, as analgesics for acute pain 
conditions. The role of prostaglandin E2 in peripheral sensitisation will be reviewed in 
further detail in Chapter 5.  
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Figure 4. Biosynthetic pathway of prostaglandins. 
Prostaglandins are synthesized in the cell from fatty acids which are converted to 
arachidonic acid(AA) via phospholipase A2 (PLA2). AA is broken down by 
cyclooxygenases (COX-1, COX-2) to a precursor prostaglandin H2 (PGH2) which, in 
turn, is broken down by different enzymes to produce thromboxanes (TXA2), 




1.5.1.2. Bradykinin  
 
The kinin peptide, bradykinin, was first identified as an algogenic substance in 
human inflammatory exudates such as in fluids from arthritic joints (Armstrong et al., 
1957). Bradykinin is a nonapeptide, endogenously released from kininogen 
precursors in plasma and tissues by the action of kallikrein-kinin enzyme. Its release 
is triggered in response to tissue damage or inflammation (Figure 5).  
 
Bradykinin acts on two known GPCR receptors with 36% sequence homology; 
B1(B1R) and B2(B2R) (Menke et al., 1994). B2 is thought to be constitutively 
expressed on both primary afferent neurons, post-ganglionic sympathetic fibres, 
endothelium and macrophages under physiological conditions, whereas B1 
receptors are primarily inducible following tissue injury and/or inflammation, as a 
result of increased transcription and subsequent protein synthesis (Ahluwalia and 
Perretti, 1999; Couture et al., 2001; Marceau and Bachvarov, 1998; Walker et al., 
1995). The role of the B1 and B2 receptor in inflammatory pain has been 
demonstrated over the past decade by several knockout studies as well as the use 
of B1 and B2 selective antagonists in rodents (Ferreira et al., 2002; Mizumura et al., 
2009; Pesquero et al., 2000). Signalling mechanisms downstream of kinin receptor 
activation have also been elucidated.  Intramuscular formalin injection  has been 
found to increase the expression of B1 and B2 receptors, which contributes to 
mechanical hyperalgesia via the PKC and p38/MAPK signaling pathways (Meotti et 
al., 2012). Human studies have confirmed the role of bradykinin as a pain-inducing 
mediator. Moreover, local anaesthetics such as lidocaine have been shown to 
supress the inflammatory action of bradykinin significantly (Dias et al., 2008). The 
mechanism underlying this remains to be elucidated however, it was postulated that 
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local anaesthetics may inhibit signalling of Gq-coupled GPCRs. In support of this, 
bupivacaine, a local anaesthetic, has been shown to inhibit PGE2-EP1 downstream 
signalling via direct interaction with the G protein or GPCR (Honemann et al., 2001).  
Moreover, a study showed that administration of BK via injection or iontophoresis 
results in dose-dependent pain and pruritus. The same study reported that B2R 
signaling is predominant during physiological conditions, whereas potentiated B1R-
mediated effects are observed following inflammatory insult using ultraviolet B (UVB) 
radiation. Another interesting observation from this study was that the sensitising 
effects of bradykinin are independent of mast cell degranulation and histamine 
release, at low doses at least (Paterson et al., 2013). Thus, it could be possible that 
the sensitizing effects of bradykinin are dependent on its direct action on B1R and 




Figure 5. Biosynthetic pathway for bradykinin. 
Kininogen precursors are cleaved by the protease kallikrein found in tissue and 
plasma to produce Bradykinin. Bradykinin acts on GPCR receptors B1R and B2R, 
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and can be metabolized by Kininase I to produce Des-Arg9-Bradykinin, which is 
more selective for B1R, than for B2R.   
 
1.5.1.3. Histamine  
 
Histamine is a multifunctional molecule which is known to be involved in 
inflammation, neurotransmission and immune modulation. It is synthesized from the 
decarboxylation of L-histidine and it is stored in cytoplasmic granules of mast cells, 
basophils, and histaminergic neurons (Jutel et al., 2006). Following tissue damage, 
activation of mast cells and basophils results in degranulation or stimulus exocytosis 
through which histamine is released at the site of injury. Histamine mediates its 
functions via action on 4 histamine receptors subtypes; H1, H2, H3 and H4. H1R is a 
GPCR associated with Gq/11 protein; therefore, its activation initiates activation of 
the PLC signaling pathway. By contrast, H3R and H4R activation instigate the MAPK 
pathways (Ichikawa and Tanaka, 2012).  
 
Expression of H1, H3 and H4 was detected in peripheral sensory neurons 
innervating the skin in a recent study (Rossbach et al., 2011). All four histamine 
receptor antagonists have been suggested to display anti-nociceptive efficacy by 
reducing allodynia and hyperalgesia in rodent models of inflammatory and 
neuropathic pain (Hsieh et al., 2010; Medhurst et al., 2007; Medhurst et al., 2008; 
Mobarakeh et al., 2006). Efficacy of antihistamines for specific human painful 
conditions, such as IBS and severe bone pain have also been reported. A clinical 
study showed that treatment with H1 receptor antagonist reduced visceral 
hypersensitivity and abdominal pain in rectal biopsies from IBS patients (Wouters et 
al., 2016). By contrast, loratadine, an H1R antagonist failed to reduce bone pain in a 
randomized phase II study (Moukharskaya et al., 2016). Clinical studies assessing 
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the analgesic action of histamine antagonists have been equivocal. Therefore, 
further clinical evidence is required for antihistamines to be considered as analgesics 
for the management of pain. Notwithstanding, taken together, these studies confirm 
a role of histamine as a key mediator of the inflammatory response.  
1.5.1.4. Serotonin  
 
Serotonin, is a monoamine neurotransmitter synthesized by decarboxylation of 
tryptophan, its precursor molecule. Serotonin is involved in a number of physiological 
functions in the central nervous system such as the regulation of mood, appetite, 
sleep, and vasoconstriction. However, its role in the PNS is becoming increasingly 
apparent and has been established as an inflammatory modulator of acute and 
chronic pain (Bardin, 2011). Abundant levels of 5HT are found in peripheral tissue 
and endogenous 5HT levels have shown to be increased after inflammatory insult in 
humans and inflammatory rodent models (Ernberg et al., 2000; Kopp, 1998; Sasaki 
et al., 2006). 
 
Serotonin receptors are classified into 7 isoforms (5HT1-7), with 5HT1 and 5HT2 
further divided into subtypes 5HT1A, 5HT1B, 5HT1D and 5HT2A-C, respectively. All 
of these receptors are GPCRs, except 5HT3 which is a ligand-gated ion channel. 
There has been evidence for 5HT1B, 5HT1D, 5HT2A and 5HT3 expression in rat 
DRG (Van Steenwinckel et al., 2009; Zeitz et al., 2002). However, the lack of 
antibodies for the different 5HT receptor subtypes make it difficult to understand 
peripheral expression patterns of these receptors. Distinct serotonin receptors are 
responsible for different mechanisms underlying pain and inflammation. For 
instance, 5HT2A receptors are GPCRs, which trigger the Gq signalling pathway 
resulting in phosphorylation of TRPV1 via PLC/PKC. Obata et al., showed that 
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peripheral 5HT2A receptors play a role in mediating formalin-induced hyperalgesia in 
rats (Obata et al., 2000; Sasaki et al., 2006). Whereas, 5HT1B/1D receptors are 
GPCRs coupled to the Gi/Go which reduces cAMP signalling, resulting in decreased 
neurotransmission. The only 5HT selective agonist clinically used is 5HT1B/1D, 
sumatriptan, which is prescribed for patients suffering from migraines and cluster 
headaches. A recent randomized phase III clinical trial also tested the efficacy and 
safety of duloxetine, a selective 5HT- norepinephrine reuptake inhibitor, in 
fibromyalgia patients. The study reports that the drug was well tolerated and reduced 
pain scores in patients given duloxetine compared to placebo (Murakami et al., 
2015). Future strategies aim towards targeting the peripheral structures only.  
1.5.1.5. Adenosine Triphosphate (ATP)   
 
It was not until the early 70s that the ubiquitously expressed metabolite responsible 
for energetic metabolism, ATP, was found to evoke pain sensation (Blehen & Keele, 
1977; Tominaga et al., 2001). It is now widely accepted that extracellular ATP is also 
a neurotransmitter and a neuromodulator. A neurotransmitter is a chemical 
messenger released at the end of a nerve fibre by the arrival of a nerve impulse and 
through diffusion across a synapse or junction, effects the transfer of the nerve 
impulse to another nerve or muscle fibre or another effector cell. A neuromodulator is 
a neurotransmitter that is not taken up by the pre-synaptic neuron or broken down 
into a metabolite, as its receptor is present on the post-synaptic neuron or effector 
cell. Peripheral administration of ATP or P2X agonists evoke nociceptive behaviours 
and are responsible for sensitisation of sensory neurons in both rodents and human 
models (Hamilton et al., 1999; Hamilton et al., 2000; Jarvis, 2003).  
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ATP acts as an agonist for 2 classes of purinergic receptors:  ligand gated-ion 
channel P2X receptors and metabotropic GPCR P2Y receptors (Obata et al., 2000). 
Eight isoforms of the P2Y receptor, and seven subtypes of the P2X receptor have 
been identified (Khakh et al., 2001; Sak and Webb, 2002). P2X3 (homomultimer) 
and P2X2/3 (heteromultimer) receptors have been found to be selectively expressed 
on small-diameter sensory neurons in DRG and have been shown to be responsible 
for ATP-induced neuronal excitability (Chen et al., 1995; Lewis et al., 1995). 
Receptors for ATP have been considered as therapeutic targets for inflammatory 
pain. Clinical studies testing the efficacy of AF-219 compound, the only P2X3 
antagonists known to have advanced to clinical trials as an anti-tussive, caused 
significant taste disturbance in patients (Abdulqawi et al., 2015). Moreover, activation 
of P2X7 receptors found on human macrophages cells triggers the release of several 
cytokines, which is why it has been considered as a therapeutic target for 
inflammatory pain. However, the P2X7 antagonists failed in phase II clinical trials 
when their efficacy was tested in patients with rheumatoid arthritis (Keystone et al., 
2012; Stock et al., 2012).  
1.5.1.6. Nerve Growth Factor (NGF) 
 
NGF was the first molecule from the family of growth factors to be discovered back in 
1948. It was first recognized for its role in the survival and development of sensory 
neurons during their embryonic phase. As neurons evolve into the adult phase they 
become less dependent on NGF (Easton et al., 1997).  
 
Two main receptors for NGF are found on C- fibre nociceptors; low affinity p75 
neurotrophin receptor and high affinity Tyrosine Kinase receptor (TrkA). NGF is 
considered an important component of the chemical milieu of inflammation at the site 
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of tissue damage.  It is released by both, neuronal and non-neuronal cells at the site 
of injury. Early studies carried out in both rodents and humans proved that a single 
application of exogenous NGF can produce a long-lasting hyperalgesic phenotype 
(Dyck et al., 1997; Lewin et al., 1993). 
 
NGF is responsible for mediating rapid functional changes as well as transcriptional 
alterations of pain-mediating proteins. For instance, NGF has shown to be 
responsible for potentiated gene expression of substance P, TRPV1 and Nav1.8 
(Chao, 2003). Moreover, it has also been demonstrated that the polymodal TRPV1 
channel is plays an important role contributing towards NGF-induced sensitisation of 
nociceptors in vitro and NGF-induced hyperalgesia in rodents (Chuang et al., 2001; 
Eskander et al., 2015). Moreover, an autosomal recessive, loss of function mutation 
of the gene encoding for TrKA (NTRK1) and NGF results in congenital insensitivity 
to pain (CIP) disorders in humans, characterised by absence of reaction to noxious 
stimuli, inability to sweat, and mental retardation (Carvalho et al., 2011; Einarsdottir 
et al., 2004). Based on all the evidence supporting the role of NGF as an important 
pain mediator, a humanised monoclonal antibody which selectively binds and targets 
NGF, Tanezumab, is currently being tested in a global, phase 3 clinical trial in 
patients with chronic lower back pain, osteoarthritis or cancer pain who have not 
received pain relief or cannot tolerate currently available analgesics.  
1.5.2.  Main Signalling Pathways activated by IM  
A number of ion channels and their downstream signalling pathways have been 
highlighted as important mediators of inflammatory pain conditions. The first 
signalling cascade identified to play a role in the nociceptive activity of inflammatory 
mediators was the cAMP/PKA pathway (Taiwo et al., 1989). The cAMP/PKA 
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pathway is triggered downstream of the activation of GPCR receptors. Activation of 
GPCR with Gs type G subunit results in activation of adenylate cyclase, which 
converts ATP to cAMP. Increase in intracellular cAMP levels then results in 
activation of protein kinase A. For instance, some prostaglandin receptors (EP2, 
EP4) and 5HT receptors (5HT4, 5HT6 and 5HT7) are GPCRs with a Gs type G 
subunit and therefore trigger the cAMP/PKA pathway after activation (Meves, 2006).  
 
Another important signalling cascade is the Gq/PLC pathway, which leads to 
activation of protein kinase C and has been associated with sensitisation of several 
ion channels (Patapoutian et al., 2009b). As examples, histamine receptors, 
bradykinin B2 receptor as well as the prostaglandin receptor EP1 are coupled to the 
Gq type G subunit. Activation of these receptors results in stimulation of PLC, 
which in turn causes the hydrolysis of PIP2, into DAG and IP3 (Couture et al., 2001; 
Kühn et al., 1996; Meves, 2006). DAG causes activation of PKC whereas IP3 
induces an increase in intracellular Ca2+ concentration thereby triggering a number of 
Ca2+ -dependent processes. Both pathways have been reported to play an important 
role in inflammatory pain mechanisms, and are downstream effectors of a number of 
ion channels. For instance, bradykinin-induced acute sensitization of TRPA1 occurs 
via PLC signalling pathways (Wang et al., 2008). Cang and co-workers also  
suggested that the potentiation of Nav1.8 current via NK1 activation is dependent on 
the PKC signaling pathway (Cang et al., 2009).  
 
Other signaling pathways associated with inflammatory pain include MAPK and 
PI3K, which are activated downstream of receptors for growth factor receptors such 
as TrkA. These pathways have been involved in the sensitization (Zhu and Oxford, 
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2007) and insertion of TRPV1 channel into the plasma membrane of primary afferent 
neurons (Constantin et al., 2008; Tsantoulas et al., 2013; Zhang et al., 2005). 
Further, Binshtok and colleagues demonstrated that Interleukin-1 (IL-1) enhanced 
TTX-R currents near threshold via the MAPK signaling pathway (Binshtok et al., 
2008). Similarly, tumor necrosis factor (TNF) has been shown to be implicated in 
modulation of TTX-resistant currents, which was reversed by a p38-MAPK inhibitor 
(Jin and Gereau, 2006). These signalling pathways act synergistically in vivo, 
secondary to inflammatory mediator release at the site of injury. Collectively, all four 
major signalling pathways mentioned above contribute towards altered expression 
and function of different receptors and ion channels found along DRG neurons as 
described in the examples above, which ultimately leads to hyperexcitability of 
nociceptors during inflammatory pain conditions.  
1.5.3.  Ion channels as Peripheral Targets of IM 
Binding pro-inflammatory substances to ion channels directly or indirect activation of 
ion channels via GPCR receptor activation, triggers signaling cascades leading to 
production of cyclic-adenosine monophosphate (cAMP), PKA, PKC or MAPK known 
to alter functional properties of ion channels via several mechanisms which will be 
discussed extensively in the following sections. Understanding the mechanisms 
underlying modulation of ion channels, by inflammatory mediators and their 
downstream effectors would not only aid our understanding of key players of 
peripheral sensitisation but also holds a great benefit from a therapeutic point of 
view. Modulation of functional properties of ion channels at the nerve endings could 
attenuate unwanted effects mediated by pro-inflammatory mediators, without 
deteriorating the immune system. In the sections below, ion channels which have 
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been identified and characterized at nerve terminals and have been linked to key 
inflammatory mediator-mediated mechanisms will be discussed.  
1.5.3.1. Transient Receptor Potential Vanilloid 1 (TRPV1) channel 
 
An important group of channels in the context of inflammatory pain are TRP 
channels which have been discovered and characterized on primary afferents, as 
important sensors of temperature. Although there are several TRP channels known 
to play a role in inflammatory pain (e.g. TRPA1), I will focus on TRPV1 as a 
prototypical example of TRP channel sensitisation in the context of inflammatory 
pain. TRPV1 is a non-selective cation channel which can also be activated by 
noxious temperature, low pH and monoacylglycerols (Caterina et al., 2000; Zygmunt 
et al., 2013). TRPV1 channels are polymodal, and therefore are activated by a 
number of stimuli (Tominaga et al., 1998). A number of groups have reported that 
pro-inflammatory agents such as protons and anandemides (Zygmunt et al., 1999)  
act on TRPV1 channels indirectly, via the activation of second messenger pathways, 
to cause pain. Several preclinical models of inflammation give evidence for the 
activation, up-regulated expression and increased phosphorylation of TRPV1 
channels by disease associated inflammatory mediators cytokines such as IL-1 and 
IL-6, as well as eicosanoids (Zhang et al. 2005).  
 
TRPV1 channels can be modulated by inflammatory mediators via rapid changes 
involving the activation of signalling cascades and subsequent phosphorylation of 
the ion channel, ultimately resulting in an amplification of the TRPV1-response. 
Additionally, the effects of TRPV1 can also be amplified due to increased expression 
levels of TRPV1 at the nociceptor. Long term exposure to inflammatory mediators 
result in transcriptional and translational alterations, which contribute towards an 
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increase in TRPV1 protein levels at the cell membrane. Both types of changes will 
be discussed further providing evidence using relevant examples.  Positive 
modulation of TRPV1 can occur via G protein-mediated signalling pathways 
involving phosphorylation by PKC and PKA (Zhang and Oppenheim, 2005). For 
instance, bradykinin and NGF have been shown to act via B2 receptor and TRK A 
receptor, respectively, to activate intracellular PLC/phosphoinositide pathway in 
sensory neurons. This leads to phosphorylation of TRPV1 resulting in both positive 
modulation and rapid translocation of this channel to the membrane via exocytosis 
(De Petrocellis and Di Marzo, 2005). Other pro-inflammatory mediators such as IL-6 
and IL-1 have been linked to TRPV1 sensitisation, and are thought to modulate its 
functional properties via phosphorylation by PKC (Obreja et al., 2002). 
Phosphorylation of the channel leads to a positive shift in temperature and ligand-
concentration dependency of the ion channel. 
 
Increased expression and transport of TRPV1 has been observed in response to 
TNF and NGF exposure in culture, resulting in an augmentation of proton and heat 
sensitivity (Amaya et al., 2004; White et al., 2010). Different signalling pathways 
have been shown to be responsible for these transcriptional and translational 
changes. NGF-induced increase in TRPV1 protein levels are mediated by PI3K and 
Src-mediated signaling pathways, whereas TNF-induced sensitisation of the receptor 
has been thought to be mediated by the p38/MAPK pathway (Constantin et al., 2008; 
Ji et al., 2002; Stein et al., 2006). The TRPV1 receptor has not only been shown to 
play a role in the context of inflammation, but also inflammatory conditions which are 
strongly associated with pain, such as in rheumatoid arthritis and inflammatory bowel 
disease (Akbar et al., 2010; Engler et al., 2007). In addition, TRPV1 channels have 
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been highlighted as important mediators of primary afferent sensitization in visceral 
distention and colitis models (Jones et al., 2005; Miranda et al., 2007). 
 
Taken together, these studies point towards the pivotal role of these channels in 
integrating both chemical and noxious stimuli in the peripheral nervous system 
during inflammatory conditions (Caterina, 2000).  
 
1.5.3.2. Hyperpolarisation cyclic nucleotide-gated (HCN) channels  
 
Hyperpolarisation-activated cyclic nucleotide-gated cation channels (HCN) have 
been traditionally known for their role in the heart and were first described as the 
“funny channels” in the 1970s. Cloning of HCN channels in the 1990s aided the 
understanding of their contribution towards spontaneous activity of pacemaker cells 
in the heart (Baruscotti et al. 2010). They belong to a superfamily of cyclic nucleotide 
gated (CNG) channels and voltage-dependent potassium (Kv), with a similar 
structural arrangement as the latter. They are permeable to both Na+ and K+ ions, 
and conduct an inward current called If current in cardiac cells or Ih current in 
neurons. HCN channels can be dually activated, by both a hyperpolarising 
membrane potential (-60mV and -90mV) as well as by intracellular cAMP at their C-
terminal, which is what makes them unique (Baruscotti et al., 2010; DiFrancesco, 
1999). There are four isoforms that belong to this class of channels (HCN1-4). These 
4 isoforms vary their biophysical properties, including their sensitivity to cAMP, and 
activation and deactivation kinetics, as well as their expression profiles. These will be 
discussed in further detail in Chapter 5.  
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There have been varied reported findings with regards to the role of HCN2 in the 
context of inflammatory pain, depending on the chosen model and readout. A study 
carried out by Schorr and colleagues showed that cAMP analogue administration did 
not lead to development of inflammatory pain behaviour in absence of the HCN2 
gene, using a HCN2 mutant snsHCN2KO (Schnorr et al., 2014). However, in PGE2-
induced inflammation both thermal and mechanical hyperalgesia were evident. 
Another group demonstrated that nociceptive phenotype was dramatically decreased 
in conditional Nav1.8/HCN2 KO mice in both, the carrageenan and the PGE2-
induced inflammation in vivo models (Emery et al., 2011a; Emery et al., 2012). Thus, 
these data present an interesting hypothesis suggesting an important role for HCN2 
channels in inflammatory pain. However, further investigation is required to confirm 
the role of HCN2 in peripheral inflammatory pain mechanisms. This idea will be 
explored and discussed in further detail in Chapter 5.  
1.5.3.3. Voltage-gated Sodium Channels (VGSC) 
 
VGSCs are imperative for the generation and propagation of action potentials in 
nociceptors. The Nav channel family includes nine mammalian isoforms that have 
been identified including Nav1.1 to Nav1.9 (Ertel et al., 2000). There are a number of 
natural toxins such as tetrodotoxin (TTX) that block these channels extracellularly. Of 
note, the different subtypes are classified into two classes, based on their sensitivity 
to TTX. Nav1.1- Nav1.4, Nav1.6 and Nav1.7 belong to the TTX-sensitive (TTX-S) 
category, with an IC50 <30nM of TTX whereas, Nav1.5, Nav1.8 and Nav1.9 belong to 




The importance of voltage-gated sodium channels in pain sensation is highlighted by 
the well-established and regular clinical use of non-selective sodium channels as 
local anaesthetics and analgesics (e.g. lidocaine and procaine). In particular, specific 
isoforms such as Nav1.8, Nav1.9, Nav1.7 have attracted most attention of academics 
and pharmaceutical companies. In fact, the discovery of a dozen of human mutations 
linked to these ion channels alongside in vivo experiments performed over the past 
decade confirm the critical role of these channels in inflammatory and neuropathic 
pain (Cummins et al., 2004). Novel mechanisms underlying inflammation-induced 
nociceptor sensitisation, such as the potentiation of sodium currents and their 
associated signaling pathways, are being discovered every year and will be 
discussed in this section.  
 
Lack of hyperalgesia in mice knock out for the Nav1.9 channel stimulated with 
intraplantar administration of bradykinin, IL-1, P2Y agonists and prostaglandin E2 
confirmed the role of Nav1.9 in inflammatory mechanisms (Amaya et al., 2006). This 
was further supported by another study where DRG neurons exposed to TNF on its 
own or a cocktail of inflammatory mediators displayed potentiated Nav1.9 channel-
mediated currents (Jin and Gereau, 2006; Maingret et al., 2008).  
 
The importance of Nav1.8 channels in inflammatory mechanisms have also been 
highlighted by knockout studies where deletion of Nav1.8-positive neurons resulted in 
reduced hyperalgesia in the commonly used, formalin and CFA-induced 
inflammatory animal models (Abrahamsen et al., 2008). Sensitisation of Nav1.8- 
positive nociceptors by pro-inflammatory and proalgesic agents, and their underlying 
mechanisms were first documented back in the 90s. Reports showed evidence for 
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PGE2, NGF and 5-HT inducing sensory neuron excitability via a shift in voltage 
dependence for activation and increase in the magnitude of Nav1.8 currents (Gold et 
al., 1998b). More recently, it was demonstrated that direct phosphorylation of two 
residues in loop 1 of Nav1.8 activates p38 MAPK pathway resulting in increased 
Nav1.8 current density (Hudmon et al., 2008). Other groups have supported this idea 
and reported that PGE2, NGF and endothelin-1 (ET-1) increase Nav current TTX 
density, and a reduction in activation threshold whereas TNF induces an increase in 
current density, without altering activation threshold of the channel (Zhang et al. 
2002; Jin & Gereau 2006).  
 
The critical role of Nav1.7 was initially revealed by the finding that a mutation in 
SCN9A gene encoding for Nav1.7 ion channel leads to pain hypersensitivity in 
patients affected by inherited erythromelalgia (EM) or “man on fire” syndrome 
occurred due to a mutation in SCN9A gene encoding for Nav1.7 ion channel, leading 
to pain hypersensitivity in these patients (Dib-Hajj et al., 2010). Later on, it was also 
found that a mutation of the same gene, resulting in a non-functional protein, is 
responsible for the lack of pain sensation, also known as congenital insensitivity to 
pain (CIP) in a family based in Pakistan. Over the past years, a number of other 
channelopathies associated with this particular ion channels were identified as a 
cause of a variety of human pain disorders (Dib-Hajj et al., 2010). Rodent genetic 
studies have also demonstrated a direct role of Nav1.7 in inflammatory pain by using 
a Nav1.7 knockdown approach, where deletion of this ion channel resulted in the 
absence of inflammatory pain (Nassar et al. 2004; Yeomans et al., 2005). Moreover, 
it has been shown that Nav1.7 function is modulated during inflammatory conditions.  
In the case of carrageneenan- induced inflammation, an increase TTX-S currents 
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was observed and was associated with an upregulation of Nav1.7 channels (Black et 
al., 2004). Therefore, it is not surprising that researchers and drug companies have 
invested vast amount of resources and efforts towards the development of Nav1.7 
blockers as a new generation of analgesics over the past few years. As yet, specific 
pharmacological agents targeting Nav1.7 have failed to demonstrate analgesia in the 
clinical setting. However, there are still several ongoing Phase I clinical trials testing 
Nav1.7 selective blockers from which results have not yet been released (Emery et 
al., 2016; Lee et al., 2014b).  
1.5.3.4. Voltage-gated Calcium Channels (VGCC) 
 
Voltage-gated calcium channels are found on all excitable cells and are primarily 
responsible for regulating neuronal excitability, neurotransmitter release as well as 
regulation of transcriptional changes (Wheeler et al., 1995). Nine different subtypes 
have been discovered and characterized in the mammalian nervous system and they 
are classified into two main categories: low voltage activated (LVA) and high-voltage 
activated (HVA). The HVA category include L-type or Cav1.1-1.3, P/Q-type or 
Cav2.1, N-type or Cav2.2, R-type or Cav2.3, whereas the LVA category encompass 
T-type channel subtypes or Cav3.1-Cav3.3 (Yusaf et al., 2001).  
 
The importance of VGCCs in chronic pain mechanisms is confirmed by the common 
use of gabapentin and pregabalin, the only current treatments for patients suffering 
from neuropathic pain conditions. In particular, gabapentinoids mechanism of action 
involves binding to auxiliary VGCC subunit 2-1 (Patel et al., 2013). However, it has 
been proposed that their analgesic effects involve inhibition of the increase in axonal 
trafficking of the subunit 2-1 observed after nerve damage (Bauer et al., 2009).  
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In addition to their role in neuropathic pain conditions, there has been a large body of 
evidence suggesting the contribution of Cav channels to inflammatory pain. A recent 
study reported that treatment with pregabalin caused a notable reduction in 
capsaicin-induced facial grooming, an attenuation in the second phase of the 
formalin response as well as a decrease in carrageenan-induced heat hyperalgesia, 
thus suggesting pregabalin may be effective in inflammatory pain as well (Hummig et 
al., 2014). In line with this, it has also been shown that chronic inflammation induces 
an alteration in VGCC distribution in rodent cutaneous DRG in vitro (Lu et al., 2010). 
Based on these findings, Cav-channels have been explored as a therapeutic target 
for inflammatory pain conditions. Within the N-type channels a state-dependent N-
type blocker, TROX-1, with a selectivity similar for all three subtypes (Cav2.1, 2.2 
and 2.3) has been developed. TROX-1 was shown to reverse behavioral 
hypersensitivity in the iodoacetate model of osteoarthritis, equivalent to effects of 
NSAIDs in rats (Abbadie et al., 2010). Further, this compound has been proposed as 
a potential treatment for osteoarthritis with neuropathic pain features (Patel et al., 
2017). Several studies have suggested the role of T-type channels in inflammatory 
pain mechanisms (Lee et al., 2010). For instance, it was shown that T-type channel 
blockers reduces histamine-induced paw inflammation in rodents (Bilici et al., 2001). 
Out of the T-type calcium channels, Cav3.2 is of particular interest as it is expressed 
primarily in the nerve endings of DRGs. TTA-A2, a pan Cav3 blocker, was found to 
produce a dose-dependent reduction in hyperalgesia in the IBS model. The same 
study showed that TTA-A2 was ineffective in Cav3.2 knockout mice, suggesting that 
its effects are mediated primarily via the Cav3.2 channel (Francois et al., 2013). The 
critical role of these channels in neurotransmitter release, the effectiveness of VGCC 
blockers in hypersensitivity in vivo, as well as the effectiveness of calcium channel 
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blockers in reducing inflammation parameters in hypertensive patients  argues that 
they could serve as good targets for chronic pain conditions (Farah, 2013; Patel et 
al., 2017).  
 
Taken together, there is a substantial amount of literature suggesting that all the pro-
inflammatory mediators and ion channels described above play an important role in 
inflammatory pain conditions. The effectiveness of strategies targeting these players 
has been demonstrated in a number of preclinical models, however the translatability 
of preclinical findings could be improved through the development of better models. 
The lack of translatability within pain research will be discussed in the following 
section with a focus on challenges and limitations of both in vitro and in vivo 
inflammatory pain models.  
 
 
1.5. The translatability of animal models used to understand 
pain mechanisms 
 
1.6.1. Animal Models of Inflammatory Pain 
Routinely used inflammatory pain animal models commonly involve the 
administration of an irritant that induces quantifiable pain-related behaviours. These 
include the formalin test, complete Freud’s adjuvant (CFA) test, carrageenan test or 
the zymozan test, and are used to model conditions with both acute and chronic 
inflammation (Beecher, 1957; Le Bars et al., 2001). Another method of modelling 
inflammatory pain responses is via an injection of individual pro-algesic substances 
known to sensitise nerve fibres such as prostaglandins, kinins, serotonin and 
cytokines. These are used to model specific stimulus- evoked behavioral pain 
responses in vivo (Rang et al., 1991). In contrast, there are more disease-specific 
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animal models which mimic key characteristics of chronic pain-associated human 
conditions. For instance, an insult to the bowel using 2,4,6-trinitrobenzene (TNBS) is 
commonly used as a model of colitis.  Similarly, the intra-articular injection of 
monosodium iodoacetate is a common model of arthritis, along with other adjuvant 
induced poly- and mono-arthritic models (Neugebauer et al., 2007).  
 
Despite the regular use of the animal models mentioned above, a number of 
limitations which may account for the lack of translatability of the findings from 
preclinical research. The limitations of animal models of inflammatory pain in terms 
of the validity of the models, and the parameters evaluated will be discussed in this 
section. Well-established animal models are commonly validated with a clinically 
effective and commonly used drug treatment. In the case of inflammatory pain 
states, models are often validated against NSAIDs. However, it should be taken into 
account that NSAIDs are only effective in a subpopulation of arthritic patients and 
are only recommended to be given at the lowest doses, for the shortest time required 
in high risk OA patients or patients with co-morbid conditions (Crofford, 2013; Laine 
et al., 2008). This is due to the risks associated with chronic administration of 
NSAIDs including renal, gastric and cardiovascular adverse effects (Marcum and 
Hanlon, 2010).  Thus, validation of animal models with NSAIDs could introduce a 
bias towards specific mechanisms or readouts when assessing drug effects.  
 
Lack of “pain fingerprints” or biomarkers for pain has forced researchers to rely on 
human questionnaires or quantifiable animal behaviour readouts, such as simple 
reflexes or the innate responses (i.e. licking, grooming, grimace scales). 
Hypersensitivity and drug effects are commonly quantified by observational rating of 
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mechanical or thermal stimulus-induced paw withdrawal responses or stimulus 
evoked changes in paw pressure against the floor while walking. Typical readouts 
include responses to von Frey filaments (Chaplan et al., 1994), deep pressure 
(Santos-Nogueira et al., 2012) or heat stimuli also known as the Hargreaves test 
(Hargreaves et al., 1988). Undoubtedly, observational rating is likely to introduce a 
certain degree of subjectivity and variability in results. Efforts have been made to 
reduce subjectivity of these models by ensuring blinding of experimenter whilst 
carrying out procedures. Moreover, the rapid advancement of technology has given 
rise to the creation of more automated systems. Novel methods such as video-
tracking systems and video-based behavioral algorithms are being developed to 
assess hypersensitivity over longer periods of rodents in their home cages (Roughan 
et al., 2009). These methods would minimize confounds associated with handling, 
housing conditions and social behavioral factors, which have shown to have an 
impact on the hyperalgesic phenotype in rodents (Balcombe et al., 2004; Raber and 
Devor, 2002; Robinson et al., 2004).  
 
Efficacy outcomes used in animal studies differ significantly from those used in 
humans. For instance, clinical trials data is analysed as a change from baseline 
within each individual, whereas in animal studies treated groups are often compared 
to naïve or vehicle groups (Quessy, 2009). Moreover, the predominant complaint of 
chronic pain patients is ongoing pain. Consequently, the primary efficacy outcome of 
clinical studies is ongoing pain, whereas currently available animal models’ readouts 
focus predominantly on measuring hyperalgesia induced by thermal or mechanical 
stimulation and it has been difficult to model ongoing pain in vivo. In support of this, 
only 10% of published articles in the journal of Pain reported a measure of 
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spontaneous pain, whereas 42% to 48% published hypersensitivity data during a 
ten-year period (Mogil et al., 2009). In efforts to tackle this, the use of spontaneous 
flinching, licking and guarding of the paw as readouts for ongoing pain has been 
suggested (Tappe-Theodor and Kuner, 2014). Moreover, a recent study evaluating 
the effects of a dopamine receptor antagonist in the CFA-induced arthritis model 
showed efficacy of this drug in reducing spontaneous pain-like behaviours such as 
spontaneous flinching and guarding of the paw (Robledo-Gonzalez et al., 2017).   
 
Taken together, there are a number of limitations that contribute to the lack of 
translatability of animal models. The use of more clinically relevant controls for the 
validation of these models as well as appropriate choice of outcomes/measured 
parameters is imperative. Using measures of ongoing pain, in addition to evoked 
pain will guide clinical usefulness of treatment in question.  
1.6.2. In vitro Models used to study Pain  
Unquestionably, in vivo experiments are essential for our understanding of the 
mechanisms taking place in the intact, living organism. However, in order to decipher 
mechanisms at a cellular level, researchers opt for in vitro or ex vivo preparations. 
Commonly used techniques in pain research include cell culture, patch clamp, and 
calcium imaging, which allow the study of electrophysiological properties of 
nociceptors. Advantages of these techniques include the ability to exploit key 
aspects of ion channel functionality such as alteration in membrane potential and 
neuronal firing in a controlled environment. Moreover, increased accessibility to 
human DRG cells from different disease patients has opened up new exciting 
avenues for in vitro scientists, which will be discussed in further detail in chapter 6. 
However, the recording techniques for studying electrophysiological properties of 
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nociceptors have remained the same since the days of Zotterman’s fundamental 
discoveries in the 1950s.  Importantly, these techniques focus primarily only one 
component of the nociceptor: the cell body or soma as they cannot be applied to 
nociceptive terminals. The difficulty of recording from thin, and tiny structures of 
small diameter axons has been the reason for our inability to distinguish between 
somatic, axonal and sensory terminal mediated mechanisms of chemosensitivity and 
nerve fibre sensitisation. Further, the development of in vitro models that better 
represent the biology of pain signalling would not only improve our understanding of 
cell-autonomous mechanisms responsible for painful conditions but would also have 
a positive impact on the reduction, refinement and replacement (3Rs) of animal 
usage for pain research, by significantly reducing the number of animals required for 
the study of pain signalling. 
1.6.2.1. The need for alternative in vitro models 
 
Despite the dramatic progress in our understanding of nociceptor excitability thanks 
to available in vitro techniques, the cell-autonomous mechanisms responsible for 
sensitisation of nociceptors remain to be fully elucidated. In recent years the study of 
axonal physiology and pathophysiology has gained momentum in the field of 
neuroscience, with the aim of shedding light on axonally-exclusive mechanisms 
responsible for axonal dysfunction- a common feature of neurodegenerative 
diseases. The availability of novel compartmentalized cell culture systems such as 
the microfluidic-based platforms allow the study of axonal-based mechanisms, 
independent of the cell body at a molecular level (Park et al., 2006a; Taylor et al., 
2005). Latest generation microdevices not only provide a controlled and isolated 
environment to grow axons, but also enable the investigation of the 
electrophysiological properties of axons in vitro, for the first time.  Microfluidic 
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technology enables the ability accurately model and/or control changes in neuronal 
microenvironments more accurately. The design and applicability of this tool will be 
discussed in further detail in Chapter 3.  
 
1.7. Why study axons?  
Traditionally the role of axons has thought to be limited to the transportation or 
conduction of signals from nerve terminals to higher centres of the nervous system. 
However, axonal malfunction is a prominent common factor of a wide range of 
neurological diseases. Currently, a large portion of our knowledge of molecular and 
cellular changes responsible for nociceptor sensitisation are based on in vitro studies 
carried out at the DRG soma, which has long been used as a model of primary 
afferents. Undoubtedly, the DRG soma expresses molecular markers similar to those 
found in the axon and nerve terminals. However, there have been some reports 
highlighting significant shortcomings of nociceptive soma as a model of the nerve 
endings. St Pierre and co-workers reported lack of tackyphylaxis, or rapidly 
diminishing response, to repeated applications of low pH and showed evidence for 
differences between proton sensitivity of cultured DRG cell bodies compared to that 
of DRG nerve endings (St Pierre et al., 2009). Further evidence of the presence of 
completely different mechanisms at the soma and nerve terminals was shown in a 
novel model of hyperalgesic priming, mimicking the transition from acute to chronic 
pain in the rat in vivo. This model involves “priming” of sensory neurons via the 
injection of a cAMP agonist, 8-bromo-cAMP. Once, the acute hyperalgesia caused 
by this injection is resolved, the intradermal injection of PGE2 induces a long-lasting 
(up to 24 hours) hyperalgesia in primed neurons, compared to a short-term 
hyperalgesia (up to 1 hour) observed in non-primed animals. Priming induced by 
intraganglionic injection of 8-bromo-cAMP was reversed by the antisense of the 
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transcription factor for CREB, and by pharmacological block of the translocation of 
activated CREB into the nucleus. Conversely, pharmacological block of protein 
translation at the peripheral terminals, not at the ganglion, reversed priming of 
nociceptors. They suggest that hyperalgesic priming involves gene transcription 
changes occur at the soma, whereas translation occurring at peripheral nerve 
endings during the chronification of pain (Ferrari et al., 2015). The same study 
showed that different agents induced priming when injected in the cell body or at the 
peripheral terminals. Whilst injection of 8-bromo-cAMP in the ganglion caused 
priming, injection of the same agent in the peripheral terminals did not induce 
priming and the opposite was true for other priming agents tested including NGF and 
TNF. These differences stress the importance for validating findings from 
experiments focusing on somal mechanisms using preparations allowing the study of 
peripheral components of the neuron, the axons and nerve terminals.  
 
Furthermore, there is a large body of work reporting that messenger RNA (mRNA) 
are transported and locally translated in mammalian dendrites and axons (Andreassi 
et al., 2010). Reports have shown that the regenerative ability of sensory axons, 
including those with removed cell bodies, is dependent on local protein synthesis 
and degradation after axotomy (Verma et al., 2005). Axonal protein translation has 
also been investigated in the context of nociception. A study reported local protein 
synthesis is essential for nociceptor function in a subset of sensory fibres (Jiménez-
Díaz et al., 2008). A more recent study showed, for the first time, the presence of 
inflammation and immune-related mRNAs in adult DRG axons and not in embryonic 
DRG axons (Gumy et al., 2011).  Further, it has been suggested that local axonal 
mRNA machinery is responsible for the regulation of local expression of ion channels 
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and signal transduction molecules (Jung et al. 2012). Supporting this, a study 
reported an accumulation of Nav1.8 mRNA in peripheral axons of DRG neurons after 
unilateral sciatic nerve entrapment injury in rats (Thakor et al., 2009). Similarly, an 
accumulation of Nav1.8 channels in regenerating axons in vitro axotomy has also 
been reported (Tsantoulas et al., 2013). Taken together, these studies provide 
evidence for the existence of axonally-exclusive mechanisms which may contribute 
towards the genesis and maintenance of painful conditions. 
 
In recent years, there has been significant evidence in favour of the idea that 
peripheral mechanisms are key drivers of pain. Of note, the arrival of pain signals to 
central structures is dependent on the activation of peripheral ion channels found 
along the nociceptor nerve terminals. In support of this theory, a topical application of 
lidocaine results in reduced spontaneous discharge, and attenuated mechanical 
hyperalgesia in animal models of inflammatory pain (Xiao and Bennett, 2008). 
Moreover, clinical evidence suggests that the lidocaine patch, a targeted peripheral 
analgesic, has shown to provide significant pain relief in cases of episodic 
erythromelalgia (Davis and Sandroni, 2005; Devers and Galer, 2000). These studies 
suggest that aberrant pain signals initiated in the nerve endings and axons contribute 
to pathological pain. Thus, there has been a push towards developing peripherally 
targeted drugs to not only target pain at its source, but also reduce the number of 
side effects associated with systemic delivery of analgesics (McDougall, 2011). 
Better understanding of peripheral mechanisms involved in sensitisation of the 
nervous system would allow us to find better targets for therapeutic intervention. 
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In conclusion, our knowledge regarding cell-autonomous mechanisms underlying 
changes in excitability of nociceptive terminals is primitive. Identification the role of 
various ion channels in determining membrane threshold changes, as well as 
changes in expression and distribution following injury and/or inflammation would 
provide important insights to understanding of peripheral hyperexcitability, a key 
aspect of all chronic pain conditions. Hence, the overarching aim of this thesis is to 
describe and utilize an in vitro model that recapitulates key aspects of nociceptor 
sensitisation, in order to delineate axonal mechanisms involved in inflammatory pain 
conditions.  
 
1.8.  Aims of the Work  
As discussed above, the changes in excitability of nociceptive axons at the site of 
injury and inflammation in painful conditions is a significant contributor to pain 
originating at the periphery. We hypothesised that following inflammation and/or 
nerve damage, nociceptor sensitisation and spontaneous activity observed arises 
from the modulation of ion channels and hyperexcitability at the nociceptive nerve 
terminals and axons. With increasing evidence regarding the contribution of many 
ion channels to the sensation of nociceptors during painful conditions, it is likely that 
a combination of ion channels contributes towards peripheral hyperexcitability at the 
nerve terminals. Currently our knowledge of the mechanisms underlying these 
changes in excitability as well as the role of various ion channels that determine 
these threshold changes at the nerve terminals and axons is extrapolated from in 
vitro models focusing on the cell bodies or in vivo models where multicellular 
responses complicate the identification of mechanisms intrinsic to peripheral nerve 
terminals. Thus, there is a need for the development of in vitro models that enable 
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investigation of axonal mechanisms, and how these mechanisms are altered by 
different stimuli during painful conditions. Better understanding of key axonal players 
will lead to improved translatability of preclinical findings and aid the development of 
better analgesics for pain management. Therefore, this PhD thesis set out four aims:  
 
Objective 1:  
To develop and validate an in vitro model of peripheral sensitisation of nociceptive 
axons using a microfluidic-based culture platform:  Firstly, I aimed to demonstrate 
axonal isolation in MFCs using adult DRG sensory neurons. Next, I aimed to validate 
the use of calcium imaging at the cell soma as a readout to measure axonal function 
and characterise axonal and somal responses to chemical stimulation in MFCs. 
Combining the MFC-based platform and the calcium imaging set-up, I aimed to 
measure functional changes in DRG axons following localized inflammatory insult as 
a model of peripheral inflammatory sensitisation in vivo. This is crucial as it 
recapitulates peripheral injury and inflammation in humans, where the cell bodies are 
not directly exposed to inflammatory mediators.   
Objective 2:  
To identify key axonal players underlying the effects of PGE2, a potent inflammatory 
and pain mediator, on nerve terminals and axons: The aim was to study the changes 
in axonal excitability in response to PGE2 only. In addition, I aimed to identify 
prominent axonal players contributing towards PGE2-induced changes in axonal 
excitability using pharmacological tools.  
Objective 3:  
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To determine the role of axonal HCN2 channels as a mediator of inflammation-
induced nociceptor sensitisation and activation: I aimed to investigate whether 
axonal HCN2 channels are important mediators of the functional changes induced by 
a combination of inflammatory mediators, as well as PGE2 only. Pharmacological 
and genetic approaches were used to understand the role these ion channels 
following inflammatory insult and/or injury.  
Objective 4:  
To develop a microfluidic-based in vitro assay using human inducible pluripotent 
stem cell (hIPSC)- derived sensory neurons: I aimed to establish optimal culture 
conditions to readily maintain and isolate hIPSC-derived sensory neuronal axons in 
MFCs. Next, I aimed to characterise the different populations of neurons present at 4 
weeks in vitro. Additionally, our objective was to characterise axonal responses of 
hIPSC-derived sensory neurons to chemical stimuli, and develop an MFC- based 
model of peripheral sensitisation to investigate functional changes in human 












2. MATERIALS & METHODS 
 
 
2.1. Reagents  
Stock solutions of PGE2 (Sigma), PF-01247324 (Sigma), Lidocaine (Sigma), 
Zatebradine (Tocris) and in-house developed HCN2 selective antagonist were 
dissolved in DMSO. Bradykinin (Sigma) was dissolved in 0.1 acetic acid, as a stock 
solution and diluted to desired final concentration in Hank’s Balanced Salt Solution 
(HBSS, Invitrogen). Histamine (Sigma), 5-HT (Sigma), Rp-cAMPS (Tocris) were all 
dissolved in deionised water (dH20). HCN2 selective antagonist developed by 
McNaughton Lab, King’s College London.  
 
2.2. Sensory neuron culture 
Dissociated primary DRG cultures were prepared from adult mice (8 weeks, 
C57BL/6, Charles Rivers UK). Mice were culled via Schedule 1 method of cervical 
dislocation. An incision was made through the dorsal skin along the spine, until the 
spine was exposed. The vertebral column was excised and was held by a pair of 
large forceps while a hemisection was carried out through the middle of the column. 
The spinal cord was removed carefully from either side, exposing the DRG capsules. 
DRGs from thoracic, cervical and lumbar spinal levels were aseptically excised and 
kept in HBSS on ice. Approximately, 25-30 ganglia were collected per mouse. DRGs 
were then microdissected to remove attached roots from the DRG capsule, and 
placed in a petri dish containing fresh HBSS solution. DRGs were then digested 
using an enzyme mixture containing 0.125% collagenase type XI (Sigma) and 
10mg/ml dispase (Gibco), which was filter sterilised using a 2mL syringe and 0.22m 
filter. DRGs were incubated in filter-sterilised enzyme mix for 50 min at 37°C and 5% 
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CO2 in a humidified incubator. Enzyme mix was then removed, and DRGs were 
washed in 1 ml of Neurobasal growth medium-A (NB-A, Invitrogen) supplemented 
with 2% B27 supplement (Invitrogen), 1% Glutamax, followed by gentle mechanical 
dissociation using a fire-polished Pasteur glass pipette. Triturated cells were pelleted 
by centrifugation (900rpm approx. for 10 min) through a 10% bovine serum albumin 
(BSA) cushion, prepared by mixing 1mL of HBSS with 0.5 ml 30% BSA Fraction V 
solution (Sigma). 1mL of cell suspension was added to BSA solution in dropwise 
fashion to avoid mixture of two layers and formation of bubbles. Supernatant was 
removed and pellet was washed in 1ml of NB-A medium and spun down again at 
900rpm for 10 minutes. Supernatant was discarded and cells were resuspended in 
appropriate volume of NB-A medium to achieve optimum cell density. Protocol used 
in this study for sensory neuron dissociation was adapted from previously published 
DRG dissociation protocols (Malin et al., 2007). 
 
 
2.3. Preparation of microfluidic chamber (MFC) devices 
MFCs were prepared using a modification of published protocols (Tsantoulas et al., 
2013). Glass dishes (GWst-5040, WillCo Wells) were sonicated in dH20 for 50 min, 
sterilised in 70% ethanol for 5-10 min, rinsed in dH20 three times and left to dry for 2-
3 hours. Sterilised glass dishes were then coated overnight at 37ºC with 0.8mg/ml 
Poly-L-Lysine. Microfluidic devices (Xona Microfluidics, LLC) were sterilized in 70% 
ethanol for 5 min and left to dry out overnight.  
 
The following day, glass dishes were rinsed 3 times with dH20 and left to dry for a 
minimum of 3 hours. Through a series of optimizations, we found that the 3 hour-
drying period was critical for optimal attachment of PDMS MFC to glass plate. As 
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depicted in Figure 6, two types of MFC configurations were used for experiments. 
The 2-channel MFCs enables separation of DRG neurons into 2 compartments 
(DRG soma and DRG axon), and is useful for the interrogation of axonal responses 
to different stimuli such as depolarising stimuli (i.e. KCl), or inflammatory mediators. 
The 3-channel MFC, enables separation of DRG neurons into 3 components: DRG 
soma, the proximal axon and the distal axon. The benefit of using this configuration, 
is that it facilitates the use of pharmacological agents to assess how these can alter 
signals being generated in the distal axons, and the propagation of these signals to 
the cell soma. For instance, a depolarising stimulus such as KCl could be applied to 
the distal axon compartment, which then generates a signal that is propagated to the 
cell body. The propagation of this signal can be blocked by application of 
pharmacological agents to the proximal axon compartment. Thus, further dividing the 
axons into 2 compartments using the 3-channel MFC enables a sophisticated 
method to identify important axonal players responsible for generation and 
propagation of signals in peripheral axons during physiological and pathological 
conditions.  
 
For attachment of the device to the glass dish, the devices were placed on the 
coated glass bottom with the imprinted (microgroove) side down and gentle but firm 
pressure was applied with forceps to form a seal. 200l of 20mg/ml laminin was 
added to the top left (somal side). The laminin was then forced through the channel 
towards the interconnecting well by pipetting at the channel entrance, taking care to 
avoid bubble formation in the device. The chamber was equilibrated at RT for 10 min 
to establish liquid flow through the microgrooves. Once microgrooves were filled up, 
100l of 20mg/ml laminin was added to the top right well (axonal side), in the same 
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manner as the soma side allowing it to flow through the chamber to the 
interconnecting well. Optimal attachment also allows maximised flow rate within the 
chambers. Laminin-coated plates attached to MFC chambers were allowed to 
incubate at 37ºC for overnight.  
 
Figure 6. Different components of microfluidic culture devices. 
A and C) SND450 and TCND500 devices with 450µm and 500µm length of 
microgrooves, respectively, mounted on glass coverslips. B) 2-channel MFC device, 
indicating 4 wells, 2 channels and 450m length of microgrooves. D) 3-channel MFC 
device, with 6 wells, 3 channels and 500m length of microgrooves.  
 
For cell loading, laminin was removed from all wells using a suction glass pipette and 
5l of cell suspension at the appropriate dilution was added at the entrance of the 
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somal channel. Cells would typically enter the channel and slowly move towards the 
exit to the bottom well; when movement was restricted due to high cell density/debris 
or suboptimal flow, then gentle suction was applied to the exit to assist homogenous 
cell dispersion throughout the channel. Chambers should be positioned with a tilt for 
approximately one minute in order for cells to settle close to the microgrooves. This 
procedure was adopted to maximise the number of axonal crossings to the other 
compartment. Next, chambers should be placed on a flat surface for 10 minutes to 
allow cells to attach and settle. Any movement causes cells to lift off the plate at this 
stage, and flow back out of the chambers into the wells. Next, the MFC were placed 
in the incubator at 37ºC for 1-1.5 hours to allow cell attachment. Each well of the 
somal compartment was then supplemented with 200l of 50ng/ml NGF 
supplemented media, which was added taking care to keep the volumes as 
equilibrated as possible to minimize liquid flow through somal channel which would 
disturb cells. The axonal compartment wells were filled with 100µl of 100ng/ml NGF 
supplemented media. NGF was supplemented to facilitate axonal growth through 
microgrooves. Media supplemented with NGF was refreshed every 48 hours, to 
ensure optimal health of cells. Initially two configurations of the MFC device were 
tested: SND150 (microgroove length 150µm) and SND450 (microgroove length 
450µm). However, in the case of SND150, it was observed that a higher number 
non-neuronal cells crossed over to the axonal compartment. We therefore concluded 
that SND450 would be used for most experiments unless specified otherwise. 
 
2.4. DiI Trancing of cell bodies with axons traversing the microgrooves  
After 5 days in culture, the neurons with axons that had traversed through the 
microgrooves and into the axonal compartment were stained with a fluorescent 
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tracer, DiI (Invitrogen, 1:200). The DiI tracer is a fluorescent lipophilic cationic 
indocarbocyanine dye usually made as a perchlorate salt, which is commonly used 
for in vivo tracing of neurons (Perrin and Stoeckli, 2000). DiI tracer was loaded to the 
axonal compartment, and was then retrogradely transported to the cell bodies in the 
somal compartment overnight via lateral diffusion in the plasma membrane. This 
property enables tracing axonal projections over long distances, and which can be 
maintained over long periods (Godement et al., 1987).  
 
More specifically, media was removed from axonal wells, and 200 µl of 1:200 DiI was 
added to the top axonal well to allow dye to flow through chamber to the bottom 
axonal well. 200 µl of DiI was then added to the bottom axonal well. Microfluidic 
chambers were incubated with DiI for 1 hour. DiI solution was then removed, and 
NB-A media was added to the axonal compartment. Cell bodies in the somal 
compartment stained with the dye were visualized 24 hours after DiI-staining of 
axonal compartment using RITC filter set on a microscope with epifluorescence 
optics (Nikon Eclipse TE200). 
 
 The use of the DiI tracer in this system was crucial to enable the following:  
 1. Identification of the DRG cell bodies in somal compartment with axons that 
had traversed to the axonal compartment by Div 5, from those cell bodies with 
axons that had not crossed over. Only the DiI-stained cell bodies (indicative of 
axonal crossing to axonal compartment) were chosen for further analysis.  
2. Ensured that further analysis such as calcium imaging recordings as 
detailed in the next section, was carried out in neuronal cell bodies as 
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opposed to non-neuronal cells present in the somal compartment, as the DiI 
diffuses from the axons and can only diffuse laterally within the neuronal cell.  
 
2.5. Calcium Imaging and Analysis 
Neurons in the somal compartment were loaded with 2 µM of the calcium indicator 
dye Fura-2-AM (Invitrogen) and 1mM probenecid (Sigma) in imaging buffer for 45 
min at 37°C. Imaging buffer consisting of Ca2+ and Mg2+ -free HBSS, (Gibco) 
containing 5.3mM KCl, 0.44mM KH2PO4, 4.1mM NaOHCO3, 137mM NaCl, 0.33mM 
Na2PHO4, 5.55mM D-Glucose and 0.03mM Phenol Red, was supplemented with 1 
mM MgCl2, 2 mM CaCl2, 10 mM HEPES (Gibco). Both MFC compartments were 
washed twice with imaging buffer before the assay commenced. Microfluidic cultures 
were mounted on an inverted microscope connected to an EasyRatioPro imaging 
system (Photon Technology International, UK), comprising of an ORCA 4.2 sCMOS 
camera (Hamamatsu, Japan) and analysis software (EasyRatio Pro). First, bright 
field and DiI staining were visualised and only neurons exhibiting staining in the 
soma (indicative of axonal crossing) were chosen for further analysis. Areas of 
interest (ROI) were drawn around the corresponding cell soma and fluorescent 
images at 510nm were collected at 3.3Hz using 340 and 380 nm excitation 
wavelengths produced by a monochromator (Photon Technology International, UK).  
 
Of note, KCl solutions were made up using Ca2+ imaging buffer containing 5.3mM 
KCl and therefore, making up 15mM KCl, 30mM and 60mM KCl in Ca2+ imaging 
buffer, resulted in a final bath concentration of 20mM, 35mM KCl, and 65mM, 
respectively. Axonal responses were always acquired first, while somal stimulation 
was applied at the end of the assay to avoid desensitization or apoptotic cell death 
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due to larger Ca2+ influx upon direct somal stimulation. Each drug application was 
separated by two washes in imaging buffer followed by a 10-minute rest period. 
Throughout the assay, caution was taken to retain the fluidic isolation between somal 
and axonal compartments (i.e. for axonal stimulation volume was higher on the 
somal compartment and this was reversed for somal stimulation). Protocol for 
calcium imaging in MFC chambers was adapted from a report previously published 
by our lab (Tsantoulas et al., 2013). 
 
2.6. Treatment of Nociceptive Axons with Inflammatory Mediators 
On day 6, the axonal responses were assayed. Baseline calcium responses of DiI-
positive cell bodies was recorded as a readout for baseline axonal excitability with a 
short 20 sec stimulation with 20mM added to the axonal compartment. Following this 
baseline recording, the imaging buffer in the axonal compartment was then replaced 
with media containing a cocktail of inflammatory mediators (IM) consisting of 10mM 
PGE2, 10mM Histamine, 10mM Bradykinin and 10mM Serotonin and incubated at 
37C for 2 hours. These particular IMs and concentrations were chosen based on 
published studies in the literature, showing that exposure of this combination of IM to 
neuronal cultures in vitro results in a significant sensitisation of neuronal cell bodies 
and in single nerve-fibre preparations in vivo (Grossmann et al., 2009; Ma et al., 
2006). Wells on the soma side were topped up with media to maintain a difference in 
volume of 100µL between compartments ensuring an adequate pressure gradient 
and fluidic isolation was sustained throughout experiments. Media was removed 
from both wells on the axonal side, and 150 µl of IM was added to the axonal 
compartment. Chambers were incubated at 37C with IM for 2 hours. Finally, the 
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same field of cells and ROIs used for the baseline recordings were used to repeat 
the axonal stimulation with 20mM KCl added after IM treatment (Figure 7).  
 
 
Figure 7. Protocol used for assessing changes in axonal excitability before 
and after IM treatment. 
Protocol used is divided into three main steps. Step 1: Axonal responses were 
recorded to initial 20 second stimulus with 20mM KCl. Step 2: Axonal compartment 
was incubated with IM treatment for 2 hours. Step 3: Same FoV was found, and 
same ROIs were chosen as in step 1 were selected. Axonal responses were 
recorded after IM treatment, to 20 second stimulus with 20mM KCl.  
 
 
2.7. Voltage Imaging and Analysis 
For voltage imaging experiments, the voltage indicator Fluovolt (purchased from Life 
technologies) was used. Fluovolt voltage sensor is able to detect changes in voltage 
by modulation of photo-induced electron transfer (PeT) from an electron donor 
through a membrane-spanning synthetic molecular wire to a fluorophore or 
fluorescent reporter. Briefly, when a cell is hyperpolarised, the electric field is aligned 
opposite to the direction the electron transfer which results in effective PeT, and 
quenching of fluorescence. However, at depolarising potentials, the electric field is 
aligned parallel to the transfer of electrons resulting in reduced electron transfer, and 
thereby increasing fluorescence (Miller et al., 2012). DRG axons in the axonal 
compartment were loaded with the voltage indicator Fluovolt (Life Technologies), 
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and PowerLoad Concentrate (Life Technologies) in imaging buffer for 15 min at 37°C 
according to the manufacturer’s manual for Fluovolt Membrane Potential Kit (Life 
Technologies). Following dye loading, the MFCs were mounted on an inverted 
microscope connected to an EasyRatioPro imaging system (Photon Technology 
International, UK), comprising of a CMOS camera (Hamamatsu, Japan) and analysis 
software (EasyRatio Pro) capable of acquiring digitized images every 20 ms upon 
illumination with the appropriate light source. Standard FITC filters were used for 
visualization and imaging Fluovolt. Fluorescent images at 388nm excitation were 
collected at 50 Hz using a 535nm emission. 
 
2.8. Immunocytochemistry 
For optimal incubation of DRG cells with any antibody solution or wash buffer, the 
following steps were carried out: solution was added to the somal top well (A) and 
allowed 30 seconds to flow to the somal bottom well (B). Following this, both A and B 
wells were topped up and allowed 1 minute for solution to flow across microgrooves. 
Finally, solution was added to the axonal top well (C) and allowed 30 seconds to flow 
through to the axonal bottom well (D) (Figure 8).  
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Figure 8. Steps followed for optimal antibody incubations and washes in MFC 
system. 
Solution should be added to Well A, and allowed 30 seconds to flow through the 
channel to fill up Well B, a change in colour should be noted as the solution flows 
through. Next, top up both Well A and Well B, and allow 1 minute for solution to flow 
through microgrooves. Finally, add solution to Well C and allow 30 seconds for 
solution to flow through to Well D.  
 
 
Media was removed from all MFC wells and washed with D-PBS once. Cells were 
fixed with 4% PFA at RT for 15 minutes. Next, cells were washed 3 times with D-
PBS for 5 minutes.  
D-PBS was removed and cells were incubated with blocking solution (10% normal 
donkey serum in 0.2% PBS-Tritan X, with 0.2% Sodium Azide) for 60 minutes. 
Blocking solution was then removed and primary antibody solution containing mouse 
Nav1.8 (1:500, Neuromab) and rabbit EP4 C-terminal (1:500, Cayman chemicals) 
primary antibodies in 10% normal donkey serum in 0.2% PBS-Tritan X, with 0.2% 
Sodium Azide. Cells were incubated with primary antibody overnight at 4ºC, in the 
dark. On the following day, primary antibody solution was removed and washed 4 
times with D-PBS. Secondary antibody solutions Alexa 488 anti-mouse and Alexa 
546 anti-rabbit antibodies in blocking buffer were added. Cells were incubated with 
secondary antibody solution in the dark for 60 minutes at room temperature (RT). 
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Negative controls received secondary antibody solution only. Finally, cells were 
washed 4 times with D-PBS.  
During the last wash with D-PBS, MFC devices were kept at 4ºC for 5 minutes to 
allow detachment of PDMS device glass bottom plate. Using forceps, the PDMS 
device was gently lifted off Willco glass plate. Finally, coverslips were mounted with 
fluorescence mounting medium containing 4,6-diamidino-2-phenylindole (DAPI) and 
placed on the area of the glass with the MFC print. Cells were kept at 4ºC in the dark 
before visualization.  
2.9. HCN2 knockout mice  
All animals were housed in a designated facility, maintained in accordance with 
Home Office regulations. Animals were kept in a 12hr light-dark cycle and fed ad 
libitum. Animals were sacrificed using Schedule 1 method of cervical dislocation. 
Globally deficient HCN2 mice were generated as published previously in 
supplementary methods section by Emery et al., 2011. Briefly, heterozygotes (HCN+/-
) were bred and HCN+/+, HCN+/- and HCN-/- were obtained in Mendelian ratios. Ear 
snips were taken from each animal at Day 21 by animal facility staff and tail snips 
were taken after dissection of DRGs to cross-check genotype.  
 
DNeasy Blood and Tissue Kit, (Quiagen) was used for purification and extraction of 
genomic DNA. Resulting total DNA was quantified by spectrophotometric 
absorbance at 260/280nm on a NanoDrop system. Master mix for PCR was made 
containing 5µL of GoTaq Green Mastermix (Promega), 1µL of common forward 







Table 1), and 1µL of RNAse-free H20 per reaction. 9 µL of Master Mix was then 
added in Eppendorf PCR tubes (Sigma), after which 1 µL of DNA sample was added 









Table 1. List of primer pairs used for genotyping of HCN KO and WT mice. 
 
Sealed Eppendorf PCR tubes were placed in a thermal cycler (GeneAmp PCR 
System 9700, Thermo Fisher Scientific), used for amplification of DNA. The PCR 
protocol comprised of the following: pre-incubation at 94C for 5 minutes, 
denaturation at 94C for 30 seconds, annealing at 57C for 30 seconds and 
extension reaction at 72C for 40 seconds, followed by a final extension for 7 
minutes.  40 repeat cycles were performed and tubes were held at 4C at the end of 
the protocol. PCR products were resolved on 0.8% agarose gel, made up in TBE 
buffer (45mM Tris-Borate and 1mM EDTA). PCR products were loaded onto wells 
and gel was run at 95V for 30 minutes.  
 
 Primer Pairs 
HCN KO  
FW: AAGCCTTCTCTGCGGTCTGG  
Rev: GCTGGCAGGCATCAGATACC  
HCN WT 
FW: AAGCCTTCTCTGCGGTCTGG  
Rev: AGAACCTGGAGAGAGGCAGG  
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Pairing of the common forward primer (FWD), a sequence complementary to the 
intronic sequence upstream of exon 2, with the HCN2 WT primer (REV WT), a 
sequence that binds to exon 2, gives a product of 415bp, indicative of the presence 
of the HCN2 gene. Whereas, pairing of the common forward primer and the HCN2 
KO reverse primer, a sequence complementary to the intronic sequence 
downstream of exon three, giving a product of 800bp indicative of HCN2 gene 
deletion (Figure 9). 
 
Figure 9. Genotyping of HCN2 WT and KO mice.  
A) Common forward primer (Fwd) is complementary to the intronic sequence 
upstream of Exon 2. The reverse WT primer (Rev WT) binds within Exon 2. Pairing 
of Fwd and Rev WT, gives a product 415bp, verifying the presence of the HCN2 
gene. B) Exons 2 and 3, which code for 5 of the 6 transmembrane regions of the 
HCN2 channel, were flanked with LoxP sites. Mice with HCN2 gene flanked with 
loxP sites, floxed, were provided by MSD Pharmaceutical, Scotland. C) Global HCN2 
KO mice were generated by pairing homozygous floxed HCN2 mice with mice with 
globally expressed Cre, resulting in excision of Exons 2 and 3.  D) Pairing of Fwd 
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with reverse KO primer (Rev KO), results in a product of 800bp, verifying the deletion 
of the HCN2 gene. (Adapted from (Emery et al., 2011b). 
 
 
Heterozygous HCN2+/-  mice were bred and produced willd type, HCN+/- and HCN-/- 
offspring in Mendelian ratios. Cre/LoxP system was used to delete gene encoding 
HCN2. Exons 2 and 3, coding for 5 and 6 transmembrane segments of the channel, 
were deleted to produce global HCN KO-/-.  HCN KO and WT mice were genotyped. 
Two bands were identified for HCN+/-, one band of 415bp was observed for HCN WT 
mice and 800bp band was observed for HCN KO mice (Figure 10). Phenotypical 
differences were also notable, as HCN2 KO mice appeared also to be smaller size 




Figure 10. PCR of genomic DNA from DRG of HCN+/+, HCN -/- and HCN +/- 
All primers were mixed together prior to amplification. Forward common primer + WT 
reverse primer yields one band of 415bp, indicative of the presence of exon 2 and 
the intact HCN2 gene (415 bp). Forward common primer + KO reverse primer yields 
one band of 800bp, indicative of the excised HCN2 gene without exons 2 and 3. Two 
bands (800bp and 415bp) were observed in the case of heterozygote mice (HCN+/-). 
 
2.10. iPSC-derived human nociceptive neurons 
Human-derived induced pluripotent stem cells were provided by Axol Bioscience, 
UK. Cells were thawed according to the manufacturer’s protocols. Briefly, thawed 
cell suspension was transferred into a 15mL falcon conical and resuspended in 9mL 
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of Neural-XF Plating Medium in a slow, drop-wise manner. Cells were then 
centrifuged at 200rpm for 5 minutes at room temperature. Supernatant was 
discarded and cells were resuspended in 1mL of Neural-XF plating Medium to 
achieve single cell suspension. Cells were resuspended in appropriate volume of 
Neural-XF plating medium to achieve optimal cell loading and density for coverslips 
or MFCs. The day after plating, Neural-XF plating medium was replaced with 
Sensory Neuron Maintenance Medium supplemented with growth factors (25ng/ml 
GDNF, 25ng/ml NGF, 10ng/ml BDNF and 10ng/ml NT-3). In some cultures, as stated 
in chapter 6, GDNF concentration was increased to 125ng/ml. In order to prevent 
growth of non-neuronal cells in culture, 3 days after plating all cultures treated with 
Sensory Neuron Maintenance medium containing 3µg/ml Mitomycin-C. Cells were 
incubated for 1 hour at 37C. After incubation period, cells were washed gently twice 
with Ca2+ and Mg2+ -free D-PBS (1x) and cells were supplemented with Sensory 
Maintenance Medium supplemented with growth factors.  
 
To ensure optimal culture conditions, half the volume of medium was replaced with 
pre-warmed medium every 3 days. Neurons were maintained in culture for 4 weeks, 
to allow growth and maturation of neurons. Endpoint assays were carried out 4 
weeks after plating.   
2.10.1. Preparation of coverslips for hIPSCs   
Glass coverslips were sonicated in dH20 for 40 min, sterilised in 70% ethanol for 5-
10 min, rinsed in dH20 three times and left to dry for 2-3 hours. Sterilised glass 
dishes were then coated for different durations at 37C with ReadySet (Axol 
Biosciences, USA) to establish optimal coating conditions as discussed further in 
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chapter 6. An equal volume of dH20 was used to wash the glass plates, 4 times for a 
duration of 5 minutes each.  
 
 
2.10.2. Preparation of MFCs for hIPSCs   
Microfluidic devices (Xona Microfluidics, LLC) were sterilized in 70% ethanol for 5 
minutes and left to dry out overnight. The TCND500 design (triple compartment 
chamber, with microgroove length of 500µm) was used for these experiments.  
 
For attachment of the device to the glass dish, the MFC chamber was placed on the 
dry, coated glass bottom with the imprinted (microgroove) side down and gentle but 
firm pressure was applied with forceps to form a seal. SureBond (Axol Biosciences, 
USA) diluted in D-PBS was used, for second coating stage.  Surebond solution was 
added to the MFC chamber following the steps illustrated in Figure 8 for optimal and 
even coating across microgrooves and all channels. Chambers were allowed to 
incubate at 37C for 1 hour.  
 
For MFC loading approximately 70,000 were loaded per chamber. SureBond was 
removed from all wells using a suction glass pipette and 5µl of cell suspension in the 
appropriate dilution was added at the entrance of the somal channel. Next, the 
chambers were placed in the incubator at 37C for 90 minutes to allow cell 
attachment. Following this, each well of the somal compartment was supplemented 
with 200µl of Neural- XF plating Medium (Axol Bioscience, UK), taking care to keep 
the volumes as equilibrated as possible to minimize liquid flow through somal 
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channel which would disturb cells. The axonal compartment wells were filled with 
100µl of Neural- XF Plating Medium.  
 
2.11. Data Analysis  
For Ca2+ imaging experiments, Fura-2AM dye was used to quantify changes in 
intracellular Ca2+ levels by calculating the ratio of emission at 340nm and 380nm 
excitation wavelengths, expressed as fluorescence intensity F340/F380 ratio (Fratio).  
Fratio was plotted against time (seconds) for each DiI-stained cell body, selected as a 
region of interest (ROI). Fluorescence intensity measurements from all ROIs were 
imported into Clampfit 9.0 software for calculation of maximum response (ΔFratio), 
calculated as difference between the maximum response and baseline (Figure 11), 
as well as area under the curve (AUC). Percentage of responders out of DiI-stained 
neurons were counted manually, through visual inspection of all ratio plots. For 
neuronal IM-induced sensitisation experiments, changes in the amplitude of 
response were expressed as fold change, measured as changes in maximum 
response to KCl stimulus after IM-treatment over maximum response to KCl stimulus 
before IM-treatment.  
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Figure 11. Measure of fluorescence intensity in calcium imaging experiments 
Illustration of representative trace of fluorescence intensity or F340/F380 (Fratio) 
measured over time. Change in fluorescence intensity using Fluo-4 dye and Fratio 
using Fura-2 dye were measured as the difference between the baseline and 
maximum response.  
 
 
For analysis of voltage signals, scripts were created for automated analysis of 
images compatible with Fiji software (Schindelin et al., 2012). The first 200 images 
(before application of stimulus) were averaged to calculate the mean baseline image. 
The calculated average baseline image was then subtracted from all images to 
create F/F images, highlighting the responding areas along the DRG axon. Fiji 
particle analysis tool was used to select responding areas Sequence of images were 
visually inspected to discard artefacts of movement. Fiji software’s particle analysis 
tool was used to select responding areas as ROIs across all F/F images. A positive 
response was assigned to a neuron when a maximum increase in Fratio greater 
than 3 times the standard deviation above baseline (calculated at least 5s prior to 
drug application), following drug application. All positive responses and maximum 
responses were confirmed by visual inspection of the ratio plots.  
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Statistical testing was performed using Microsoft Excel and GraphPad Prism 
software (Version 5.02, 2008, GraphPad Software Inc.). Two-tailed student’s t-test, 
was used to determine statistical significance between two groups, whereas  one-
way analysis of variance (ANOVA) was used for experiments with 2 or more groups. 
Tukey’s post-hoc test was used to analyse the data further for multiple comparisons. 
For normalised data, non-parametric statistical tests were used. Man-Whitney U test 
was used for comparison between two groups, and the Kruskal-Wallis test was used 






3. Development of MFC-based in vitro assay to model 
peripheral sensitisation   
 
 
3.1. Introduction  
 
3.1.1. Current models of inflammatory peripheral sensitization  
There are a number of animal models that have been used over the years for the 
study of inflammatory pain sensitisation. Compounds can be injected into the joint, 
muscle or plantar surface of the hind paw to produce sensitisation of peripheral 
sensory fibres. CFA, carrageenan, capsaicin, formalin, zymosan, and the mustard oil 
models are the most commonly used (Dobretsov et al., 2011). These models have 
been essential in the discovery of inflammatory pain mechanisms, yet significant 
gaps in our understanding of evoked and ongoing pain in human pain conditions 
remain. Technical difficulties often preclude the use of in vivo models to test 
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hypotheses at a molecular level. Further, multicellular responses in vivo complicate 
interpretation of the data when trying to elucidate mechanisms intrinsic to a particular 
cell-type. Hence, there is a need for in vitro models that allow interrogation of the 
molecular underpinning of inflammatory pain mechanisms, specific to peripheral 
neurons. However, currently, in vitro models focus primarily on IM-induced functional 
and expression changes occurring only at the neuronal cell bodies, side-lining other 
important structural components of peripheral sensory fibres. Moreover, during an 
inflammatory response in vivo, IMs are released at the site of injury and act on 
peripheral terminals whereas DRG cell bodies are not exposed to IMs directly. 
 
The need for peripherally targeted therapeutic agents with reduced unwanted side 
effects has focused researchers’ attention towards understanding how IM induced- 
changes in ion channel function and expression at the nerve terminals contribute to 
altered nociceptor function, as these findings could form the basis of new therapeutic 
strategies. It is assumed that ion channel properties and expression patterns are 
similar at the level of the cell body, axon, and nerve terminals despite the clear 
structural differences between the different sub-compartments of the neuron.  In 
order to gain knowledge of the mechanisms underlying the interaction of IMs with ion 
channels found along the nerve endings, new models need to be developed. 
 
3.1.2. Currently available methods to study functional properties of primary 
afferents  
Both in vivo and ex vivo methodologies, such as the skin-nerve preparation, have 
enabled single unit recordings from nerve fibres have been critical for revealing the 
different types of nociceptor activated by noxious stimuli (Lawson, 2002; 
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Zimmermann et al., 2009). However, this technique is notoriously hard to maintain 
for multiple hours, producing low signal-to-noise ratio data that is difficult to interpret.  
 
Campenot introduced in vitro systems that allow compartmentalization of the neuron 
into two separate areas containing either the cell body or neurite (Campenot, 1994).  
These first generation microdevices comprised of a Petri dish attached to a Teflon 
divider with silicon grease, which provided separation of the cell bodies and axons. 
Over the past decade, several adaptations of the compartmentalized cell culture 
system have been reported. Usoskin and colleagues reported the use of a gel-
cushion axonal compartment, with a microenvironment that mimics the in vivo 
environment of nerve endings (Usoskin et al., 2010).  However, important caveats of 
this technique include lack of reproducibility between devices, leakiness and 
significant challenges in assembly of the device which have been reported.  
 
Recent publications have reported the use of porous filters for isolation of axons from 
sensory neurons, where axons pass through pores and grow along the bottom 
surface of the filter whilst neuronal cell bodies remain isolated on top. This technique 
results in the isolation of a population of pure axons, without contamination from non-
neuronal cells. A major disadvantage of this technique however is its reliance on the 
use of still-developing embryonic DRG, as mature DRG neurons are not able to 
survive in this system (Unsain et al., 2014).  
3.1.3. Use of microfluidic chambers to study axonal mechanisms  
“Microfluidics” refers to a system that allows manipulation of extremely small (10-9L 
or 10nL) volumes of fluids through a network of channels and chambers ranging 
from tens to hundreds of micrometres in size (Gross et al., 2007). High resistance 
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microchannels between both compartments allow a slow and sustained flow, which 
provides a barrier to the diffusion of molecules between the compartments (Taylor 
and Jeon, 2010). Compartmentalised microfluidic-based systems use 
polydimethylsiloxane (PDMS) soft lithography to produce devices enabling fluidic 
isolation of the two compartments of a neuron: an “axonal” and cell body or “somal” 
compartment. The advantages of this system include low reagent volumes required, 
better control of cellular microenvironments and highly sequential experimentation 
(Kim et al., 2012). This enables isolated treatment of both compartments, facilitating 
the investigation of axonal properties that are independent of the cell body.  
 
Microfluidic devices have gained popularity and have been used for a number of 
applications such as the delivery of biochemical molecules, flow cytometric cell 
counting, and cell sorting (Huh et al., 2005; Kartalov and Quake, 2004; Kartalov et 
al., 2006; Sackmann et al., 2014). Recently, microfluidics has been adapted for use 
in neurobiology as peripheral axons can be isolated and grown in a particular 
direction, in the presence or absence of neurotrophins, providing an extremely 
versatile and adaptable system to model many aspects of neuronal sensitisation and 

































3.2. Rationale and Aims 
 
The objective of the initial part of my project, as described in this chapter, was to use 
a microfluidic based platform to develop a model enabling the study of mechanisms 
intrinsic to peripheral nerve fibres contributing towards nociceptor sensitisation, 
during inflammatory environments.  
 
My objective was to develop and validate a microfluidic-based in vitro assay of 
peripheral sensitisation using adult DRG neurons in MFCs. This was achieved by 
isolating adult DRG axons in different configurations of MFC devices, to be able to 
distinguish between different mechanisms occurring in different components of DRG 
neurons. Next, we characterised distinct responses to locally applied chemical 
stimuli, in the axonal and somal neuronal compartments and aimed to exploit the 
developed MFC system as a tool to model peripheral sensitization more accurately 
allowing localized treatment of inflammatory mediators of isolated axons. 
Development of this model would enable better understanding of axonal 
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3.3. Results  
 
3.3.1. Culturing adult DRG neurons in MFCs 
 
 
Tsantoulas and co-workers had previously developed a MFC-based platform for the 
use of embryonic DRG neurons, in which case successful crossing of embryonic 
DRG axons through the microgrooves and into the axonal compartment was 
achieved by setting up a NGF gradient across the different compartments, with the 
somal compartment containing medium supplemented with 50ng/ml NGF, and the 
axonal compartment with medium supplemented with 100ng/ml NGF (Tsantoulas et 
al., 2013). Studies have demonstrated that NGF acts as a chemoattractant for 
embryonic sensory neurons, and is required for target innervation (Gundersen and 
Barrett, 1979; Paves and Saarma, 1997). However, it has been shown that NGF 
dependence of DRG neurons is only prominent during embryonic stages, as both 
rodent and human adult DRG neurons are able to survive and conserve their 
sensory modalities in the absence of NGF (Dodge et al., 2002; Ruit et al., 1992; 
Sosa et al., 1998). In support of this, a study demonstrated that using an NGF 
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gradient failed to direct growth of adult naïve DRG axons in vitro (Webber et al., 
2008). Thus, we aimed to assess whether growth of axons of adult DRG neurons 
could be directed towards the microgrooves and the axonal compartment of the MFC 
device, and whether axonal isolation could be achieved using adult DRG neurons.  
 
Here, we demonstrate that adult DRG axons do traverse the microgrooves and we 
were able to obtain axonal isolation in MFCs by DIV 5 (Figure 12B-C). To visualize 
the cell bodies with axons that have crossed the microchannels, DiI tracer was 
applied to the axonal compartment. DiI was incorporated into the cell membrane of 
the axons, before retrograde transportation to the cell bodies allowing for 
visualisation 24 hours post-staining. Positive DiI staining indicates cell bodies with 
axons that have crossed over to the axonal compartment (Figure 12D-E). Cell 
bodies closer to the microgrooves typically showed a stronger signal, as those 




Figure 12. DiI stain indicative of DRG cell bodies with axons that have 
traversed to the axonal compartment 
Representative images of adult DRG neurons at DIV 7 in MFCs. A) Schematic 
showing diagram of MFC device, highlighting somal and axonal compartments and 
indicating application of DiI to the axonal compartment. B) Bright field (BF) image of 
somal compartment of MFC, showing total number of cell bodies in a given field. C) 
BF image of axons shown in axonal compartment of MFC. D) DiI-stained soma in the 
somal compartment are observed, indicative of cell bodies that have crossed over to 
the axonal compartment. E) DiI-stained axons in the axonal compartment (n=3 mice, 




We next aimed to see whether axons of adult DRG neurons can be fluidically 
isolated and readily maintained in the 3-channel MFC device. Using the 3-channel 
MFC would enable more specific pharmacological investigation for future 
experimentation, as it divides DRG neurons into three subcellular components: the 
distal axons, proximal axons and cell bodies. Our lab had previously published the 
use of this configuration of the MFC device using embryonic mice (Tsantoulas et al., 
2013). In our hands, we found that fluidic isolation adult DRG axons was achieved in 
3-channel MFC device (Figure 13E-H), in a similar manner to that observed in the 2-
channel MFC device (Figure 13A-C). DiI was added to the distal axonal 
compartment (Figure 13H) before being retrogradely transported to the cell bodies in 
the somal compartment. Adult DRG neurons were able to cross over to the distal 
axonal compartment by DIV 7 in 3-channel device. Percentage of DiI-positive cell 
bodies (or neurons with axons that cross over to distal axonal compartment), and 
percentage of cell bodies that respond to KCl stimulation of distal axons in the 3-
channel device. Firstly, it was found that not all the cell bodies had axons that had 
traversed through the microgrooves. In the 2-channel MFC device (Figure 13D), 
approximately, 60% of the cell bodies out of the total number of DRG soma found in 
the somal compartment were positive for DiI, indicating that only 60% of the total 
number of cell bodies’ axons had reached the axonal compartment by DIV 5. 
Surprisingly, we also found that only 40% of the DiI- stained neurons are responsive 
to axonal stimulation with 20mM KCl. The exact reason for this is not known, 
however we speculate that lack of maturity of axons at DIV 5 may explain why some 
cell bodies don’t exhibit responses to stimulation of axons with 20mM KCl. In the 3-
channel MFC device (Figure 13I), an average of 32% of the total number of cell 
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bodies’ axons reached the distal axonal compartment 5 days after plating and only a 
24% of the DiI- stained neurons are responsive to axonal stimulation with 20mM KCl. 
Although the 3-channel MFC device enables more detailed interrogation of 
subcellular components of adult DRG neurons, the 2-channel MFC device is a more 
high-throughput system enabling the study of axonal function in a greater number of 




Figure 13. Adult DRG neurons in 2-channel and 3-channel MFC devices 
A) Schematic of 2-channel MFC B) DiI-stained cell bodies in somal compartment of 
2-channel MFC. C) DiI-stained axons traversing across microgrooves into axonal 
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compartment of 2-channel MFC. D) Bar graph illustrating number of DiI-stained cell 
bodies, and axonal responders to 20mM KCl in 2-channel MFC device. E) Schematic 
of 3-channel MFC. F) DiI-stained cell bodies in somal compartment of 3-channel 
MFC. G) DiI-stained axons traversing across microgrooves into axonal compartment 
of 3-channel MFC. H) DiI-stained axons in peripheral terminal compartment of 3-
channel MFC. I) Bar graph illustrating number of DiI-stained cell bodies, and axonal 
responders to 20mM KCl in 3-channel MFC device. Bar graphs illustrating mean ± 
S.E.M, where bars represent the % of cell bodies per field of view, including the total 
number of cell bodies, DiI- stained cell bodies (indicative of axonal crossing), and the 
responders to axonal 20mM KCl stimulation (n=8 mice, 14 MFCs, 56-60 DRG 
neurons). Scale bars, 100m. 
 
Next, we set out to establish a robust and reproducible method to measure axonal 
function in vitro taking advantage of the MFC platform. Fluidically isolated axons 
were stimulated by application of increasing concentrations of KCl in the axonal 
compartment.  Ca2+ responses were recorded from the neuronal cell bodies in the 
somal compartment as a readout for axonal excitability (Figure 14A). We aimed to 
establish the optimal concentration required to depolarise all axons and to produce a 
detectable signal at the cell body. Application of 20mM, 35mM and 65mM KCl 
solution to the axonal compartment resulted in a rapid increase in fluorescence 
signal in neurons with axons that had crossed into the axonal compartment (DiI-
positive) at DIV 5 (Figure 14B-F). Axonal stimulation with KCl resulted in a transient 
response, characterised by a rapid onset and return to baseline before wash-out of 
KCl, as reported previously by (Tsantoulas et al., 2013).  Percentage of responders 
after axonal and somal stimulation with KCl were also quantified. Axonal stimulation 
with 20mM, 35mM and 65mM KCl showed 51.5% ± 6.5, 50% ± 2.5 and 48% ± 7 
responders in a given field, respectively at DIV 7 (Figure 14G). The percentage 
responders did not linearly correlate with increasing concentrations of KCl (20mM, 
35mM and 65mM, respectively). Using a lower concentration of KCl could perhaps 
provide a graded response in terms of the number of responders, this could be 
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tested in future experiments. However, these data suggest that application of 20mM 
KCl is sufficient to depolarize all the axons that have crossed through the 
microgrooves. If stimulation with 20mM was subthreshold, it would be expected that 
stimulation with a higher concentration of KCl (in this case 35mM and 65mM) would 
result in larger percentage of responders.  
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Figure 14. Characterisation of axonal responses to KCl in the MFC system. 
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Representative traces showing changes in Ca2+ concentration at the soma in 
response to KCl stimulation in the axonal compartment. A) Experimental set up: 
axonal compartment was stimulated with a given chemical stimulus and changes in 
[Ca2+]in in the cell bodies were measured. B) Changes in [Ca2+]in are measured as 
∆Fratio in response to axonal stimulation with added 20mM KCl. C) Changes in 
[Ca2+]in in response to axonal stimulation with 35mM KCl. D) Changes in [Ca2+]in in 
response to axonal stimulation with added 65mM KCl. E) Quantification of maximum 
responses to added 20mM, 35mM and 65mM KCl. F) Quantification of AUC of 
responses to added 20mM, 35mM and 65mM KCl. G) Percentage of responders 
from the DiI-stained cell bodies in a given field. Bar graphs showing data as mean ± 
S.E.M, where white bars represent response to axonal stimulation and black bars 
represent response to somal stimulation with KCl (n=3 mice, 5 MFCs, 20-25 DRG 
neurons). 
 
In order to validate our method of measuring axonal function (stimulating axons and 
recording at the cell bodies), we stimulated cell bodies directly with increasing 
concentrations of KCl. We found that stimulation of cell bodies in somal compartment 
exhibited markedly different kinetics compared to the Ca2+ responses obtained from 
axonal stimulation with 35mM and 65mM KCl (Figure 15A-C). Maximal responses 
and AUC of responses to axonal stimulation with KCl were also quantified (Figure 
15D-E). Responses to somal stimulation displayed a slower onset, with a return to 
baseline only after the wash-out of KCl. Somal stimulation with KCl produced a 
100% response rate at all concentrations, whereas approximately 50% of neurons 
were responsive axonal stimulation with KCl (Figure 15F). The clear difference in 
the type of responses when stimulating the axonal compartment compared to when 
we stimulated the somal compartment with KCl, provides evidence validating our 
method as a robust and reproducible technique to measure axonal function in vitro. 
Moreover, somal stimulation with KCl served as a positive control in future 
experiments as an indicator of health of the neurons, optimal culture conditions and 





Figure 15. Characterisation of somal responses to KCl in the MFC system. 
A)Experimental set up: somal compartment was stimulated with a given chemical 
stimulus and changes in [Ca2+]in in the cell bodies were measured. B) Changes in 
[Ca2+]in at the soma measured as ∆Fratio in response to stimulation with 35mM KCl. 
C) Changes in [Ca2+]in at the soma measured as ∆Fratio in response to stimulation 
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with 65mM KCl in the somal compartment. D) Quantification of maximum responses 
to 35mM and 65mM KCl. E) Quantification of AUC of responses to 35mM and 65mM 
KCl. F) Percentage of responders as determined by DiI-stained cell bodies in a given 
field. Bar graphs showing data as mean ± S.E.M, where white bars represent 
response to axonal stimulation and black bars represent response to somal 
stimulation with KCl (n=3 mice, 5 MFCs, 20-25 DRG neurons). 
 
Using the 3-channel MFC, Tsantoulas and co-workers demonstrated that electrical 
stimulation in the distal axonal compartment results in AP arriving at the DRG cell 
soma, which can be blocked by perfusion of lidocaine to the middle axonal 
compartment (Tsantoulas et al., 2013). The reported findings and the notably distinct 
kinetics of KCl responses after axonal and somal stimulation observed in this study, 
suggest that distinct mechanisms are responsible for the generation of Ca2+ signals 
at the DRG cell body compared to the DRG axon. We propose that stimulation of 
DRG axons with KCl results in the depolarisation of axons and generation of bursts 
of Aps that propagate towards the cell soma, resulting in a transient Ca2+ signal. On 
the other hand, stimulation of the DRG cell bodies with KCl results in depolarisation 
of the somal membrane, and the direct opening of voltage-gated Ca2+ channels at 
the somal membrane resulting in an influx somal Ca2+ which is maintained until the 
washout of KCl (Figure 16). In future experiments, it would be interesting to test this 
hypothesis by assessing whether application of a known voltage-gated calcium 
channel blocker to the somal compartment inhibits the somal Ca2+ response to KCl. 
Nonetheless, taken together, these experiments demonstrate that nociceptive axons 
from adult mouse DRG neurons in MFCs respond to stimulation in isolation from the 
soma, and their response to stimulation can be assayed by measuring a local 





Figure 16. Distinct mechanisms underlying somal and axonal stimulation in 
DRG neurons. 
A) Axonal stimulation leads to generation of a volley of action potentials travelling to 
the soma, which then depolarize the somal membrane. B) Somal stimulation results 




3.3.2. Development of a MFC-based in vitro assay of peripheral sensitisation  
We next sought to understand whether treatment of nociceptive axons with 
inflammatory mediators in isolation from the soma, can sensitise axonal responses 
to stimulation in vitro.  Acute peripheral sensitisation has been explored using patch 
clamp electrophysiology, where it has been demonstrated that application of Ims 
composed of histamine, bradykinin, serotonin, and PGE2, for two hours induced 
changes in neuronal excitability (Grossmann et al., 2009; Ma et al., 2006). 
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In preliminary experiments, we explored whether acute (2-hour) treatment with the 
same cocktail of Ims could induce a significant increase in neuronal responses 
detectable using Ca2+ imaging at the DRG soma using conventional cultures. At DIV 
5, coverslips of DRG neurons were treated with Ims for 2 hours and control 
coverslips were treated with vehicle only (Figure 17A). Responses to KCl were 
measured using Ca2+ imaging and we observed a significant increase in Ca2+ signal 
expressed as maximum response and AUC, in IM-treated DRGs in comparison to 
control groups. Average maximum responses to 20mM and 35mM KCl were 
significantly increased in the IM-treated groups, compared to vehicle treated 
neurons, displaying a 1.45-fold increase (from 0.39 ± 0.03 to 0.57 ± 0.19) and 1.3-
fold increase (from 0.35 ± 0.03 to 0.46 ± 0.04), respectively (Figure 17B and D). 
Thus, we concluded that this combination of Ims induces a significant change in 
neuronal responses to KCl stimulation, which are detectable measuring changes in 






 Figure 17. Changes in excitability in DRG neurons after sensitisation with IM. 
A) Schematic of experimental set up: DRG neuron cultured in conventional 
coverslips were exposed to vehicle or IM-containing media for 2 hours at Div 5 post-
plating. Following the 2-hour incubation, DRG neurons were loaded with fura-2 and 
Ca2+ responses to 25mM (B) and 30mM KCl (C) were recorded using calcium 
imaging. B) IM-treated DRG neurons showed a significantly higher maximum 
response after stimulation with 20mM KCl, in comparison to untreated DRG neurons, 
where ***p<0.001. C) IM-treated DRG neurons showed a significantly higher 
maximum response after stimulation with 35mM KCl, in comparison to untreated 
DRG neurons, where *p<0.05, respectively. Data expressed as mean ± S.E.M., 
black dots representing untreated DRG and red dots representing DRG treated with 




In the case of conventional culture systems, which are used extensively in cellular 
studies testing the effects of Ims, the observed sensitisation is likely to be due to a 
number of synergistic factors including changes in the excitability of the soma, 
changes in the excitability of the axon as well as the potentiation of VGCCs leading 
to enhanced Ca2+ influx in response to KCl stimulation. Thus, we sought to develop a 
model of peripheral inflammatory sensitisation that is more relevant to in vivo 
models, where the DRG cell body is not exposed to IMs directly. Therefore, the 
impact of a 2-hour IM-treatment, localised to the axonal compartment of DRG MFC 
cultures, on axonal responses to depolarizing stimulation with KCl was investigated 
(Figure 18). Axons treated with IMs showed a significant increase in Ca2+ influx at 
the soma in response to stimulation of the axons with KCl, following IM-treatment. 
Using 20mM KCl, a 7.4–fold increase (from 0.009 ± 0.001 to 0.067 ± 0.02) was 
observed in IM-treated groups compared to vehicle treated, whereas using 35mM 
KCl, a 3.7-fold increase in average maximum response (from 0.02 ± 0.005 to 0.08 ± 
0.02) was observed in average maximum response of Ca2+ responses of neurons 
with IM-treated DRG axons compared to vehicle treated (Figure 18B).  
 
Stimulation of axons with 20mM KCl resulted in a greater fold increase in average 
maximum response to that observed with 35mM KCl. Taken together, we conclude 
that 20mM KCl is not only sufficient to depolarise axons, but also the optimal 
concentration to detect significant changes in KCl response at the soma following 
axonal IM-treatment and hence, 20mM concentration was chosen for subsequent 
experiments. These results indicate that 2 hours of axonal treatment with IM results 
in a robust increase in excitability of nociceptive axons and that the MFC cultures are 





Figure 18. Changes in axonal excitability detected after localised sensitisation 
with IM using the MFC system.  
Axonal treatment with IM resulted in increased excitability in comparison to untreated 
axons. A) Schematic of experimental set up: DRG neurons were cultured in MFCs, 
DiI was applied to the axonal compartment on Div 4. 24-hours following axonal DiI 
staining (Div 5), DiI stained cell bodies were identified. IM or vehicle containing 
media was applied to the axonal compartment for 2 hours. Following the 2-hour 
incubation of DRG axons with IM or vehicle, the somal compartment was loaded with 
Fura-2 and Ca2+ responses at the soma were recorded to stimulation of axons with 
25mM KCl (B) and 30mM KCl (C) using calcium imaging. B) IM-treated DRG axons 
showed a significant increase in maximum response to 20mM KCl, in comparison to 
vehicle-treated DRG neurons, where *p<0.05. C) IM-treated DRG axons showed a 
higher maximum response after stimulation with 35mM KCl, in comparison to vehicle 
DRG neurons, where *p<0.05. Data expressed as mean ± S.E.M., black dots 
representing untreated DRG and red dots representing DRG treated with IM.  
(Unpaired t-test, n=3 mice, 10-24 DRG neurons). 
 
 
At the end of every experiment, the DRG soma were stimulated with maximal KCl, 
as a positive control indicative of the health of cells as well as optimal culture 
conditions. We found that responses of the DRG soma varied greatly between 
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coverslips/MFCs.  This suggested that differences between culture conditions and 
health of cells could be a confounding factor when interpreting differences between 
coverslips/MFCs as these variants are not taken into account. Using this protocol, it 
was difficult to conclude whether the observed differences in responses to KCl 
between coverslips were attributed to the given treatments (in this case IM or 
vehicle) or other variants such as the number of cells per FoV, health of cells and 
culture conditions. Therefore, we sought to develop a more robust method in order to 
reduce variability observed between coverslips, and enable more accurate 
interpretation of data. 
 
With the objective of optimising our experimental method, we used a protocol which 
enabled the investigation of changes in axonal excitability before and after 
inflammatory insult in individual neurons, where each cell is its own control. Briefly, I 
recorded Ca2+ influx in DiI-stained DRG soma as a result of stimulation of DRG 
axons with 20mM KCl as a baseline response. Next, the axonal compartment was 
perfused with medium containing IM for 2 hours. Following IM-treatment, changes in 
Ca2+ influx at the DRG soma in response to stimulation of axons with 20mM KCl of 
the same cells selected for the baseline responses were recorded (Figure 7). Two 
types of axonal sensitisation after IM-treatment were identified by using this protocol: 
a decrease in activation threshold and a potentiation in Ca2+ response at the soma. 
Axons that were unresponsive to 20mM KCl stimulation, became responsive to the 
same concentration of KCl after 2-hour treatment with IM (Figure 19A). Moreover, 
axons that displayed a response to 20mM KCl, had an enhanced response to the 
same stimulus after IM-treatment (Figure 19B). A significant increase in maximum 
response was observed in cells treated with IM, compared to those exposed to 2-
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hour vehicle treatment displaying a 2.3-fold increase (from 1.9 ± 0.2 to 0.86 ± 0.1) 
(Figure 19C). Furthermore, a significant increase in the average percentage of 
responders within the DiI- stained cell bodies was also observed after IM treatment, 
with a 3.7-fold increase in percentage responders (from 18.7 ± 3.2% to 70.5 ± 6.6%) 
(Figure 19D). This protocol displayed more robust and reproducible results, allowing 
us to identify DRG neurons with axons that are readily sensitized after localized IM-
treatment, and show enhanced magnitude of responses as well as an increased 




Figure 19. Axonal sensitisation in response to localised 2 hour IM-treatment. 
After localised two-hour axonal treatment with IM, resulted in two types of axonal 
sensitisation. A-B) Representative responses of DRG axons to 20mM KCl before 
and after IM treatment; black trace represents axons before treatment, and red trace 
represents axons after treatment A) Representative trace of unresponsive (black) vs. 
responsive (red) axons B) Representative trace of responsive neuron (black), and 
comparatively enhanced response (red). C) Data expressed as the mean ± S.E.M, 
showing an increase in fold change of the maximum response to 20mM KCl before 
and after axonal treatment with vehicle or IM. IM- treated neurons showed a 
significantly increased fold change to KCl stimulation after IM-treatment compared to 
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vehicle-treated neurons (***p<0.0007, two-tailed, Mann-Whitney U test, n=3 mice, 
15-25 DRG neurons). D) Data expressed as the mean percentage of responders KCl 
per MFC.  Graph showing an increase in the number of DRG responders after IM 
treatment compared to those given vehicle treatment (*p<0.02, two-tailed Mann-
Whitney U test, n=3 mice, 15-25 DRG neurons). 
 
 
Using the 2-hour IM treatment protocol we were able to detect a significant 
sensitisation of DRG axons, however this particular time-point was chosen based on 
the literature, where it has been shown that 2-hour treatment with IMs induces 
sensitisation of the DRG cell bodies resulted in a significant reduction of rheobase 
(Lee et al., 2014a). However, we hypothesised that a shorter exposure to IM (in 
minutes) would be sufficient to trigger sensitisation at the DRG axons. Moreover, it is 
well documented that nociceptors are not only sensitised, but can also be activated 
by inflammatory stimuli. A study showed that serotonin, bradykinin and PGE2 have 
been shown to evoke calcium influx in rat DRG soma (Linhart et al., 2003). At the 
primary afferent level, a study using canine testis-spermatic nerve preparation 
showed histamine and bradykinin were able to induce excitation of nociceptors 
(Koda and Mizumura, 2002b). Thus, we set out to investigate whether DRG axons 
can be sensitised after exposure to IM-treatment for 2 minutes, and whether 
application of IM could activate nociceptive axons directly.  
 
To answer these questions, we used a protocol that enabled both 1. to test for 
sensitisation of axonal responses by measuring changes somal Ca2+ signals to KCl- 
stimulation of axons before and after 2-minute IM- treatment (localised to the axonal 
compartment) and 2. to test for nociceptor activation by monitoring changes in Ca2+ 
signal at the DRG soma throughout the duration of the experiment (including the 
duration of the IM-treatment). We found that axonal responses to 20mM KCl were 
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potentiated after 2-minute IM treatment, compared to baseline axonal response to 
20mM KCl (Figure 20A). A significant increase in maximum response to KCl 
stimulation after IM-treatment was observed when compared to responses to 
baseline KCl stimulation before treatment, displaying a 3.9-fold increase (from 0.86 ± 
0.03 to 3.37 ± 0.5) between groups (Figure 20B). There was a significant increase in 
percentage responders out of DiI-stained cell bodies after treatment with IM, with a 
2.5-fold increase compared to the percentage of responders to baseline KCl 
stimulation (from 31 ± 8.4% to 81 ± 6.3%) (Figure 20C). Of note, as mentioned 
previously, not all DiI-stained cell bodies respond to KCl stimulation of axons.  
 
We found that axonal responses to KCl are potentiated after treatment with a cocktail 
of IMs containing PGE2, histamine, bradykinin and serotonin for a duration of both 2 
hours and as little as 2 minutes. The MFC model allows us to identify two types of 
sensitisation at the axonal level, increased responsiveness as well as recruitment of 
otherwise non-responsive neurons, which we were able to model robustly and 
reproducibly using this protocol. Furthermore, we were also show direct activation of 





Figure 20. Axonal sensitisation in response to localised 2 minute IM-treatment. 
Acute localised axonal treatment with inflammatory soup resulted in two types of 
sensitisation of the axon. A) Representative trace showing axonal responses to first 
KCl stimulation (20 second), IM stimulation (2 minutes) and a potentiated response 
to the second KCl stimulation (20 seconds), which is maintained in the third 
response to KCl stimulation (20 seconds) after a 10-minute wash period. B) Data 
expressed as mean ± S.E.M, where graph displays fold change in KCl response 
after vehicle treatment, compared to IM treatment. IM- treated neurons showed a 
significantly higher maximum response to KCl stimulation after treatment compared 
to vehicle treated neurons (***p<0.0002, two-tailed, Mann-Whitney U t-test, n=18-20 
DRG, 4 mice). C) Data expressed as the mean percentage of responders to KCl per 
MFC. Graph showing a significant increase in the number of DRG responders to KCl 
stimulation after two-minute IM treatment compared to KCl stimulation before IM 







Figure 21. Direct responses of axons to IMs, PGE2 only and BK alone in the 
MFC system 
A) Representative trace highlighting direct activation of a subpopulation of neurons, 
with axons that are responsive to inflammatory mediators. Traces demonstrate 
changes in Ca2+ concentration at the soma in response to application of the 
following to the axonal compartment: KCl stimulation (20 second), second KCl 
stimulation (20 seconds), IM stimulation (2 minutes) and a potentiated response to 
the second KCl stimulation (20 seconds) with 5-minute washout periods between 
each stimulation. Red circle highlights a subpopulation of neurons in which 
application of IM to the axonal compartment results in a Ca2+ transient at the soma. 
B) Representative trace showing direct transient responses of axons to 10M 
bradykinin (1-minute application), as well as potentiation of KCl responses after 
treatment with bradykinin. C) Representative trace showing direct responses of 
axons to 10M PGE2 (2-minute application), displaying short, repetitive bursts of 
activity in response to treatment with PGE2 only. D) Maximum peak of direct 
responses of DRG axons to IM compared to BK alone (*p<0.05, two-tailed, unpaired 
t-test, n= 9-13 DRG neurons, n=3 mice, 9 MFCs) 
 
 
In order to be able to tease out the molecular mechanisms underlying sensitising and 
excitatory effects of different IMs, we aimed to study the effects of individual IMs on 
peripheral nociceptors. Taking advantage of the MFC model, we studied the effects 
of bradykinin, PGE2 and histamine on DRG axons and found that axons respond 
differentially to exogenous application of these mediators. Treatment with 10M 
bradykinin (1-minute application) displayed both sensitising and excitatory effects, 
resulting in increased number of responders to KCl, as well as evoking a transient 
Ca2+ signal similar to that seen with KCl (Figure 21B). No axonal responses were 
observed to 10M histamine (data not shown). We found that treatment with 10M 
PGE2 (2-minute application) resulted in a different type of axonal response. Short 
and repetitive Ca2+ transients were detected at the soma in response to a localized, 
short treatment of axons with PGE2 (Figure 21C). The direct responses to IM were 
significantly higher compared to direct responses to BK only, suggesting that other 
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mediators used in this assay other than BK are likely to contribute towards the direct 
response of axons to IMs (Figure 21D).  
 
Interestingly, the different types of responses observed at the cell bodies in response 
to treatment of axons with BK and PGE2 point towards important mechanistic 
differences underlying the effects of both mediators. The ability of BK to activate 
nociceptors, and mechanisms underlying its excitatory action been studied 
extensively (Banik et al., 2001; Jeftinija, 1994; Kano et al., 1994; Mizumura et al., 
2009; Wu and Pan, 2007). Moreover, responses to BK in single-fibre recordings and 
have been typically associated with significant tackyphylaxis, which may explain why 
responses to BK were transient in nature and did not result in repetitive activity 
(Banik et al., 2001). Conversely, ion channels and second messenger pathways 
involved in PGE2-induced neuronal discharge have not been studied in detail as the 
excitatory effects of PGE2 remain to be a contentious subject matter as reviewed in 
Section 4.1.4. Hence, in the next chapter we will aim to further understand the 














3.4. Summary  
In order to develop an in vitro assay to study changes in axonal excitability an MFC 
platform was used allowing isolation of subcellular components of DRG neurons. We 
show that adult DRG neurons are readily maintained in MFC chambers and their 
DRG axons are able to traverse through the microgrooves to a fluidically isolated 
chamber. We also demonstrate how DiI staining can be used to identify neurons with 
axons that had traversed to the axonal compartment. Responses of axons to 
depolarization were measured using changes Ca2+ concentration at the soma, 
resulting from APs generated at the axons, as a readout (Tsantoulas et al., 2013). 
This technique provides a robust and reproducible measure of axonal function due to 
specific stimulation of the axonal compartment of the neuron. Next, we took 
advantage of the MFC platform to model inflammation-induced peripheral 
sensitisation of nerve fibres in vitro and showed that nociceptive axons are 
sensitised in response to a cocktail of IMs. We observed two types of axonal 
sensitization using our assay. Fluidically isolated axons treated with IMs exhibited 
increased responsiveness to stimulation, and a reduction in nociceptor activation 
threshold. This was observed after both, 2-hour localized axonal treatment with IM 
as well as with a shorter treatment of 2 minutes. We also found that localized axonal 
IM-treatment not only results detectable sensitization, but also direct activation of a 
subpopulation of neurons. Exogenous application of inflammatory mediators resulted 
in responses with different kinetic properties. In comparison to the well-studied 
excitatory action of bradykinin on nociceptors, the ability of PGE2 to activate 
nociceptors directly and the underlying mechanisms remain elusive. Hence, we set 
out to further investigate molecular players responsible for PGE2-induced persistent 
activity at the primary afferent level in the next chapter.  
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4. Investigating axonal mechanisms underlying PGE2- 




4.1. Introduction  
4.1.1. The role of Prostaglandin E2 in health and pathology  
Prostaglandin E2 is responsible for homeostatic responses in several human 
systems including reproductive, gastrointestinal, and neuroendocrine (Dey et al., 
2006; Duffy and Stouffer, 2001). However, the production of PGE2 increases 
dramatically during an inflammatory response and thus, is thought to mediate 
pathological features of inflammation (Kawabata, 2011). The accumulation of PGE2 
at the site of injury causes PGE2-induced arterial dilatation and increased 
microvascular permeability resulting in redness and oedema (Omori et al., 2014). 
PGE2 also plays an important role in febrile responses and their action on key sites 
of the pain pathways such as peripheral sensory neurons, the spinal cord and the 
brain leads to the experience of somatic pain (Dinarello et al., 1984; Funk, 2001).  
 
4.1.2. EP receptors and downstream signalling pathways  
PGE2 acts via EP receptors (EP1, EP2, EP3 and EP4), which belong to the 
rhodopsin-like G-protein coupled receptors (GPCRs) family, comprised of seven 
transmembrane domains and intracellularly coupled to different G proteins. All four 
isoforms are coupled to distinct signal transduction pathways. EP2 and EP4, for 
instance, are coupled to Gs protein through which they activate adenylate cyclase 
(AC), leading to an increase in intracellular cAMP levels (Fujino et al., 2005; Regan, 
2003).  EP2 and EP4 have similar functions however, EP4 has higher affinity for 
PGE2 whereas, EP2 has a lower affinity for PGE2. EP1 is coupled to Gq protein, 
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triggering formation of inositol phosphate with the mobilization of intracellular free 
calcium, whereas EP3 couples with Gi/o resulting in a reduction in intracellular cAMP 
levels (Ji et al., 2010; Sugimoto et al., 1992). EP1-4 have all been found to be 
expressed on sensory neurons (Narumiya, 2009). The importance of EP4 receptors 
in pain has been highlighted by studies showing how a number of EP4 antagonists 
show analgesic efficacy in inflammation-induced behavioral hyperalgesia in both, the 
CFA and carrageenan rodent models (Murase et al., 2008). Evidence has also 
suggested an important role for PGE2/EP4 molecular pathway in animal models of 
rheumatoid arthritis and osteoarthritis (Clark et al., 2008; McCoy et al., 2002).  
4.1.3. Peripheral sensitisation by PGE2  
The sensitising effects of PGE2 to chemical, heat and mechanical stimuli has been 
supported by several groups. PGE2 was recognized as a potent sensitising agent 
since the 1990’s, where pain responses elicited in healthy human subjects after 
injection of bradykinin into an isolated hand vein segment, were potentiated after 
pre-treatment with PGE2 (Kindgen-Milles, 1995). PGE2 has been shown to increase 
discharge activity of C-fibres to capsaicin and adenosine in anaesthetized rats, as 
well as enhance 5HT-induced responses in the rat skin-nerve preparation (Ho et al., 
2000; Lang et al., 1990). PGE2 has been suggested to sensitise nerve endings to 
other pain-inducing molecules such as ATP and TRPA1 (Bang et al., 2007; Wang et 
al., 2007; Zhang et al., 2008).  
 
PGE2 has been shown to potentiate heat-induced neuronal discharge at the 
peripheral terminals in isolated rat-skin nerve preparations and canine testicular 
nociceptors, in vitro (Derow et al., 2007; Kumazawa et al., 1996).  Similarly, stable 
analogues of cAMP enhanced heat responses in rat cutaneous nociceptors (Kress et 
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al., 1996). Consistent with these reports, in vivo studies carried out in rats and 
rhesus monkeys have demonstrated the ability of PGE2 to induce heat hyperalgesia 
after interplantar and subcutaneous tail injection of PGE2, respectively (Negus et al., 
2004; Schuligoi et al., 1994). Further, an intradermal injection of PGE2 was reported 
to reduce heat thresholds in humans (Rukwied et al., 2007).  
 
There is a vast amount of studies suggesting potential molecular players responsible 
for PGE2-induced heat sensitisation. A study used an isolated sciatic nerve axon 
model to understand mechanisms underlying heat-induced sensitisation, and 
showed that showed that PGE2 sensitised heat responses in peripheral nerve axons 
(Fischer and Reeh, 2007). The same study demonstrated that effect was mimicked 
by application of forskolin, which raises intracellular cAMP levels, and was inhibited 
by application of H89, a PKA inhibitor. Fischer and Reeh also revealed application of 
a combination of PGE2 and BK did not sensitise heat responses of axons from 
TRPV1 KO mice. Furthermore, studies have reported that PGE2-induced heat 
hyperalgesia, which was measured using paw withdrawal latency as a readout, was 
reduced in EP1 KO, TRPV1 KO mice, and Nav1.9 KO mice suggesting their 
involvement in thermal sensitisation caused by PGE2 (Amaya et al., 2006; 
Johansson et al., 2011; Moriyama et al., 2005). In vitro studies have also suggested 
the involvement of Nav1.8 channels by using Nav1.8 selective blockers that inhibited 
the sensitising effects of PGE2 (Payne et al., 2015a). However, in Nav1.8 KO mice 
PGE2-induced thermal hyperalgesia was unaffected, suggesting that Nav1.8 
channels do not play a prominent role in PGE2-induced heat hyperalgesia (Kerr et 
al., 2001).  
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Mechanical sensitising effects of PGE2 in vitro have been debated as different 
studies have reported opposing findings. Using single-fibre recording experiments, 
studies have reported a decrease in activation threshold of nociceptors to 
mechanical stimuli and an increase in neuronal spikes, mediated by the cAMP/PKA 
pathway (Koda and Mizumura, 2002b; Wang et al., 1996). A similar effect was 
observed when stable analogues of cAMP were applied to the rat skin-nerve 
preparation (Kress et al., 1996). Conversely, other studies have used the same 
preparation and reported that both PGE2 and IM did not alter mechanical von Frey 
thresholds or enhance the number of spikes observed (Lang et al., 1990; Schlegel et 
al., 2004). However, in vivo studies have consistently shown that interplantar 
injection of PGE2 results in pronounced mechanical hyperalgesia, which is mediated 
by PKA-cAMP pathway in the first 30 minutes and PKC is required for the long-
lasting effects at 90 minutes (Sachs et al., 2009). Others have suggested the role of 
Nav1.9 and chemokine receptor 2 (CXCR2) in PGE2-induced mechanical 
hyperalgesia in vivo (Amaya et al., 2006; Manjavachi et al., 2010). More recent 
studies have shown that interplantar injection of PGE2 induces a significant 
mechanical allodynia, which can be reduced by cAMP, PKA, PKC, EP1 and EP4 
inhibitors as well as IL-6 neutralising antibodies pointing towards important molecular 
players underlying PGE2-induced mechanical hyperalgesia (St-Jacques and Ma, 
2014).  
 
Although there is ample evidence for role of PGE2 as a potent sensitiser of 
nociceptors, its ability to activate nociceptors or induce pain has been controversial. 
Undoubtedly, COX blockers provide analgesia and prostaglandin inhibitors have 
been shown to reverse capsaicin-induced pain responses (Schmelz and Kress, 
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1996; Steen et al., 2000; Steen et al., 1995). However, application of PGE2 via 
intradermal microdyalisis membranes in humans produced only weak itch and pain 
at high concentrations (Neisius et al., 2002; Schmelz et al., 2003). Thus, there is an 
inconsistency the in effects of augmenting PGE2 and reducing PGE2 levels in 
humans. The evidence regarding the ability of PGE2 to cause pain and excite 
nociceptors directly will be discussed further in the following section.  
4.1.4. PGE2-induced nociceptor activation   
Over the years there has been conflicting data regarding the excitatory action of 
exogenously applied PGE2 on DRG somata in vitro as well as in nerve-fibre 
preparations. At the primary afferent level, older studies have reported that PGE2 
fails to evoke spike discharge in visceral afferents and skin-saphenous nerve 
preparations (Brunsden and Grundy, 1999; Lang et al., 1990; Mizumura et al., 1993; 
Mizumura et al., 1987). On the other hand, PGE2 has been reported to induce spike 
discharge in joint afferents (Schaible and Schmidt, 1988). More recent studies 
studying the excitatory action of PGE2 on sensory neurons focus on the cell soma, 
10uM PGE2 was shown to evoke Ca2+ influx in dissociated rat DRG neurons (Linhart 
et al., 2003). Whereas others have reported that exogenous application of the same 
concentration of PGE2 did not elicit an increase in intracellular Ca2+ levels in DRG 
cell bodies (Nicolson et al., 2007). Thus, further research is required to address 
whether or not PGE2 exerts an excitatory effect directly on nociceptors, and the ion 
channels and signal transduction pathways underlying this phenomenon remain to 





4.2.  Aims 
Using conventional in vitro preparations have enabled the mechanistic 
understanding of PGE2-induced sensitising effects at level of the DRG cell body, 
however to our knowledge, the ion channels and signal transduction mechanisms 
underlying PGE2-induced activation of primary afferent neurons remains limited. 
Given the prominent role of PGE2 as an inflammatory mediator, which is abundantly 
produced in inflamed tissue, we investigated the changes in axonal excitability in 
response to PGE2. Taking advantage of the MFC platform to study the function of 
sensory axons, the aim was to further characterise the modulation of axonal 





























4.3. Results   
We first assessed the sensitising effects of PGE2 in our assay. Using the 2-channel 
chamber, we tested whether PGE2 on its own is sufficient to sensitise nociceptive 
axons and result in enhanced responses as well as increased number of responders 
to KCl stimulation, similar to that observed with treatment of a combination of IMs. 
We examined the magnitude of responses as well as the number of responders 
observed at the cell body to depolarisation of axons with KCl after treatment with 
PGE2 only, compared to before treatment.  The magnitude of Ca2+ signals were 
increased after two-minute treatment with 10M PGE2, compared to KCl responses 
before PGE2 treatment, displaying a 2.7 -fold increase, from 0.88 ± 0.03 to 2.38 ± 
0.12 (Figure 22A-B). Percentage of DiI-stained neuronal cell bodies that responded 
to axonal stimulation were also quantified. Although not significant, there was an 
upward trend in the number of responders after localized axonal treatment with 
PGE2 in comparison to vehicle treated DRGs (Figure 22C). Thus, PGE2 on its own 
is able to cause a significant sensitisation of DRG axons, which is comparable to that 




Figure 22. Axonal sensitisation to KCl responses by acute, localised PGE2 
treatment. 
A) Schematic of experimental set up. B) Representative trace showing potentiation 
of somal response to axonal stimulation with 20mM KCl, after 2-minute treatment 
with 10M PGE2.  C) Data expressed as the mean ± S.E.M; PGE2- treated neurons 
showed a significantly increased response to KCl stimulation after treatment 
compared to vehicle treated neurons, ***p<0.0001 (Mann-Whitney U test, n=15-30 
DRG, n=4 mice). D) Percentage of DiI- positive neurons responding to KCl showing 
an upward trend after PGE2 treatment compared to neurons with vehicle-treated 
axons, where p=0.154 (Chi-square test, n=15-30 DRG, n=4 mice). 
 
 
Next, we tested whether localised application of PGE2 can excite nociceptors 
directly by resulting in the generation of APs that are propagated to the DRG soma. 
We tested this hypothesis using the 3-channel MFC device, which would enable us 
to assess whether the propagation of axonal signals to the DRG cell body can be 
blocked by perfusion of pharmacological agents to the middle axonal chamber.  
 
We first tested if application of PGE2 in the distal axonal compartment resulted in 
persistent Ca2+ transients detected at the soma (Figure 23A).  We observed that 2-
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minute application of PGE2 resulted in axonal activity that persisted after wash-out of 
PGE2 application (Figure 23B and D). We then tested whether the application of 
lidocaine to the middle axonal chamber blocked the propagation of signals generated 
by PGE2 application. To answer this question, PGE2 was applied to the distal axonal 
compartment (Figure 23C, green), after which lidocaine was applied to the middle 
axonal compartment (Figure 23C, white) which resulted in an a complete block of 
PGE2-induced axonal signals arriving at the cell bodies (Figure 23B-C). Throughout 
the experiment, PGE2-induced axonal activity was monitored by recording from the 
cell soma and PGE2-induced ongoing activity was quantified as the number of 
transients observed per 3 minutes after application of PGE2. Application of 10µM 
PGE2 to the distal axons resulted in significantly increased number of transients/3 
minutes compared to baseline (Figure 23D). Transients were considered a positive 
response when the maximum peak in Fratio was greater than 3 times the standard 
deviation above the baseline, which was calculated from at least 10 seconds before 
application of stimulus. No Ca2+ transients were observed with the application of 
DMSO vehicle (data not shown) whereas, PGE2 induced Ca2+ transients at an 
average rate of 6.12 ± 0.63, per 3-minute after PGE2 application. Treatment with 
5mM lidocaine completely abolished transients arriving at the cell soma. This 
experiment demonstrates that PGE2 on its own can excite DRG axons directly and 





Figure 23. PGE2-induced ongoing neuronal activity is abolished by lidocaine 
A) Schematic of experimental set up used for data shown in B, 3-channel MFC is 
depicted with the somal compartment in pink, and middle axonal compartment in 
grey and distal axonal compartment in green. PGE2 was applied to the distal axonal 
compartment. B) Representative trace showing Ca2+ transients recorded at the soma 
in response to distal axons treated with PGE2. Perfusion of 10M PGE2 for 2 
minutes results in ongoing axonal activity detected at the soma, which persists after 
washout of PGE2.  C) Schematic of experimental set up used for data shown in D 
and E, 3-channel MFC was used. KCl and PGE2 were applied to the distal axonal 
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compartment. After application of PGE2, 5mM lidocaine was applied to the middle 
axonal compartment. Throughout experiment Ca2+ signals were recorded from the 
cell bodies in the somal compartment. D) Representative trace showing response to 
20mM KCl axonal stimulation, and ongoing activity induced by PGE2 which is 
blocked after application of 5mM lidocaine to the middle axonal compartment. Red 
arrows indicating calcium transients. E) Quantification of the number of transients 
observed after application of stimulus, for a duration of 3 minutes. Data expressed as 
mean ± S.E.M, showing a significant increase in the number of transients after 
application of PGE2 compared to baseline (***p<0.006), and a significant decrease 
in number of transients after application of lidocaine (****p<0.0001). (One-way 
ANOVA with Tukey’s multiple comparisons test was used, n=10 DRG, n=4 mice).  
 
 
Next, we aimed to establish whether the application of PGE2 to the distal axons 
results in direct depolarisation of the axonal membrane. In order to answer this 
question, we sought to set up a simple method that enables direct measurement of 
the axonal transmembrane potential, which would give us more accurate information 
of the timing and location of subthreshold events taking place. For this purpose, the 
Fluovolt voltage sensor was used, which is a fast voltage-responding fluorescent dye 
that takes advantage of photo-induced electron transfer (PET) technology to detect 
changes in membrane potential (Miller et al., 2012). We first tested whether we could 
observe detectable changes in fluorescence signal (expressed as F/F ratio) along 
DRG axons after stimulation with KCl (Figure 24A). We found that application of 
20mM KCl to the axonal compartment resulted in depolarisation of the axonal 
membrane, which was maintained until washout of KCl (Figure 24C-E). This 
experiment served as a good positive control, demonstrating that using fluovolt dye 




Figure 24. Measuring changes in axonal membrane potential to KCl using 
Fluovolt dye. 
A) Schematic of experimental set up used for data shown in B-E, two-chamber 
compartment model MFC was used, with cell body compartment in pink, and axonal 
compartment in green. 20mM KCl was applied for 1-minute duration to the axonal 
compartment, and changes in fluorescence were recorded from the axonal 
compartment. B) Bright field image showing chosen field of view (FoV) in the axonal 
compartment of the MFC. C) Background subtracted F/F image of the same FoV as 
B, before application of KCl.  D) F/F image showing same FoV after KCl application 
to the axonal compartment. White arrows highlighting examples of axons where 
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changes in fluorescence intensity increased in response to stimulation with KCl. E) 
Representative trace illustrating changes in fluorescence expressed as F/F, of one 
section of an axon in response to KCl application. Change in fluorescence returns to 
baseline after wash-out of KCl stimulation. Scale bars, 100m.  
 
We next tested whether application of PGE2, using the same concentration and 
duration which induced generation of ongoing activity in DRG axons, could result in 
depolarisation of the axonal membrane. 10M PGE2 was perfused to the axonal 
compartment for 2 minutes, and changes in fluorescence signal were recorded from 
selected ROIs encompassing the axons (Figure 25A). We found that PGE2 resulted 
in a significant change in fluorescence signal as shown in the F/F image (Figure 
25D-F), indicating that direct depolarization of axonal membrane occurs in response 
to PGE2 application. In contrast to axonal depolarisation observed with KCl, where 
the fluorescent signal intensity returned to baseline after washout of KCl, the fluovolt 
fluorescence intensity in axon segments responding to PGE2 did not return to 
baseline after washout of PGE2 indicating a persistent depolarisation of axonal 
segments following removal of PGE2 stimulus. Thus, the sustained depolarisation 
induced by 10M PGE2 is the likely mechanism for the generation of persistent 
axonal activity. Of note, calibration experiments of the fluovolt dye response in 
cochlear epithelial cells as well as HEK cells have reported an average voltage 
sensitivity of 22-25% increase in fluorescence per 100mV depolarisation (Ceriani 
and Mammano, 2013; Miller et al., 2012). However, for an accurate measure of the 
change in axonal membrane potential, a calibration study of the dye response in 





Figure 25. PGE2 induces a sustained depolarisation of the axonal membrane. 
A) Schematic of experimental set up used for data shown in B-E, 2-channel MFC 
was used, with cell body compartment in pink, and axonal compartment in green. 
10uM PGE2 was applied for 2-minute duration to the axonal compartment, and 
changes in fluorescence were recorded from the axonal compartment. B) Bright field 
image showing chosen FoV in the axonal compartment of the MFC. C) F/F image 
of the same FoV as shown in B, before application of PGE2.  D) F/F image showing 
FoV after PGE2 application. White arrows highlighting axonal areas responding to 
stimulation with PGE2. E) Representative trace illustrating changes in Fluovolt 
Fluorescence (F/F), of an axon segment in response to PGE2 application. Change 
in fluorescence is maintained after wash-out of PGE2. F) Quantification of maximum 
response of fluovolt fluorescence signal (F/F) in response to 20mM KCl and 10M 
PGE2 (n=19-20 DRG, 8 MFCs, 3 mice). Scale bars, 100m.  
 
 
Binding of PGE2 to EP2 or EP4, which are both coupled to Gs protein, results in an 
increase in intracellular cAMP levels (Fujino et al., 2005; Regan, 2003).  We found 
that PGE2-induced depolarisation of the axonal membrane lasts beyond wash-out of 
PGE2 application. Moreover, the maintained depolarization observed could explain 
ongoing persistent activity observed in the DRG soma in response to treatment of 
axons with PGE2 (Figure 26). We hypothesized that second messenger pathways 
may be involved in the long-lasting effects of PGE2. Therefore, we assessed 
whether the cAMP/PKA pathway is an important player responsible for PGE2-
induced ongoing activity. The cAMP analogue, Rp-cAMPS was chosen to test this 
hypothesis as its mechanism is well understood and has been routinely used to 
establish the role of the cAMP/PKA pathway in vitro and in vivo (Aley and Levine, 
1999; Song et al., 2006). In addition, it has a better selectivity profile in comparison 
to another routinely used PKA inhibitor, H89, which has been shown to act on 8 
other kinases displaying PKA-independent effects (Lochner and Moolman, 2006).  
Moreover, a study demonstrated tested increasing concentrations (ranging from 5 to 
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500M) Rp-cAMPS, and showed a dose-dependent reduction in discharge rate of 
spontaneous activity in teased dorsal root filaments from chronically compressed 
DRG neurons (Hu et al., 2001). In our assay, we found that the localised axonal 
ongoing activity is reversibly blocked by 20M of Rp-cAMPS, a cAMP analogue and 
inhibitor of PKA activation (Figure 26A). The number of transients/3 minutes 
recorded at the soma after application of PGE2 to the axonal compartment were 
significantly reduced by Rp-cAMPS. Interestingly, the axonal ongoing activity 
returned after washout of Rp-cAMPS in a subpopulation of neurons (Figure 26B-C). 
Although the 3-channel compartment MFC was set up for experiments involving 
pharmacological intervention, the following two studies were carried out in the 2-
channel compartment, which is less technically challenging and enables more high 




Figure 26. PGE2-induced ongoing activity is dependent on the cAMP/PKA 
pathway at the axonal level. 
A) Schematic of experimental protocol: After overnight DiI staining of axons, cell 
bodies were labelled with Fura-2 and only DiI-stained cell bodies were selected for 
calcium imaging analysis. Axonal chamber was stimulated with 10uM PGE2, 
followed by a 5-minute wash-out, after which the Rp-cAMPS was applied to the 
axonal chamber to test its effect on the number of transients induced by PGE2 for 3 
minutes, which was subsequently washed out. B) Representative trace showing 
ongoing activity recorded at the soma in response to 1-minute second axonal 
stimulation with PGE2, which is reversibly blocked with the application of 20M Rp-
cAMPS (cAMP-induced PKA activation inhibitor) for 3 minutes. C) Quantification of 
the Ca2+ transients observed after application of stimulus. Data expressed as mean ± 
S.E.M, showing a significant decrease in the number of PGE2-induced transients 
after application of Rp-cAMPS (****p<0.0001). The activity partially recovered 
following washout of Rp-cAMPS, where *p<0.05 (One-way ANOVA with Tukey’s 





To identify what ion channels are responsible for PGE2-induced ongoing axonal 
activity, we investigated whether VSGC had a role to play in PGE2-induced ongoing 
activity. We found that ongoing axonal activity was unaffected by application of 
500nM TTX, applied for 3 minutes (Figure 27A). This concentration of TTX was 
chosen as it has been used to both block TTX-S currents, as well as test the 
specificity of Nav1.8 blockers on TTX-R currents present in DRG neurons after 
exposure to 500nM TTX (Tan et al., 2014). There was no significant difference in the 
number of transients after application of the TTX, suggesting that TTX-S channels 
are not directly involved in PGE2-evoked ongoing activity (Figure 27B). Lidocaine is 
a non-selective VSGC blocker, thus blocks both TTX-S and TTX-R currents. The fact 
that lidocaine completely blocks PGE2-induced calcium transients (Figure 23D) but 
TTX did not have a significant effect (Figure 27) suggests that TTX-R channels may 




Figure 27. PGE2-induced ongoing activity is not dependent on TTX-S VGSCs at 
the axonal level. 
A) Schematic of experimental set up: After overnight DiI staining of axons, cell 
bodies were labelled with Fura-2 and only DiI-stained cell bodies were selected for 
calcium imaging analysis. Axonal chamber was stimulated with 10uM PGE2, 
followed by a 5-minute wash-out, after which the TTX was applied to the axonal 
chamber. B) Representative trace showing ongoing activity recorded at the soma in 
response 1-minute axonal stimulation with PGE2, which is maintained despite 
treatment with 500nM TTX for 3 minutes. C) Quantification of the number of 
transients/3 minutes observed after application of stimulus. Data expressed as mean 
± S.E.M, showing no significant change in the number of PGE2-induced transients 
after application of 500nM TTX, where p=0.1261. (One-way ANOVA with Tukey’s 
multiple comparisons test, n=13 DRG, n=3 mice) 
 
To test whether specific TTX-R channels are responsible for PGE2-induced ongoing 
activity we used more specific blockers. A number of publications have linked Nav1.8 
channels with the effects of PGE2 at the DRG (Liu et al., 2010). A novel Nav1.8 
selective channel blocker, PF- 01247324, was shown to reduce the potentiation of 
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neuronal excitability caused by PGE2 at the cell body at 1M (Payne et al., 2015b). 
The same study showed that at 3M PF- 01247324 begins to have non-specific 
effects as it acts on other Navs including Nav1.4, Nav1.6, Nav1,5; thus the 
concentration of 2M was chosen to test whether Nav1.8 channels play a role in 
PGE2-induced activity in DRG axons. It was found that the localised ongoing axonal 
activity is significantly blocked by 2M of PF- 01247324, a selective Nav1.8 blocker 
(Figure 28A-B). The number of transients/3 minutes where significantly reduced 
after application of PF- 01247324 (Figure 28C). 
 
 
Figure 28. PGE2-induced ongoing activity is mediated by axonal Nav1.8 
channels. 
A) Schematic of experimental set up: After overnight DiI staining of axons, cell 
bodies were labelled with Fura-2 and only DiI-stained cell bodies in the somal 
compartment were selected for calcium imaging analysis. Distal axonal chamber was 
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stimulated with 10uM PGE2, followed by a 5-minute wash-out, after which Nav1.8 
selective blocker was was applied to the middle axonal chamber. B) Representative 
trace showing repetitive ongoing activity recorded at the soma in response to 1-
minute axonal stimulation with PGE2, which is partially blocked with the application 
of 2M PF-01247324. C) Quantification of the number of transients observed after 
application of stimulus. Data expressed as mean ± S.E.M, showing a significant 
decrease in the number of PGE2-induced transients after application of PF-
01247324, where ****p<0.0001 (Paired, two tailed, Student’s t-test was used, n=10 
DRG, n=3 mice). 
 
Given the involvement of Nav1.8 channels in PGE2-induced ongoing activity 
observed in our hands, and the importance of EP4 receptors which has been 
suggested by several groups as reviewed in Section 4.1.2, we carried out 
immunocytochemistry to investigate the expression and distribution of EP4 and 
Nav1.8 along the axonal membrane. In a set of preliminary experiments, we 
demonstrate the expression of EP4 receptors along the axons demarcated with ß-3-
tubulin providing evidence for the expression of EP4 receptors along the axons of 
adult mouse DRG neurons (Figure 29A-D).  We also studied the co-expression 
patterns of EP4 receptors, and Nav1.8 channel and found that both EP4 receptors 
and Nav1.8 channels are co-expressed along adult DRG axons (Figure 30A-B). EP4 





Figure 29. EP4 receptor expression along isolated adult DRG axons. 
 
A) Preliminary data: representative image of axonal compartment showing 
expression and distribution pattern of EP4 receptor along DRG axons. B) 
Representative image of axonal compartment showing counter staining with ß-3-





Figure 30. Co-localisation of EP4 receptors and Nav1.8 channels along the 
axonal membrane. 
Preliminary data: Representative images of adult DRG axons taken at DIV 5. A) 
Expression of EP4 in DRG axons in the MFC axonal compartment B) Nav1.8 staining 
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in same FoV as B. C) DRG axons in distal axonal compartment showing image of 
control MFC treated with secondary antibody alone for EP4 stain. D) DRG axons in 
peripheral terminal compartment showing image of control MFC treated with 
secondary antibody alone for Nav1.8 stain. E) An overlay of EP4 (red) and 
Nav1.8(green) staining from A and B, respectively showing co-localisation of EP4 























4.4. Summary  
 
In this chapter, we take advantage of the MFC-based in vitro system to provide 
evidence to show that PGE2 can not only sensitise nerve endings but also activate 
nociceptors directly. Using novel voltage imaging techniques, we show that local 
application of PGE2 depolarized the axonal membrane. Using calcium imaging, we 
demonstrate that application of PGE2 to the distal axons resulted in repetitive Ca2+ 
transients at the soma, which persisted for 30 minutes after wash-out of PGE2. 
Moreover, the perfusion of lidocaine to the middle axonal compartment blocked the 
propagation of PGE2-induced axonal signals from the distal axons to the DRG cell 
bodies. Mechanistically, we show that PGE2-evoked persistent axonal activity is 
dependent on the cAMP/PKA pathway. We also provide evidence suggesting that 
this persistent activity generated in the distal axons is not mediated by TTX-S 
channels, but can be attenuated through inhibition of Nav1.8 channels.  
 
Taken together, we provide evidence suggesting that PGE2 has a long-lasting 
excitatory effect on nociceptive axons, as the application of PGE2 induces a 
sustained depolarisation of the axonal membrane resulting in the generation and 
propagation of persistent axonal activity arriving at the DRG cell bodies.  Although 
PGE2-evoked depolarization of nociceptive axons could potentially present a novel 
mechanism for ongoing pain associated with inflammatory disorders, further work is 
required to understand how this depolarisation comes about. We also show that 
PGE2- induced ongoing activity is dependent on local second messenger 
cAMP/PKA pathway and is mediated, at least in part, by axonal Nav1.8 channels. 
This mechanism potentially contributes to our knowledge of peripheral mechanisms 
underlying ongoing pain during inflammatory conditions.  
 136 




5.1. Introduction  
 
5.1.1.  HCN channels  
As discussed in Chapter 1, HCN channels are activated by both hyperpolarization of 
the membrane potential (<-60mV), and the presence of intracellular cAMP 
(DiFrancesco, 1999). An interesting characteristic of these channels is their 
response to increased intracellular levels of cAMP. Binding of cAMP binds to the 
cyclic-nucleotide binding domain, results in a positive shift in its activation threshold, 
towards more depolarised membrane potentials (Emery et al., 2012), which causes a 
greater inward current and also reduces the latency of the next action potential, 
thereby increasing the frequency of action potential firing (Figure 31). This 
mechanism allows HCN channels to play an important role in regulating 
spontaneous neuronal activity and frequency control of cellular excitability (Emery et 
al., 2011a).   
5.1.2. HCN Isoforms  
The main characteristic used to differentiate between all four HCN isoforms is their 
activation kinetic profiles; HCN1 being the fastest activating channel, HCN4 
displaying the slowest activation kinetics and HCN2 and HCN3 show an intermediate 
speed of activation. The HCN isoforms also differ in terms of their modulation by 
intracellular cAMP, HCN2 and HCN4 are the most sensitive to changes in cAMP 
whereas HCN1 is only partially sensitive and HCN3 is not modulated by cyclic 
nucleotides (Wainger et al., 2001). Evidence suggests that HCN channel activation 
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can be shifted to a more positive potential, through a similar mechanism as with 
cAMP, by phosphatidylinositol-4,5-biphosphate (PIP2), with all isoforms being equally 
sensitive to modulation by PIP2. (Pian et al., 2006; Zolles et al., 2006). Furthermore, 
channel activation kinetics of HCN2 and HCN4, but not HCN1 can be regulated by 
other modifications such as Src Kinase-induced tyrosine phosphorylation of the 
tyrosine residue in the C-linker region between transmembrane domain 6 and cyclic-
nucleotide binding domain (Li et al., 2009).  
 
There has been conflicting evidence published with regards to differential expression 
profiles of HCN isoforms. It was originally thought that only HCN4 was primarily 
found in the heart’s sino-atrial node, however recent evidence suggests that HCN1, 
HCN2 are also expressed; indicating that all three isoforms contribute to If current, 
an inward current activated by hyperpolarisation in cardiac cells, also known as Ih in 
neurons (Herrmann et al., 2011). In the central nervous system, all four isoforms are 
differentially expressed in different regions. HCN2 is thought to be ubiquitously 
expressed, HCN3 is mainly found in the hypothalamus, HCN4 in the thalamus and 
HCN1 in the neocortex, hippocampus and cerebellum (Notomi and Shigemoto, 
2004). In the PNS, HCN1, HCN2 and HCN4 are mainly expressed in small diameter 
neurons, whereas HCN1 is not thought to be functionally active in small neurons as 
its deletion had no effect aspects of pain in mouse models (Momin et al. 2008). The 
expression of HCN3 in small diameter neurons has been reported to be low, which 
has been supported by both electrophysiological and knock out studies (Emery et al., 
2011a; Gao et al., 2012; Momin et al., 2008a). The HCN2 channel is thought to be 
responsible for the Ih current in small diameter neurons, as genetic deletion of HCN2 
reduces the cAMP-dependent component of Ih significantly (Momin et al., 2008b).  
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5.1.3. Role of HCN Channel in Pain  
There has been ample evidence to suggest that increased activation of the Ih current 
is associated with peripheral hyperexcitability or increased excitability of nociceptors 
in both inflammatory and neuropathic pain (Luo et al., 2007; Momin et al., 2008a). 
Moreover, the widespread use of Ivabradine in the clinic for the treatment of heart 
failure, with a relatively safe side effect profile makes these channels an attractive 
target for different indications such as pain, given the involvement of HCN channels 
in neuronal excitability (Psotka and Teerlink, 2016; Tse and Mazzola, 2015). Two 
groups have reported evidence for the involvement of Ih current in both neuropathic, 
SNL and PNL models as well as inflammatory associated sensitisation in the 
formalin test (Luo et al., 2007; Takasu et al., 2010). Further, an accumulation and 
redistribution of axonal HCN channels was demonstrated by immunocytochemistry 
and western blotting in nerve injury models in vivo (Jiang et al., 2008; Smith et al., 
2015). The role of the HCN2 isoform in neuropathic pain was revealed as the 
deletion of this channel resulted in a significant reduction in mechanical and thermal 
hypersensitivity in both, CFA- and carrageenan-induced inflammatory rodent pain 
models (Emery et al. 2012). Another study suggested that heat hyperalgesia 
associated with inflammatory pain requires the expression of HCN2 in higher 
centres, not peripheral HCN2 channels (Schnorr et al., 2014).  
5.1.4. Role of HCN2 Channel in PGE2-induced axonal ongoing activity 
It has been demonstrated that inflammatory mediators, such as PGE2 act on GPCRs 
to increase intracellular cAMP levels, ultimately resulting in an increased rate of 
action potential firing (Momin et al., 2008b). Given the role of cAMP in modulating 
HCN channels and their role in regulating action potential frequency, these studies 
suggested the role of HCN channels as an important candidate responsible for 
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increased action potential frequency in response to IM at the DRG soma. Moreover, 
deletion of the HCN2 gene abolished increased neuronal firing induced by PGE2 or 
forskolin, a rapid activator of adenylate cyclase, in isolated neurons (Emery et al., 
2011a). Taken together, these findings propose an interesting hypothesis suggesting 
an important role of HCN channels in painful conditions. Moreover, these studies 
suggest the HCN2 channel are the primary downstream candidate of PGE2 –




Figure 31. Activation of HCN channels and impact on neuronal firing.  
Binding of cAMP to cyclic nucleotide-binding domain (CNBD) the C-terminal of HCN 
channel results in a positive shift in activation threshold. This causes the channel to 
reduce its latency between action potentials, as it is activated at more positive 
membrane potentials, thereby explaining an increase in action potential firing 
frequency by a rapid repolarization of the membrane potential.  
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5.2. Rationale and Aims 
 
One of the interesting aspects of axonal response to PGE2 sensitisation we 
observed was the direct depolarization of the axons and persistent activity in the 
axons after termination of the signal. Given the lack of inflammatory pain 
sensitisation in HCN2 KO mice, as well as the fact that HCN channels are heavily 
modulated by cAMP, which is a second messenger activated by PGE2, HCN 
channels appear to be good candidates as downstream effectors of PGE2-mediated 
neuronal sensitisation and activation. Initial reports using DRG neurons in 
conventional culture configuration showed that forskolin evoked changes in neuronal 
function at the cell soma, which is abolished in HCN2 KO neurons (Emery et al., 
2011a). We hypothesized that axonal HCN2 channels might respond to cAMP 
elevation downstream of PGE2-EP receptor activation, leading to subsequent 
depolarization of axons. The aim of the experiments in this chapter is to understand 
whether HCN2 channels are involved downstream of PGE2 sensitisation and 
activation of nociceptive axons. Using pharmacological blockers of HCN channels 
and HCN2 knockout mice, the contribution to axonal activity recorded at the soma 









5.3. Results   
 
Firstly, we tested to see whether HCN channels play an important role in 
inflammatory sensitisation of DRG axons. For this initial experiment, we used a non-
selective HCN channel blocker, Zatebradine, which has a similar chemical structure 
to Ivabradine. Changes in KCl response in DRG cell bodies before and after IM or 
vehicle treatment to isolated DRG axons were measured. This experiment was then 
repeated in the presence of Zatebradine or its vehicle control, pre-incubated in the 
axonal chamber for 10 minutes prior to the start of the experiment. Axonal 
sensitisation assessed using two measurements, changes in the intensity of the 
maximum response of Ca2+ signal (∆Fratio) and the changes in the number of axonal 
responders to 20mM KCl.  
 
A significant increase in fold change of the maximum response in cell bodies of IM-
treated axons compared to vehicle group (Figure 32A). However, following a 10-
minute pre-incubation with 10M Zatebradine, the potentiation in maximum response 
induced by IM was abolished. This concentration of Zatebradine was chosen based 
on published studies showing its effectiveness in inhibiting Ih current at 10M  (Gill et 
al., 2004; Van Bogaert and Pittoors, 2003). Pre-incubation with Zatebradine, resulted 
in no significant increase in the number of responders was observed, despite 
treatment with IM for two hours (Figure 32B). This data suggested that HCN 
channels in peripheral terminals are important mediators of axonal sensitisation 






Figure 32. Zatebradine, a non-selective HCN blocker, reverses IM-induced 
axonal sensitisation. 
A) Schematic of experimental set up and protocol used for different groups: KCl 
responses were recorded from cell bodies before and after IM or vehicle treatment of 
DRG axons, this was then repeated in MFCs where the axonal chamber was pre-
incubated with Zatebradine or vehicle. B) Data expressed as the mean ± S.E.M, 
showing an increase in the maximum responses to 20mM KCl after axonal treatment 
with IM compared to vehicle (*p<0.05). IM-induced potentiation of second KCl 
response was significantly reduced in neurons whose axons were pre-treated with 
10M Zatebradine, compared to those treated with IM only (****p<0.0001, Kruskal-
Wallis test with Dunn’s test for multiple comparisons, n=12-28 DRG neurons, n=3-8 
mice/group). B) Mean percentage responders to KCl. No significant changes were 
observed in number of responders in groups treated with Zatebradine. (Mann-
Whitney U test, n=12-28 DRG neurons, n=3-8 mice/group) 
 
We further investigated the role of HCN2 isoform in inflammatory axonal 
sensitisation. Taking advantage of a KO mouse model of HCN2 ablation from the 
McNaughton lab, the contribution of this channel to the sensitisation of axons was 
assessed. HCN KO mice developed ataxia after 4 weeks and did not survive past 5 
weeks. Thus, for the experiments described in this chapter, all HCN2 KO/WT mice 
were used by week 4 unless stated otherwise.  
 
Unexpectedly, it was found that both in HCN2 WT and KO mice, axonal responses to 
20mM KCl were not sensitised after IM-treatment (Figure 33A-C). No difference was 
observed between maximum response before and after IM-treatment in both HCN2 
KO and WT mice (Figure 33D). Based on this data, we postulated that IM-induced 
axonal sensitisation may be an age-dependent effect, and is therefore only present 
in older mice. To address this question, this experiment was repeated in young, 
C57bl/6 mice at 4-5 weeks of age, using the same experimental protocol and same 








Figure 33. HCN WT DRG axons are not sensitised after IM-treatment. 
A) Schematic of experimental set up and protocol used for different groups: KCl 
responses were recorded from cell bodies before and after IM or vehicle treatment of 
DRG axons from HCN2 KO and HCN2 WT mice. B) Representative trace showing 
no potentiation of KCl response after exposure to IM for 3 minutes in HCN2 WT DRG 
neurons. C) Representative trace showing no potentiation of KCl response after 
exposure to IM for 3 minutes in HCN2 KO DRG neurons. D) Data expressed as the 
mean ± S.E.M, showing no difference in maximum response to 20mM KCl after 
axonal treatment with IM was observed in either HCN2 KO and WT. (Mann- Whitney 
U, p<0.1898, n=11-12 DRG, n=6 mice) 
 
 
However, we found that IM-induced axonal sensitization to 20 mM KCl stimulation 
was present in 5-week old C57bl/6 mice (Figure 34CA-B). Maximum responses to 
20mM KCl after IM- treatment were significantly increased, with a 6.1-fold increase 
from 0.132 ± 0.01 to 0.801 ± 0.01 (Figure 34C). We also observed a significant 
increase in the number of percentage responders to KCl after IM treatment in 
comparison to baseline responses before treatment (Figure 34D).  Therefore, we 
concluded that IM-induced axonal sensitisation is present in younger mice, at 4 
weeks. The genetic background is potentially a contributing factor; although, we 
have observed sensitisation of axons by IM both in WT C57BL/6 as well as CD-1 
outbred mice (data not shown). Therefore, it is unclear why the strain of HCN2 KO 








Figure 34. IM-induced axonal sensitisation is not age-dependent. 
A) Schematic of experimental set up: KCl responses were recorded from cell bodies 
before and after IM or vehicle treatment of DRG axons in C57bl/6 mice of the same 
age as the HCN2 KO and WT used (4 weeks). B) Representative trace showing 
potentiation of KCl response after exposure to IM for 3 minutes in DRG neurons from 
4-week old C57bl/6 mice. C) Data expressed as mean ± S.E.M, where graph 
displays quantification of maximum responses to 20mM KCl before and after axonal 
treatment with IM. IM- treated neurons showed a significantly higher maximum 
response to KCl stimulation after treatment compared to vehicle treated neurons, 
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where **p<0.01 (Two-tailed, paired t-test, **p<0.01 n=10-15 DRG, n=3 mice). D) 
Mean percentage of responders to 20mM KCl significantly increased after IM 
treatment (*p<0.05, Chi-square test, n=10-15 DRG, n=3 mice). 
 
 
Next, we tested we tested whether the HCN2 isoform is a downstream effector of 
PGE2, and whether it is responsible for PGE2-mediated ongoing axonal activity. In 
order to test this hypothesis, a selective HCN2 blocker was provided by courtesy of 
the McNaughton Lab which was demonstrated to be 30x more selective for HCN2 
over Nav1.3, Nav1.7, and Nav1.8, as well as Cav1.2, Cav1.3, and Cav2.2 (Table 2, 
provided by McNaughton Lab).  
 
 
Table 2. Summary of HCN2 antagonist selectivity data. 
 
5M of the HCN2 selective compound silenced PGE2- induced ongoing axonal 
activity (Figure 35A-B).  The number of Ca2+ transients/5 minutes measured at the 
soma after treatment of axons with 10M PGE2 for 1 minute, were significantly 
reduced after application of the HCN2 selective inhibitor. The effects of the HCN2 
selective compound appeared to be irreversible, as the Ca2+ transients did not return 





Figure 35. HCN2 selective blocker silences PGE2-induced ongoing activity. 
A) Schematic of experimental set up and protocol: Only DiI-stained cell bodies were 
selected for calcium imaging analysis. Axonal chamber was stimulated with 10uM 
PGE2, followed by a wash-out, after which the selective HCN2 blocker was applied 
to the axonal chamber to test its effect on the number of transients induced by PGE2 
for 5 minutes. B) Representative trace showing PGE2-induced axonal ongoing 
activity irreversibly silenced by 5M HCN2 selective compound. B) Quantification of 
the number of transients/5 minutes observed after application of stimulus. Data 
expressed as mean ± S.E.M, showing a significant decrease in the number of PGE2-
induced spikes after application of HCN2 selective inhibitor. (One-way ANOVA with 
Tukey’s multiple comparisons test, ***p<0.001, n=12-15 DRG, n=4 mice) 
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We further addressed this question by using HCN2 KO and WT mice, and postulated 
that PGE2-induced ongoing activity would be absent in HCN2 KO mice. We found 
that the absence of HCN2 channels had no effect on PGE2-induced ongoing axonal 
activity.  PGE2-induced persistent activity was present in DRG axons of both HCN2 
KO and their WT littermates with no significant difference in number of transients/5 
minutes between both groups (Figure 36A-D). These data would suggest that HCN2 
is not strictly required for PGE2 mediated nociceptor activation and persistent activity 
in DRG axons.  
 
Taken together, the results of these experiments provide some support for 
involvement of HCN channels in IM-induced sensitisation of sensory axons. 
However, it remains unclear whether HCN2 channels are responsible for PGE2-





Figure 36. PGE2-induced ongoing activity present in both HCN2 WT and KO 
DRG axons. 
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A) Schematic of experimental set up and protocol used for different groups: the 
number of Ca2+ transients induced by 10uM PGE2 were measured in DRG axons 
from HCN2 KO mice compared to HCN2 WT mice. B) Representative trace showing 
PGE2-induced ongoing activity at the axonal level in HCN2 WT DRG neurons. C) 
Representative trace showing PGE2-induced ongoing activity at the axonal level in 
HCN2 KO DRG neurons. D) Data expressed as the mean ± S.E.M, showing no 
significant difference in number of transients/5 minutes induced by PGE2, between 





































5.4. Summary  
Based on available literature, HCN channels appear to be good candidates as 
downstream mediators of PGE2-induced nociceptor activation and persistent activity 
in DRG axons. Thus, we assessed whether HCN channels, with a particular focus on 
the HCN2 subtype, play an important role in axonal activation and sensitisation.  
 
A non-selective HCN blocker, Zatebradine, was used which reversed IM-induced 
axonal sensitization pointing towards the idea that HCN channels are important 
mediators of IM-induced sensitisation in DRG axons. Further, we investigated the 
contribution of the HCN2 isoform to IM- induced sensitization, and found that DRG 
axons of both HCN2 WT and KO could not be sensitised following inflammatory 
insult. Therefore, it remains unclear whether HCN2 is a key axonal player 
responsible for IM-induced sensitisation of peripheral axons.  
 
We also tested to see whether HCN2 acts a downstream mediator of PGE2- induced 
persistent axonal ongoing activity. Using a HCN2 selective antagonist, we were able 
to detect complete silencing of PGE2-induced ongoing activity. However, again this 
was not supported when using HCN2 KO DRG neurons, as genetic deletion of 
HCN2 did not have an effect on PGE2-induced persistent activity at the axonal level. 
Hence, it is unlikely that HCN2 channels are responsible for PGE2-mediated 





6. RESULTS IV: Development and characterisation of hIPSC-






6.1.1. Are rodent models predictive of human disease? 
Undoubtedly, animal models have been pivotal in our understanding of mechanisms 
underlying disease pathology. However, their predictive value for the development of 
clinically effective therapeutic agents remains to be a contentious subject matter. A 
systematic review reported that out of the chosen highly cited publications of animal 
studies, one third are contradicted by randomized human trials, one third remain 
untested and only one third are actually replicated as randomized human trials 
(Hackam and Redelmeier, 2006). A clear example of this, within the field of pain, is 
the history of NK1 receptor antagonists; despite their ability to block behavioral 
responses to noxious stimuli in rodents, they failed to demonstrate efficacy in clinical 
trials of a number of chronic pain states (Hill, 2000). Although blockade of NK1 
receptors is sufficient to attenuate responses to stressors in humans in a similar 
manner to what is observed in preclinical studies, it is not sufficient to provide clinical 
pain relief.  
 
Furthermore, a recent detailed study highlighted several, previously underestimated, 
differences between the transcriptome of human and mice, which are likely to 
account for important differences in physiology. They claimed that gene expression 
was more similar between different tissues of the same species as opposed to 
comparable tissue of different species (Lin et al., 2014).  
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6.1.2. Currently available tools to study disease pathology in human 
models  
The failure of a number of clinical trials over the past decade, has driven the shift 
towards developing alternative approaches to the traditional animal models used in 
the field of neuroscience, with many research groups turning towards the possibility 
of experimentation using human cells and tissues. The increasing availability and 
access to human DRG from organ donor networks, has enabled research using 
human tissue in the field of pain over the years. Studies have highlighted several 
differences in functional properties of ion channels when compared to rodent 
models. For instance, a TTX-resistant current was discovered in human DRG, which 
had not been previously identified in rodents (Dib-Hajj et al., 1999). Moreover, long-
term viability of healthy human DRG neurons in culture for up to almost a month has 
also been reported recently (Enright et al., 2016). Human DRGs have become 
increasingly popular and have been put forward as preclinical vehicles for the target 
validation of phase of the drug development process (Copits et al.; Davidson et al., 
2014; Davidson et al., 2016). 
 
However, human tissue or cellular material is generally limited and very expensive to 
acquire. Therefore, there has been a focus on using stem cells which can be 
differentiated into any cell type of the body. Furthermore, advances in stem cell 
technology have enabled the development of protocols for the generation of sensory 
neurons from adult human induced pluripotent stem cells (hIPSCs) (Cai et al., 2016; 
Park et al., 2008). Human IPSC-derived neurons have become an increasingly 
popular model for neurodegenerative disease studies and drug discovery efforts. 
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The ability to differentiate cells from patients suffering from pain syndromes could 
provide a unique opportunity to understand the cellular pathophysiology of human 
pain conditions. 
6.1.3. In vitro disease modelling using hIPSC-derived neurons  
The pluripotency of embryonic stem cells (ESC) and the use of ESC-derived cell 
lines for experimental research was first suggested in 1998 (Thomson et al., 1998). 
The ethical concerns associated with using embryonic stem cells from human 
embryos have hampered the progress within this particular field (de Miguel-Beriain, 
2015). In order to circumvent this issue, there had been interest in developing human 
inducible pluripotent stem cells (hIPSC), which are derived from adult somatic cells 
and can be reprogrammed by retroviral transduction of transcription factors such as 
Oct3/4, Sox2, Klf4, and c-Myc (Takahashi et al., 2007). The exact mechanism 
through which these four transcription factors induce pluripotency is yet unclear, 
however, IPSCs can be derived from any tissue such as neural cells, keratinocytes, 
adipose-derived cells and blood cells amongst others, and can differentiate into any 
somatic cell type (Carey et al., 2009; Soldner et al., 2009). Human IPSCs show 
similar properties to human embryonic cells in morphology, proliferation, cell surface 
markers, gene expression amongst others (Daley et al., 2009). These characteristics 
make IPSCs a cost-effective alternative to primary human neurons for studying 
molecular mechanisms of human diseases as well as drug screening. 
 
The expression profile of hIPSC-derived sensory neurons has been shown to follow 
a similar pattern in vitro when compared to human DRG samples in vivo. It was 
shown that expression of neuronal markers appeared around 9 to 16 days after 
plating and increased gradually until the end of the differentiation protocol. The 
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confirmed the functionality of GABAA receptors, HCN channels, ASIC channels and 
voltage gated potassium channels. Moreover, the differentiated cells expressed 141 
out of 168 ion channel genes found in adult human DRG samples (Young et al., 
2014b). Young and co-workers suggest that hIPSC-derived sensory neurons serve 
alternative and more physiologically relevant model to rodent DRGs for pain 
research, as they provide evidence for molecular and functional similarities between 
inducible sensory neurons and primary human DRG. Moreover, another study 
showed that inducible sensory neurons derived from human fibroblasts not only 
exhibited responses to TRP agonists, demonstrating functional properties of 
nociceptive neurons, but also showed a marked sensitisation of capsaicin responses 
after treatment with either PGE2 or oxaliplatin, a commonly used chemotherapeutic 
drug, recapitulating key mechanisms of inflammatory pain hypersensitivity and 
peripheral chemotherapy-induced neuropathy (Wainger et al., 2015).  
 
The availability of hIPSCs has significantly increased the usage of in vitro disease 
modelling. Reports have been published for the first set of drug candidates to be 
tested in clinical trials based on findings obtained from iPSC-derived neurons 
(Mullard, 2015). Furthermore, hIPSCs are being used for models of pain, such as 
chemotherapy induced peripheral neuropathy (Morrison et al., 2016; Wainger et al., 
2015). The use of in vitro-differentiated sensory neurons have the potential to 
accelerate our understanding of pain-related signalling pathways and functional 










6.2. Rationale and Aims  
 
The use of hIPSC-derived neurons in conventional cultures is now routinely 
performed however, culturing these neurons in MFC will enable the study of axonal 
function in human nociceptive neurons as a more physiological model of human 
pain. The aim of this chapter was to assess whether it would be feasible to maintain 
commercially sourced hIPSC-derived neurons in MFCs and the use of this platform 
to investigate axonal function. 
 
In this chapter I aimed to establish in vitro conditions for maintaining healthy hIPSC-
derived sensory neurons on glass coverslips as well as maintaining hIPSC-derived 
sensory neuronal axons in the 3-channel MFC system for 4 weeks. In addition, I 
aimed to characterise and identify different cell populations present in these in vitro 
cultures at 4 weeks post-plating, using pharmacological tools. Finally, to characterise 


















6.3. Results   
Human IPSC- sensory neuron progenitors were provided by Axol Biosciences, which 
had been derived from IPSCs of healthy male donors and had been differentiated to 
sensory neurons progenitors using small molecule inhibitors. Data from other labs 
using human iPSC-derived neuron progenitors provided by Axol Biosciences had 
shown expression of important pain markers such as Nav1.7, Nav1.8 and Nav1.9 at 4 
weeks post-plating (Axol Biosciences, personal communication, 2017).  Thus, we 
aimed to establish optimal in vitro culture conditions with adequate cell adherence for 
at least 4 weeks post-plating on both conventional cultures and in MFC system. In 
order to achieve this, different combinations of coating substrates were tested. 
Coating substrates kindly provided by Axol Biosciences, including ReadySet and 
Surebond, which were tested at different durations as well as against matrigel, which 
has been reported as the coating substrate of choice in several reports 
characterising hIPSC-derived neurons (Young et al., 2014; Cai et al., 2016).  
 
The combination of 24-hour incubation ReadySet and 1-hour Surebond was first 
tested, which resulted in extensive clumping of cell bodies in somal compartment by 
week 2 (Figure 37B). Clumping of cell bodies presents a significant issue for 
carrying out calcium imaging or patch clamping experiments, as it makes analysis of 
signals single-cell signals difficult. Axonal degeneration was also observed by week 
2, in both axonal and peripheral terminal compartment of the MFC system (Figure 
37C-D). This protocol was therefore not optimal for cell attachment of hIPSC-derived 
sensory neurons in the 3-channel MFC system. To address the source of this issue, 
we aimed to identify the optimal coating substrate on regular glass coverslips first. 
We compared the combination of 1-hour ReadySet + 1-hour Surebond to coating for 
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2 hours with a thin layer of 1:40 diluted matrigel on regular glass coverslips. No 
differences were observed between groups during the first 2 weeks in vitro, however 
extensive somal clumping was apparent by week 4 with matrigel-coating coverslips 
(Figure 38C-D), compared to coating with 1-hour ReadySet + 1-hour Surebond 
(Figure 38A-B). Finally, we tested whether the 1-hour ReadySet + 1-hour Surebond 
combination would enable optimal cell adherence in the 3-channel MFC system. This 
combination enabled optimal maintenance of hIPSC-derived sensory neurons in 
MFCs for 4 weeks, with reduced somal clumping and no axonal blebbing (Figure 
39B-C). Therefore, this coating protocol was chosen for future experiments. Table 3 





Figure 37. 24-hour ReadySet + 1-hour Surebond coating combination in MFCs. 
Representative images of different compartments 1-day post plating and 2 weeks 
post plating.  A) hIPSC-derived sensory cell bodies in somal compartment 1 day 
post-plating. B) hIPSC-derived sensory neurons in somal compartment showing 
clumping of cell bodies 2 weeks post-plating. C) hIPSC-derived sensory axons in 
proximal axonal compartment showing axonal degeneration 2 weeks post-plating. D) 
hIPSC-derived sensory axons in distal axonal compartment showing axonal 




Figure 38. 1-hour ReadySet + 1-hour Surebond combination vs. matrigel 
coating on glass coverslips. 
Representative images at 4-weeks post plating. A-B) hIPSC-derived sensory 
neurons on glass coverslips coated with ReadySet + Surebond combination. C-D) 
hIPSC-derived sensory neurons on glass coverslips coated with 1:40 matrigel for 2 





Figure 39. 1-hour ReadySet + 1-hour Surebond coating combination in MFCs. 
Representative images of different compartments 1-day post-plating and 4 weeks 
post-plating.  A) hIPSC-derived sensory cell bodies in somal compartment 1 day 
post-plating. B) hIPSC-derived sensory neurons in somal compartment with no 
clumping of cell bodies observed 4 weeks post-plating. C) hIPSC-derived sensory 
axons in proximal axonal compartment with no axonal degeneration observed 4 
weeks post-plating. D) hIPSC-derived sensory axons in distal axonal compartment 




Table 3. Summary of different coating combinations tested for optimal 
adhesion of hIPSC-derived sensory neurons. 
 
To characterise the populations of the cells being produced using the current 
protocol, we next assessed the functional properties of the different populations of 
cells present in our hIPSC-derived sensory neuron cultures based on their 
responses to TRP channel agonists including icilin, AITC, and capsaicin.  
 
In the first set of experiments where functional properties of neurons on glass 
coverslips were tested. We found that hIPSC-derived sensory neurons were 
responsive to 20mM KCl, 1M icilin and 65mM KCl (Figure 40A, B and D). No 
responses to AITC were observed (Figure 40C). The magnitude of responses to 
20mM KCl, 100M AITC and 1M icilin were quantified as maximum responses 
normalised to responses to 65mM KCl (Figure 40E). Interestingly, we found that 
33.3% of neurons were responsive to icilin and 100% of neurons responded to 
20mM KCl, whereas no response to AITC or capsaicin was detected in cultures 4 





Figure 40. hIPSC- derived sensory neurons on glass coverslips were 
responsive to different chemical stimuli, at 4 weeks in vitro 
Representative trace of responses, where each trace represents one DRG soma. A) 
Responses to 20mM KCl (1-minute application) B) Response to 1M Icilin (2.5 min 
application) C) Representative trace showing responses to 100M AITC (3 min 
application). D) Responses to 65mM KCl (1 min application). E) Bar graph 
expressed as mean ± S.E.M. showing average maximum responses to 1M icillin, 
100M AITC, 20mM KCl and 500nM Capsaicin, normalized to maximal or 65mM KCl 
response of DRG neurons. F) Bar graph expressed as mean ± S.E.M. showing 
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average % responders to 1M icilin, 100M AITC, 20mM KCl and 500nM capsaicin 




As mentioned above, using the original protocol for maintenance of hIPSC-derived 
sensory neurons, where media containing 25ng/ml GDNF, 25ng/ml NGF, 10ng/ml 
BDNF and 10ng/ml NT-3 was refreshed every 3 days, we observed no capsaicin-
sensitivity was observed in hIPSC-derived sensory neuronal cultures (Figure 41A). 
However, serendipitously we discovered that in the presence of 125ng/ml GDNF, 
neurons developed capsaicin sensitivity (Figure 41B). No capsaicin responsiveness 
was recorded in cultures maintained in media containing 25ng/ml GDNF (Figure 
41C), whereas an average of 66% of neurons were responsive to 500nM capsaicin 
when cells were maintained in media containing 125ng/ml GDNF (Figure 41D). On 
average, 70% of neurons were responsive to 20mM KCl out of the total number of 
responders to 65mM KCl (Figure 41C-D). This suggests that higher concentrations 
of GDNF may be required for TRPV1 expression in developing hIPSC-derived 
neurons. It could be that a higher concentration of GDNF is required to drive the 
neuronal differentiation process from progenitor cells to sensory neuronal 
populations expressing TRPV1 channels.  
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Figure 41. Development of capsaicin sensitivity in hIPSC- derived neurons 
depends on GDNF concentration. 
A) Representative traces of responses to 500nM capsaicin at the soma, when 
treated with 25ng/ml GDNF. B) Representative traces of responses to 500nM 
capsaicin at the soma, when treated with 125ng/ml GDNF. C) Bars representing 
mean ± S.E.M. showing average percentage of responders to 500nM capsaicin in 
presence of 25ng/ml GDNF, out of total number of responders to 65mM KCl. D) Bars 
representing mean ± S.E.M. showing average percentage of responders to 500nM 
capsaicin in presence of 125ng/ml GDNF, out of total number of responders to 




Next, we assessed whether hIPSC-derived sensory neurons could be sensitised by 
inflammatory mediators. We found that despite lack of capsaicin sensitivity observed 
in these cultures containing recommended levels of growth factors (according to 
protocol provided by Axol Biosciences), somal responses to 20mM KCl were 
potentiated after IM treatment, compared to baseline somal responses to 20mM KCl 
(Figure 42A). KCl responses at the soma were potentiated 1.3-fold after treatment 
with IM, from 0.157 ± 0.007 to 0.215 ± 0.01 (Figure 42B).  
 
Figure 42. hIPSC- derived sensory neuron cell bodies are sensitised after IM-
treatment, despite capsaicin insensitivity in MFCs. 
A) Representative trace showing responses to 20mM KCl, IM, and potentiation of 
second response to 20mM KCl. Each sweep represents one DRG neuron. B) Bar 
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graph expressed as mean ± S.E.M. showing average maximum responses to 20mM 
KCl response before and after IM-treatment. Significant increase in maximum 
response observed to 20mM KCl, where ****p<0.0001. (Two-tailed, paired student’s 




Next, we examined hIPSC-derived neurons’ axonal responses to depolarisation with 
KCl and their ability to propagate signals to the cell body in the MFC model. 
Preliminary data suggested that a small population of fluidically isolated axons were 
responsive to increasing concentrations to KCl (Figure 43). We found that many 
axons did not respond to KCl stimulation, despite a robust signal in the cell soma. 
Given the variability observed in detecting axonal function in hIPSC-derived neurons 
between all six batches provided by Axol Biosciences, we were not able to test the 
impact of IM on axonal function.  
 
 
Figure 43. Preliminary result: Isolated hIPSC-derived sensory neuronal axons 
appear to be electrically active at week 4 in vitro in MFCs. 
Representative traces, each sweep representing one neuron, showing axonal Ca2+ 








One of the difficulties in using conventional cultures of iPSC-derived neurons for cell 
physiological measurement is the clumping of the neurons and lack of sustained 
adhesion to the substrate. Here we optimized a protocol that ensures adequate cell 
adhesion and maintenance of hIPSC-derived sensory neurons for up to 4 weeks 
post-plating in MFC devices. It was established that a combination of 1-hour 
ReadySet and 1-hour Surebond, coating substrates provided by Axol Biosciences, 
were optimal for growth and cell adhesion.  
 
We characterized the phenotype of cells present at 4 weeks in vitro, and 
demonstrate responsiveness to icillin and KCl. Capsaicin sensitivity in hIPSC-derived 
sensory neurons appeared to be dependent on GDNF concentration in the media, 
despite similar levels of KCl sensitivity. Further, we found that hIPSC-derived 
sensory neuronal cell bodies can be sensitized using a cocktail of inflammatory 
mediators, despite the lack of capsaicin sensitivity observed in these cultures. 
Finally, fluidically isolated axons of hIPSC-derived neurons responded to KCl, 
although, this property varied significantly between all six batches of hIPSC-derived 
neurons tested. We postulate that this may be due to lack of maturity of hIPSC-
derived neuronal axons at 4 weeks post-plating. Although further optimization is 
required, we present proof of concept that microfluidic cultures of hIPSC-derived 












7.1. Using microfluidic-based platforms to study peripheral 
sensitisation in DRG neurons 
 
With increasing evidence pointing towards peripheral mechanisms of sensitisation as 
key drivers of pain, the study of axonal mechanisms at a molecular level would 
provide novel insights into important aspects of both inflammatory and neuropathic 
pain. However, the study of peripherally-restricted mechanisms required a robust 
system that enables interrogating DRG axons in isolation of the DRG cell soma. To 
date, there has been a lack of adequate in vitro models that enable the study of 
functional properties of axons, which motivated this work focusing on the 
development of a cell culture-based assay to test axonal function.  In this study, we 
successfully set up a microfluidic-based in vitro assay in order to study axonal 
properties under inflammatory conditions. 
7.1.1. Optimisation of the MFC system for the use of adult DRG mice  
Previously, a MFC-based in vitro system was successfully optimized and 
characterised for the study of axonal hyperexcitability using postnatal (p1) rat pups 
(Tsantoulas et al., 2013). Conversely, in this thesis, DRG cells from adult mice were 
used with the aim to make this system compatible for use of transgenic mice, to 
enable the investigation of the role of key players responsible for mediating 
significant changes in nociceptor function during inflammatory conditions in this 
system (as discussed in Chapter 5). An additional benefit of using adult mice is that it 
serves as a more clinically relevant model in comparison to postnatal or embryonic 
rodents, as chronic pain states are more common in the elderly population (Fayaz et 
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al., 2016). Several modifications of different parameters were made in order to grow 
and maintain adult DRG neurons successfully in the MFC system, as adult DRG 
neurons are notoriously difficult to maintain in culture over long periods of time. MFC 
devices required strong adhesive surfaces in order to achieve optimal flow rate 
across channels and microgrooves. In our case, we found out that increasing the 
PLL concentration improved adherence of PDMS to glass plate maximizing flow 
rates and reduced clumping of cell bodies, indicative of better adhesion to glass 
coated surfaces. Although we established different NGF concentrations in the two 
compartments, it is likely that the main parameter driving axons to cross through the 
microgrooves had been the height differential as a result of a differences in volume 
between the MFC compartments. Interestingly, Araci and colleagues reported similar 
findings for retinal ganglion neurons in microfluidic cultures (Araci et al., 2014). We 
did not formally test this hypothesis, however, the constant flow from the soma 
compartment to the axonal compartment would not have resulted in an effective 
NGF gradient. Moreover, trophic factors are known to regulate expression profiles of 
different subpopulations of neurons. In future experiments, it would be interesting to 
consider the effects of GDNF, NT3 in either compartments on crossing of axons 
through the microgrooves. Although, we found that the conditions were suitable to 
promote crossing of sufficient number of axons, an increase in the number of axons 
would lead to increased number of neurons examined in each MFC. Of note, 
Phenotypic characterisation of the sensory neurons present in the MFC system of 
those cell bodies with axonal crossings has been carried out previously 
demonstrating approximately 36% CGRP-positive neurons, 32% IB4-positive 
neurons and 17% neurofilament-200 positive neurons (Tsantoulas et al., 2013). 
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7.1.2. Validation of the use of Ca2+ imaging as a readout for axonal 
function  
Through the work presented in this thesis we demonstrate that Ca2+ imaging serves 
as an excellent measure of axonal activity. Tsantoulas and colleagues elegantly 
used patch clamp electrophysiology in combination with the 3-channel MFC system 
to demonstrate that fluidically isolated axons stimulated with KCl lead to the 
generation of APs that propagate towards the soma, causing a change in somal Ca2+ 
concentration (Tsantoulas et al., 2013). The same study showed that the 
propagation of APs from the distal axonal compartment to the soma was blocked by 
application of lidocaine to the middle axonal compartment of a 3-channel MFC 
chamber, whereas responses to somal stimulation were not affected. This 
experiment served as important proof of principle study indicating that the change in 
Ca2+ signal detected at the cell body in response to axonal stimulation with KCl was 
independent of the DRG cell body.  
 
With the aim of setting up a higher-throughput preparation, we set up the MFC 
system using Ca2+ imaging as a readout for axonal function. This enabled sampling 
of multiple neurons simultaneously, which is advantageous due to the inherent 
heterogeneity of DRG sensory neurons. The clear difference in the kinetics of 
Ca2+ signals observed in response to somal and axonal stimulation with the same 
concentration and duration of KCl, is indicative of different mechanisms of Ca2+ influx 
at the soma in response to stimulation of different subcellular compartments of DRG 
neurons. KCl induces a sustained response at the DRG soma as a result of direct 
depolarisation of the somal membrane leading to opening of VGCCs, resulting in 
sustained influx of Ca2+ until washout of KCl stimulus. We propose that the Ca2+ 
transient observed in response to treatment of axons with KCl is a result of 
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generation and propagation of bursts of APs arriving at the soma. Thus, using this 
model we were able to measure somal Ca2+ concentration as a readout for AP 
generation and propagation at an axonal level. 
 
In terms of the frequency of this phenomenon, quantified as percentage of 
responders, we observed that somal stimulation lead to 100% responders (out of 
total number of DiI- stained cell bodies in the field), as opposed to approximately 
50% when stimulating the axons with KCl. These responses to somal stimulation 
therefore served as positive controls and were used as a test for viability of cells. 
Using Ca2+ imaging enables the study of populations of neurons, serving as a more 
high-throughput method in comparison to patch clamp electrophysiology. Further, 
through characterisation of somal and axonal stimulation responses, we confirm that 
imaging Ca2+ in the soma is a robust and sensitive assay of axonal function in MFC 
cultures. The combination of the MFC system with Ca2+ imaging enables the study of 
axonal mechanisms as a model of in vivo nerve ending stimulation. Of note, although 
it would be possible to image Ca2+ signals in the axons themselves, the benefits of 
using the DRG soma as a readout include: 1. It has been shown that Ca2+ signals at 
the soma are a result of AP generated and propagating from the axons, and 2. the 
reliability and convenience of measuring signals at the soma, as they display a better 
signal-to-noise ratio.   
7.1.3. Inflammatory mediators sensitise DRG axons   
The transition from high-threshold baseline nociception to low-threshold clinical pain 
hypersensitivity is thought to involve peripheral sensitisation of 
nociceptors. Hyperexcitability of peripheral neurons through sensitisation is an 
important mechanism contributing to behavioral changes and the perception of pain 
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in the presence of inflammatory mediators, manifested as a reduction in activation 
threshold, and hyperresponsiveness to noxious stimuli in sensory neurons.  
 
In conventional cell culture models, cell bodies are exposed to inflammatory 
mediators and somal changes in responsiveness to various stimuli are determined. 
However, our model enables the study of axonally-restricted manipulations, and 
recapitulates physiological and anatomical features of the peripheral pain system 
more closely, particularly since the DRG cell bodies are not directly exposed to IMs 
during inflammatory conditions. Our current understanding is that peripheral nerve 
terminals are sensitised in response to a combination of IMs which are released 
locally, at the site of injury. In line with this, we demonstrate that localised treatment 
of axons with PGE2, histamine, bradykinin and serotonin can lead to reduced 
activation thresholds, and show significantly enhanced KCl-induced responses of 
nociceptive axons. However, we show that responses to KCl at the soma remained 
the same, confirming that the effect observed does not require the soma of the 
neuron and is localized to the axons. Thus, it is likely, that the combination of IMs 
used in this study activate local axonal pathways leading to nociceptor 
hyperexcitability. Moreover, this model enabled us to compare changes in excitability 
before and after treatment of individual neurons, reducing variability inherent in 
heterogeneous neuronal populations in culture. In addition, we consistently saw an 
increase in number of cells responding to treatment of axons with IMs or PGE2 only 
in this model, suggesting a reduction in activation threshold, where axons previously 
unresponsive to KCl stimulation became responsive due to lower thresholds. Thus, 
we provide evidence of different subtypes including silent nociceptors in our assay.  
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Chemically-induced hyperexcitability of peripheral nerve fibres have been studied 
previously using ex vivo preparations. For instance, it has been shown that protons 
cause an a long lasting sensitisation to mechanical stimuli in C-fibres in the rat skin-
saphenous nerve preparation (Steen et al., 1992). Another study used single fibre 
recordings in canine testis-spermatic nerve preparations to assess the sensitising 
effects of pro-inflammatory agents to mechanical stimuli, measuring single fibre 
recordings from canine testis-spermatic nerve preparations (Koda and Mizumura, 
2002b). This report suggested that histamine and PGE2 sensitise the mechanical 
response via cAMP and PKC signalling pathways at the level of the primary 
afferents, supporting the idea the peripheral nociceptor sensitisation is an important 
mechanism contributing to hyperalgesia to mechanical stimuli in inflammatory pain 
states (Koda and Mizumura, 2002b). Further, our study revealed that individual 
inflammatory mediators are able to sensitise responses to KCl. We found that a 
subpopulation of neurons responds directly to application PGE2 and BK. The 
excitatory effects of BK have been studied in testicular nociceptors in vitro, Koda and 
co-workers also demonstrated that application of 1nM BK alone resulted in 
nociceptor excitation (Koda and Mizumura, 2002a). Similarly, using the skin-
saphenous nerve preparation it was found that application BK induces excitation at 
primary afferent level in a concentration-dependent manner (Banik et al., 2001). 
Whilst the excitatory effects of bradykinin have been extensively studied, whether 
PGE2 induces nociceptor activation at the axonal level has is still a contentious 
subject matter.   
7.1.4. Potential mechanisms of IM-induced sensitisation of axons   
Interestingly, we found that reducing the duration of IM-treatment had no effect on 
the observed sensitisation as there was no differences between groups treated with 
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IM for 2 minutes, and those treated for 2 hours (Figure 19 and Figure 20). IM-
treatment with a duration of two minutes resulted in altered excitability of axons, 
displaying hyperresponsiveness to stimulus and reduced activation thresholds 
similar to that observed with a 2-hour treatment. This suggests that changes in 
axonal excitability are likely to be due to rapid, local changes, such as modulation of 
ion channels via phosphorylation induced by activation of local signalling pathways 
or due to insertion of pre-synthesized ion channels to the axonal membrane as 
suggested by other groups (Cardenas et al., 2001; Ma et al., 2017). There is a vast 
amount of evidence for the role of protein kinases in the alteration of nociceptor 
function through phosphorylation of ion channels found along peripheral nociceptors 
as reviewed by several groups (Basbaum et al., 2009; Linley et al., 2010a). Reports 
have also demonstrated the contribution of second messenger pathways underlying 
the sensitising effects of histamine, PGE2 and bradykinin  (Mizumura et al. 2000; 
England et al. 1996). Moreover, it was reported that ATP and BK-induced increase in 
the number of low voltage activated-positive neurons in DRG neurons was abolished 
after treatment with a PLC-inhibitor, pointing towards the involvement of PLC second 
messenger pathway downstream of these pro-inflammatory agents (Huang et al., 
2016). Further, increased externalization of EP4 receptors has been suggested to be 
responsible for the sensitising effects of PGE2 (Ma & St Jacques, 2013). There is 
also a vast amount of literature linking modulation of VGSCs via cAMP/PKA/PKC 
pathways to the sensitizing effects of 5HT, BK and PGE2 (Cardenas et al., 2001; 
Evans et al., 1999; Gold et al., 1998a). However, these studies focus primarily on 
mechanisms taking place at the DRG cell bodies in vitro. It would be interesting to 
see whether these mechanisms are conserved at the axonal level. 
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7.1.5. Limitations of MFC-system  
 
An important caveat of this system is that axons and nerve terminals are taken away 
from their physiological conditions within a living organism. Although isolating nerve 
endings enables the study of intrinsic properties of nociceptors, isolation of nerve 
endings from their biological milieu in itself may alter their properties. For instance, 
the dissociation process in itself involves an axotomy of the dorsal roots, and has 
been reported to cause hyperexcitability in DRG neurons (Zheng et al., 2007). We 
aim to overcome this important caveat by using a warmed, perfused physiological 
solution to mimic the in vivo conditions as closely as possible, and demonstrate that 
DRG axons in MFCs exhibit key aspects of nociceptors such as responsiveness to 
different chemical stimuli as well as sensitisation. Thus, we propose that studying 
axonal based mechanisms serves as an important complement, to the traditionally-
used DRG cell bodies, as it serves as a better model of in vivo free nerve endings. 
Furthermore, using changes in KCl responses as a measure of sensitisation is not 
representative of sensitisation to all the different modalities of pain (i.e. thermal, 
mechanical). However, our assay robustly demonstrates sensitisation to chemical 
stimuli and enables reproducible and sequential experimentation in MFC cultures 
without causing desensitisation of neurons, which typically occurs with the use of 
capsaicin. NGF is known for its potent sensitising effects, and has been reported to 
cause sprouting of neurons (Mearow and Kril, 1995), therefore growing the axons in 
the presence of media containing NGF for 5-6 days could potentially sensitise 
neurons. In efforts to avoid this confounding factor when interpreting the data, our 
assay enables comparisons of changes in response to IM compared to a baseline 
response with the aim of ensuring that the changes observed are due to the IM 
treatment itself. In future, it would be interesting to test whether it is possible for adult 
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DRG axons to be readily maintained and cross over to the axonal compartment in 
the MFC system, without the presence of NGF in media. Finally, another important 
limitation of this study does not evaluate the recovery to IM- induced sensitisation 
which could also provide valuable insights to understanding nociceptor sensitisation 
at the axonal level.  
 
In summary, our model allows the study of cell-autonomous mechanisms at an 
axonal level using the combination of the MFC system with calcium imaging, as an 
extremely powerful tool for studying functional properties of DRG axons, across 
populations of neurons. Furthermore, it recapitulates key characteristics of human 
chronic pain conditions, such as sensitisation of primary afferents by inflammatory 
mediators. Combining the developed MFC-based in vitro axonal hypersensitivity 
model with genetic, and pharmacological strategies, it would be possible to 
interrogate nociceptive axons to elucidate molecular mechanisms underpinning 










7.2. Identifying axonal-based mechanisms underlying PGE2-
induced nociceptor sensitisation and activation  
 
In chapter 4, we exploit the in vitro MFC system to study the effects of PGE2 on 
axonal excitability in vitro.  Firstly, we demonstrate that treatment with PGE2 on its 
own can sensitise as well as excite DRG axons. We made two intriguing 
observations 1) PGE2 stimulus induced the generation of axonal signals, recorded at 
the cell body as repetitive Ca2+ transients, 2) PGE2 induced- axonal activity 
persisted for 40 minutes even after the wash out of PGE2. Further, we demonstrate 
that axonal ongoing activity can be blocked by the perfusion of lidocaine to the 
middle axonal compartment (Figure 23). This strongly suggests that the treatment of 
distal axons with PGE2 results in the generation and propagation of repetitive bursts 
of action potentials in sensitised axons which arrive at the cell bodies, which we were 
able to detect as persistent Ca2+ transients. It also provides further evidence in 
favour of the idea that peripheral mechanisms are key drivers of ongoing pain. In line 
with this, the lidocaine patch 5% has also been shown to reduce the intensity of pain 
significantly in patients with moderate-to-severe osteoarthritis (Gammaitoni et al., 
2004). Moreover, the observation that PGE2 induces persistent activity in 
nociceptive axons suggests the possibility of such mechanisms to underpin clinical 
ongoing pain, where patients experience significant ongoing pain despite the 
resolution of the initiating cause of the pain response. For instance, there is 
increasing evidence suggesting that a large subpopulation of RA patients in 
remission experience significant persistent pain and inflammatory disease activity 
does not correlate with elevated pain(Lee et al., 2011). Similarly, a significant 
number of IBD patients experience persistent pain despite the resolution of mucosal 
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inflammation (Bielefeldt et al., 2009). Further experiments will shed light on the 
connection if any. Nevertheless, we conclude that our MFC platform recapitulated 
salient features of inflammatory pain sensitisation and serves as a useful tool to 
further understand molecular mechanisms underlying peripheral sensitisation in 
inflammatory pain conditions.  
7.2.1. Molecular mechanisms of PGE2 mediated axonal activity   
The study of electrophysiological properties of axons and detailed understanding of 
voltage-gated axonal ion channels would require patch clamping onto a section of an 
extremely thin axonal structure. These techniques are extremely difficult, requiring a 
lot of training and expertise and do not allow the study of axonal mechanisms in 
isolation of the cell body. Recently, a new generation of voltage sensitive dyes have 
been developed to be able to monitor subthreshold events at multiple areas along 
the axonal membrane, across a population of neurons (Miller et al., 2012).  To our 
knowledge, the ability of inflammatory mediators to induce localised changes in 
membrane potential along the DRG axon have not been demonstrated previously. 
By using voltage imaging dyes in our in vitro MFC system, we were able to detect 
changes in membrane potential of fluidically isolated DRG axons in response to 
treatment with KCl as well as IMs. Our results show for the first time that PGE2 
induces a localized membrane depolarization of the axonal membrane. In agreement 
with our Ca2+ imaging recordings demonstrating persistent activity arriving at the 
soma long after PGE2 application, the depolarisation induced by PGE2 persisted 
despite washout of PGE2. This suggests that the sustained depolarisation induced 
by a short PGE2 treatment is responsible for the repetitive Ca2+ transients detected 
at the DRG soma.  
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In order to understand the mechanism underlying this phenomenon we investigated 
the potential role of second messenger signalling pathways. As mentioned earlier, 
PGE2 exerts a multitude of effector functions via the activation of second messenger 
signalling pathways (Park et al., 2004; Qian et al., 2011; Steinert et al., 2009; Su et 
al., 2008). Several lines of evidence have suggested the role of cAMP/PKA in ion 
channel modification, underlying the sensitizing effects of PGE2 in DRG cell bodies 
in vitro (Evans et al., 1999; Gu et al., 2015; Gu et al., 2003). Thus, we investigated 
whether cAMP/PKA pathway had a role to play in ongoing activity induced by PGE2 
at the axonal level in our assay. We used Rp-cAMPS which is an analogue of the 
naturally occurring cAMP that competitively binds to cyclic nucleotide binding 
domains on PKA and prevents the dissociation and subsequent activation of PKA 
(Schwede et al., 2000). We found that administration of Rp-cAMPS reversibly 
blocked ongoing Ca2+ transients induced by PGE2 at an axonal level, suggesting 
the involvement of cAMP/PKA second messenger pathways. It would be interesting 
to confirm these results by using specific PKA blockers with a distinct mechanism of 
action, and testing to see whether inhibition of axonal activity occurs similar to that 
observed with Rp-cAMPS.  
 
In addition, we investigated the key axonal ion channels responsible for the observed 
PGE2-induced persistent axonal activity. We found that TTX had no effect on PGE2-
induced repetitive transients suggesting that TTX-sensitive channels including 
Nav1.7 do not play a role in PGE2-induced axonal activity. In contrast to our data, 
Nav1.7 global rodent KOs display reduced C-fibre spiking activity contributing to loss 
of inflammatory pain phenotype (Gingras et al., 2014). However, there are increasing 
reports arguing that the observed insensitivity to noxious stimuli observed in Nav1.7 
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KOs is due to compensatory mechanisms such as increased endogenous opioids, 
and decreased serotonergic signalling (Isensee et al., 2017; Minett et al., 2015). We 
also assessed the involvement of axonal Nav1.8 channels in the local effects of 
PGE2. Using PF-01247324, a Nav1.8 selective blocker, we demonstrated that 
Nav1.8 channels play an essential role in PGE2-induced ongoing activity at the 
axonal level, as the propagation of PGE2-induced axonal signals was blocked after 
perfusion of the Nav1.8 blocker to the middle axonal compartment. The role of 
Nav1.8 has been investigated using KO mice, where studies have shown that the 
development of thermal hyperalgesia induced by carrageenan was significantly 
delayed in Nav1.8 KO mice (Akopian et al., 1999). Conversely, it has been shown 
that there was no effect of the genetic deletion on PGE2-induced thermal 
hyperalgesia (Kerr et al., 2001). However, the latter has been considered to be 
largely attributed to compensatory mechanisms taking place in the Nav1.8 knockout 
mice, exhibiting an upregulation of other TTX-R channels (Akopian et al., 1999). In 
line with our findings, PGE2- induced hyperalgesia was shown to be reduced by 
antisense Nav1.8 in rats (Khasar et al., 1998). Moreover, PF-01247324 acts as a 
selective antagonist for Nav1.8 and in both rat and human DRG neurons, and 
application of the drug results in reduced repetitive firing induced by current injection 
(Payne et al., 2015a). The same study used current clamp recordings to show that in 
presence of 1uM PGE2, the percentage inhibition of AP number following application 
of PF-01247324 was reduced, suggesting a strong role for Nav1.8 underlying the 
sensitizing effects of PGE2 at the DRG cell body (Payne et al., 2015b). Our data 
provide further evidence in favour of the idea that PGE2-mediated persistent axonal 
activity occurs in Nav1.8-positive neurons and that these channels may play an 
important role in ongoing pain associated with inflammatory pain conditions. A 
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limitation of the work presented however, is the lack of vehicle controls used to 
demonstrate that the addition of vehicle solution only does not have an effect on 
PGE2-induced ongoing activity. Further, for future experiments, it would be 
interesting to test whether PGE2-induced long-lasting axonal activity is still present 
after the genetic deletion of Nav1.8. Moreover, to gain further insight into the 
molecular players responsible for PGE2-induced depolarisation, the effects of 
different blockers targeting Nav1.8 or the cAMP/PKA pathway on the changes in 
axonal membrane potential induced by PGE2, using voltage imaging techniques with 
Fluovolt dye could be tested.  
 
Further, we demonstrate preliminary data showing the expression and distribution 
pattern of EP4 receptor on isolated nociceptive axons in vitro. All four PGE2 receptor 
subtypes (EP1-4) are known to be expressed by DRGs, whereas the contribution of 
EP4 receptors to inflammatory pain hypersensitivity has been highlighted by several 
groups. For instance, the upregulation of EP4 receptor expression in DRG cell 
bodies, and not of EP1-3 receptors, following CFA-induced inflammation has been 
reported (Lin et al., 2006). In line with this, another group suggested axonal 
anterograde trafficking of EP4 receptors to the nerve terminals as a potential 
mechanism underlying PGE2-induced nociceptor sensitisation. The same group also 
demonstrated increased synthesis and axonal trafficking of EP4 receptors in the 
sciatic nerve using western blots (St-Jacques and Ma, 2014). The pilot study also 
showed co-localisation of EP4 receptors and Nav1.8 ion channels at the axonal level. 
The anatomical proximity of these receptors along DRG axons points towards the 
activation of local signalling pathways downstream the effects of EP4 receptors, 
which can lead to modulation of Nav1.8 channel function during inflammatory pain 
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states. Whether the expression of channels along the end of peripheral axons 
accurately represents nerve endings in vivo is yet to be demonstrated. Further 
experimentation and quantification of data would be required to provide concluding 
evidence demonstrating co-localisation of Nav1.8 and EP4 receptors in the 
peripheral axons and whether this is comparable to what is observed in nerve 
terminals in vivo. 
 
In summary, as illustrated in Figure 44, we propose that PGE2 acts on EP4 
receptors found along the DRG axon, which leads to the activation of cAMP/PKA 
second messenger pathway. We also show that PGE2 application depolarises the 
axonal membrane leading to bursts of action potentials arriving at the cell bodies 
long after washout of PGE2 stimulus.  As our data demonstrates, PKA activation and 
Nav1.8 are two important downstream mediators of PGE2 effect. The activation of 
PKA can lead to potentiation of Nav1.8 channels, it is unclear however, if this 
potentiation is responsible for the observed depolarization of the membrane. We 
hypothesize that PKA functionally modulates axonal Nav1.8 channels which are 
responsible for repetitive Ca2+ transients arriving at the soma (Figure 44). HCN2 
channels are also likely candidates activated by cAMP downstream of EP4 receptor 
activation. However, as discussed in the following section in detail, the data from 
HCN2 KO mice did not agree with the pharmacological blockade of the channels 
making it difficult to formulate conclusions with regards to the role of HCN2 in PGE2-
induced depolarisation of DRG axons. Therefore, further experiments will be 




Figure 44. Proposed mechanism underlying PGE2-induced ongoing axonal 
activity. 
PGE2 acts on EP4 receptor, which stimulates local cAMP/PKA secondary 
messenger pathway. We postulate that PKA activation results in phosphorylation of 
Nav1.8 channel leading to the opening of Nav1.8 channel which is partially 
responsible for persistent volleys of APs propagating to the cell body, detected as 
repetitive Ca2+ transients. However, the mechanism by which PGE2 causes a 















7.3. Evaluating the role of HCN2 in peripheral inflammatory 
sensitisation  
 
7.3.1. Role of HCN2 channels in peripheral inflammatory sensitisation  
The McNaughton group published a study in 2011 suggesting an important role for 
HCN2 channels in both inflammatory and neuropathic pain (Emery et al., 2011b). 
Behavioral data suggested that PGE2-induced heat and mechanical hyperalgesia 
was abolished in conditional Nav1.8/ HCN2-/- mice. Similarly, in a commonly used 
model of neuropathic pain, the CCI model, heat and mechanical hyperalgesia as well 
as cold allodynia were abolished in conditional HCN2 knockout mice. This lead to the 
hypothesis that HCN2 channels in Nav1.8 expressing neurons are pivotal for 
originating neuropathic pain, as well as for certain aspects of inflammatory pain 
(Emery et al., 2011). The role of HCN2 in neuropathic pain was confirmed using 
another model and the snsHCN2KO mutant mouse (Schnorr et al., 2014). Thus, we 
decided to explore these findings using our model of IM-induced axonal 
hypersensitivity. In agreement with these findings, non-specific block of HCN 
channels with Zatebradine reversed IM-mediated axonal sensitization. Zatebradine is 
structurally, very closely related to Ivabradine, which is clinically used a treatment for 
chronic stable angina and heart failure. The antagonists only differ in their binding 
sites to HCN channels (Bucchi et al., 2002).   
The compatibility of our model with the use of transgenic lines, enabled us to validate 
these results using genetic manipulations. HCN2-/- global KO were used in this study. 
HCN2-/-KO mice however, are ataxic and rarely live past 5 weeks. We found that IM-
induced axonal sensitization observed in both adult and younger mice of C57bl/6 
strain, was not reproducible in this HCN2+/+ WT littermates. We concluded that the 
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genetic background of transgenic mice may explain the discrepancy between 
findings, as IM-induced axonal sensitization was not an age-dependent effect as 
sensitisation of axons was clear in DRG from younger mice. Other groups have 
reported similar findings, where they demonstrate that peripheral inflammation alters 
electrophysiological properties of neonatal rat dorsal horn neurons (Torsney & 
Fitzgerald, 2001). Moreover, a study compared nociceptive behaviour in 12-week old 
mice and 6-week old in two behavioral models and showed that aged mice 
presented a reduced nociceptive response to zymozan and formalin (King-
Himmelreich et al., 2015). Based on both pharmacological and genetic strategies 
used, it is difficult to conclude whether HCN2 channels play an important role in IM-
induced sensitization of nociceptors at the axonal level.  
7.3.2. Role of HCN2 channels as a downstream mediator of PGE2-
induced ongoing activity 
Emery et al., (2011) hypothesized that release of the inflammatory mediator PGE2 at 
the site of injury and/or inflammation results in activation of adenylate cyclase, 
leading to increased cAMP levels and modulation of HCN2 channels promoting 
repetitive action potential firing activity. In vitro electrophysiology studies carried out 
in the DRG somata, demonstrated that forskolin or PGE2 was responsible for 
accelerated action potential firing in response to current injection, which was absent 
in conditional Nav1.8/ HCN2-/- mice. 
We explored this further and hypothesized that activation of HCN2 channels 
downstream of PGE2 could be responsible for depolarisation of the axonal 
membrane, subsequently leading to ongoing axonal activity observed in our assay. 
We used a selective HCN2 blocker, developed by the McNaughton lab, and found 
that blocking axonal HCN2 channels with this drug silenced PGE2- induced axonal 
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ongoing activity. This result supported the idea proposed by Emery and co-workers, 
pointing towards the role of HCN2 channels as downstream effector of PGE2 
pathway via modulation by increased intracellular cAMP levels.  
Following the pharmacological results, we further tested the involvement of HCN2 
channels in ongoing activity generated in DRG axons using HCN2 global knockout 
mice, and hypothesized that PGE2-induced ongoing axonal activity, observed as 
repetitive Ca2+ transients at the soma would be abolished in with a global HCN2 KO 
DRG neurons. However, we found that PGE2-induced repetitive Ca2+ transients 
were present in both WT and KO mice, suggesting that ongoing activity induced by 
localized PGE2 does not require HCN2 channels.  
Two possible reasons may provide an explanation for these findings. Although there 
is no direct evidence for this, we speculate that the global deletion of HCN2 could 
have led to compensatory mechanisms in these mice, resulting in compensatory 
upregulation of other HCN subtypes in the HCN2 global knockouts which could be 
responsible for mediating PGE2-induced effects observed in the HCN2 KO DRG 
axons. Another plausible explanation could be that a combination of ion channels 
contributes towards spontaneous activity induced by PGE2 at the axonal level. 
PGE2 increases intracellular cAMP concentrations, and has also been linked to 
activation of PKA. PKA has been demonstrated to phosphorylate a number of 
channels such as TRPV1 and TRPA1 (Brackley et al., 2017). For instance, A-kinase 
anchoring protein (AKAP), a regulatory protein of PKA was shown to facilitate PKA-
mediated phosphorylation of peripheral TRPV1 and TRPA1 channels in ex vivo 
preparations of DRG neurons.  Moreover, Nav1.8 channels have also been linked to 
PGE2-mediated effects as discussed and demonstrated in the previous section (Liu 
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et al., 2010; Payne et al., 2015a). Therefore, PGE2-induced increase in cAMP, and 
subsequent activation of PKA is likely to act on a number of ion channels, which 
collectively contribute to hyperexcitability and peripheral sensitisation in inflammatory 
pain states.  
We conclude that further research is required to establish the role of axonal HCN2 
channels in IM-induced sensitisation of nociceptive axons. Moreover, it is likely that 
HCN2 channels are not solely responsible for PGE2 mediated effects at an axonal 
level. A combination of other channels including TRPV1, TRPA1 and Nav1.8 could 
be potential candidates collectively responsible for PGE2-mediated persistent axonal 



















7.4. Development of an in vitro model of pain signalling using 
microfluidic-based cultures of hIPSC-derived sensory 
neurons 
 
IPSCs have become key tools for disease modelling, particularly in the case of cell 
types such as sensory neurons which are difficult and expensive to obtain from 
donors. In chapter 6, we extend the use of the MFC system to IPSC-derived sensory 
neurons with the aim of developing an in vitro platform enabling the study of the 
functional properties of human sensory axons from human IPSC-derived neurons.  
 
 Human primary DRG neurons have been used for in vitro modelling of pain in 
conventional cultures. Although primary human DRG neurons are a potentially better 
model for understanding molecular mechanisms, their availability is limited. 
Additionally, primary DRG neurons need to be excised in order to be plated in 
culture. Using hIPSC-derived sensory neurons enables the study of naïve and intact 
sensory neurons whereas both rodent and humans is that dissociation, and 
dissociation-induced stress has been shown to alter electrophysiological properties 
of neurons, making neurons hyperexcitable to many mediators such as cAMP- and 
cGMP. Hyperexcitability of DRG neurons caused by dissociation was similar to that 
observed in DRGs from chronic compression treatment (Zheng et al., 2007). Thus, 
not only does the use of hIPSC-derived sensory neurons serve as a more clinically 
relevant system for disease modelling but also allows the study of naïve axons, in 
comparison to those exposed to injury or inflammatory insult.  
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7.4.1. Optimisation of culture conditions for adequate cell attachment of 
hIPSC-derived sensory neurons  
We establish that 1-hour incubation with both ReadySet and 1-hour incubation with 
Surebond (coating substrates provided by Axol Biosciences) are optimal for 
attachment of PDMS to Willco glass plates, and for subsequent attachment of iPSC-
derived sensory neurons to glass surface within MFC devices. Matrigel coating lead 
to inadequate cell adherence resulting in clumping of cell bodies and eventual 
detachment from plates by 2 weeks post-plating. Hence, matrigel was not used for 
future experiments despite being the coating substrate of choice used by other 
groups previously (Young et al., 2014b). 24-hour incubation with ReadySet results in 
axonal degeneration, and eventual death. We speculated that ReadySet may 
potentially have toxic effects on neurons themselves (Personal communication, Axol 
Biosciences). Therefore, thorough washing is required after 1 hour incubation to 
ensure optimal attachment and growth of axons into the peripheral terminal and 
axonal compartments of 3-channel MFC devices.  
7.4.2. Characterisation of the functional properties of hIPSC-derived 
neurons at 4 weeks in vitro  
Concerns have been raised with regards to variability reported between hIPSC-
derived cell lines from different donors due to epigenetic memory maintained from 
different somatic cell types, in addition to variation in genetic and epigenetic factors 
due to inefficient reprogramming and prolonged periods in culture (Bar-Nur et al., 
2011; Lister et al., 2011; Newman and Cooper, 2010). In agreement with this view, a 
study reported that cell lines derived from different cell types of the same donor are 
show less genetic heterogeneity than cell line derived from same tissue type but 
different donors (Rouhani et al., 2014). Moreover, some differences in epigenetic 
markers and transcriptomes when testing 16 IPSC derived cell lines from donors of 
 193 
different sex, age and health status were also reported (Boulting et al., 2011). 
However, the extent to which these impacted the subsequent terminally 
differentiated cells was not clear. Thus, these studies point towards the importance 
of evaluation and characterization of phenotypic markers between different batches 
and cells derived from different donors.  
 
The expression of important sensory neuronal markers in hIPSC-derived sensory 
neurons was validated in a recent study, giving evidence for the presence of Kv 
channels, HCN and ASIC channels by day 9-16 in vitro (Young et al., 2014a). In our 
study, we investigated the functional properties of these cultures at 4 weeks post-
plating (DIV 30) in the presence of 25ng/ml NGF, GDNF, NT-3 and BDNF. We found 
that cell bodies are responsive to KCl, demonstrating similar responses to chemical 
stimuli, as rodent DRGs. Additionally, at 4 weeks post-plating we were able to detect 
axonal responses to KCl. We observed axonal responses to 35mM and 65mM KCl, 
recorded with calcium imaging at the soma similar to those observed in our rodent 
MFC system. However, this was highly variable between coverslips as in some 
cases axons were unresponsive, even to high KCl concentrations. Therefore, further 
optimisation is required to be able to study functional properties of hIPSC-derived 
sensory neuronal axons. We hypothesize, that 30 days in vitro may not be sufficient 
for maturation of human axons and expression of relevant ion channels in axons. For 
instance, longer differentiation period may allow ion channels to be transported from 
the cell bodies to the distal segments of the axons.  
 
The expression of TRP channels, which are markers of mature sensory neurons and 
play an important role in peripheral sensitisation, has not been well characterised in 
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iPSC-derived sensory neurons. Surprisingly, in our hands, we found no responders 
to capsaicin or AITC, indicative of a lack of TRPV1- and TRPA1-positive in hIPSC-
derived sensory neurons. Responses to icillin were detected pointing towards the 
presence of TRPM8-positive neurons, with 33% of average responders which is 
higher than what is usually observed in mouse DRG cultures where approximately 
20% of cell bodies respond to icillin (Bautista et al., 2007). Another interesting 
observation from these preliminary findings was that cell bodies of hIPSC-derived 
sensory neurons can be sensitised after inflammatory insult despite the lack of 
capsaicin sensitivity observed. This points towards the idea that that human-derived 
sensory neurons can be sensitised by inflammatory mediators in the absence of 
functional TRPV1 in these neurons.  
 
Furthermore, we found that capsaicin sensitivity appeared to be dependent on the 
level of GDNF concentration. In the presence of low GDNF concentration (25ng/ml), 
no capsaicin sensitivity was observed, whereas by increasing the level of GDNF by 
5-fold in these cultures cell bodies became capsaicin-responsive. In the presence of 
125ng/ml GDNF, hIPSC-derived neuronal cell bodies displayed 30% capsaicin 
sensitivity. Using immunohistochemistry, it has been previously demonstrated that 
GDNF and NGF facilitate an increase TRPV1 expression in IB4-positive and trkA 
neurons, respectively, in rodent DRGs. Whereas NGF-mediated increase in TRPV1 
expression is rapid and transient, GDNF-mediated effects on TRPV1 appeared to be 
gradual lasting approximately one week (Amaya et al., 2004). There has been 
contrasting evidence with regards to GDNF-induced TRPV1 expression in murine 
DRGs. On study showed that transgenic mice with overexpressed GDNF did not 
display increased TRPV1 expression, and did not show potentiated responses to 
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noxious heat in vivo (Zwick et al., 2002). Moreover, GDNF overexpressing 
transgenic mice displayed a decrease in ganglionic TRPV1 mRNA levels (Albers et 
al., 2006). In contrast, adult mice DRG cultures showed potentiated capsaicin 
responses as well as capsaicin-induced release of CGRP from nerve terminals, after 
exposure to GDNF (Schmutzler et al., 2009). In our study, exposure to high GDNF 
concentrations led to higher capsaicin sensitivity which was absent in the presence 
of low GDNF concentrations. However, it is unclear whether higher GDNF 
concentrations drove the neuronal differentiation process towards TRPV1-positive 
populations or whether exposure to high levels of GDNF, sensitised iPSC-derived 
sensory neurons resulting in increased capsaicin sensitivity.  
 
iPSCs are an invaluable tool for both a more accurate mechanistic understanding of 
diseases as well as for more efficient drug screening. However, our preliminary data 
suggest that current variability in the cultures and batches may limit their application 
beyond testing of analgesic compounds. For future use and the compatibility of 
iPSCs with the MFC system, further optimization of culture conditions is required to 
yield a more representative population of neurons maintained for longer periods. 
Maintaining hIPSC-derived sensory neurons in culture for longer periods would 
ensure their maturity, and expression of canonical markers in the neuronal cell 








7.5. Conclusions and Future Directions 
 
We have developed a robust in-vitro model that mimics key aspects of peripheral 
pain circuitry and allows the study of peripheral sensitisation in inflammatory 
pain. We have shown that using microfluidic cultures provides a convenient platform 
for axonal molecular mechanisms to be studied in detail in the context of pain as well 
as other neurological disorders. Combining other recording techniques such as patch 
clamp electrophysiology or microelectrode arrays (MEA) with MFC culture platform 
would enable gathering more detailed information on ionic mechanisms responsible 
for changes in axonal function during painful conditions.  
 
Non-neuronal cells play an important role in modulating pain responses. Hence, it 
would be interesting to study the influence of non-neuronal cells on IM-induced 
axonal sensitisation. The influence of non-neuronal cells on IM-induced effects could 
be investigated by testing whether IM-induced effects are altered in purified DRG 
neuronal cultures, using a magnetic assisted cell sorting (MACS), which isolates 
predominantly small-diameter neurons (Thakur et al., 2014).  Understanding the role 
of non-neuronal cells in axonal sensitisation in vitro would help us gain 
understanding of the extent to which non-neuronal cells influence neuronal function 
during health and disease. Moreover, understanding the cross-talk between the 
immune and nociceptive systems is an attractive area of research. Although mast 
cells and macrophages have been pointed out as important players responsible for 
the release of inflammatory mediators leading to subsequent sensitisation of 
nociceptors, the impact of other immune cells is yet to be characterised. The use of 
 197 
microfluidic platforms can be extended to the use of co-cultures in order to 
understand interactions between specific immune cells and nociceptors which could 
shed light on mechanisms underlying the modulation of nociceptors by the immune 
system and vice versa. 
 
Here, we propose an axonal-based mechanism underlying ongoing pain in during 
inflammatory pain conditions. We show for the first time that inflammatory mediators 
can cause direct depolarisation of axons, resulting in a volley of action potentials 
arriving at the cell soma and as such, demonstrate the importance of voltage 
changes in the peripheral terminals and axons in the context of inflammatory pain. 
We suggest that PGE2-induced repetitive axonal activity is caused by a local 
depolarisation, which persists beyond PGE2 application. We also show evidence for 
the cAMP/PKA pathway, and Nav1.8 channel as important mediators of ongoing 
axonal activity induced by PGE2. In future, understanding of key mediators 
underlying inflammation induced ongoing activity could lead to therapeutic 
approaches for the management of ongoing pain observed in arthritis or IBD 
patients. 
 
Finally, we optimised and characterise the functional properties of hISPC-derived 
sensory neurons in the MFC system. Optimal coating conditions were established to 
readily maintain induced sensory neurons in culture for 4 weeks. We also provide 
proof of concept for the idea that hISPC-derived sensory neurons can be used in 
MFC platform as an in vitro model of human nociceptor sensitisation.  We also show 
that the cell bodies can be sensitised by inflammatory mediators in absence of 
TRPV1 channels, and that TRPV1 expression in these neurons is GDNF-dependent. 
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Further optimisation and characterisation of this model using hIPSC-derived 
nociceptive neurons will deliver a versatile platform to model peripheral pain 
signalling in vitro.  
 
The combination of changes taking place in the peripheral nerve terminals, spinal 
cord and brain collectively contribute towards altered pain processing responsible for 
the transition from acute to chronic pain. Using the MFC platform, we were able to 
model one of these key features by demonstrating sensitisation of peripheral 
nociceptors. Our model does not account for sensitisation to different pain modalities 
such as thermal and mechanical stimuli, however we do demonstrate key 
characteristics of sensitisation to chemical stimuli: decreased activation threshold 
and increased magnitude of responses. The main players responsible for these 
phenomena however, are yet to be elucidated. Alterations in the expression and 
activity of channels such as TRPV1 following tissue injury and inflammation suggest 
that important peripheral changes do take place and other such changes may 
contribute towards altered processing of pain signals originating in response to 
noxious stimuli in the peripheral nerve endings.  
 
Moreover, the use of microfluidic platforms is extremely useful to provide a detailed 
profile of the differences between mechanisms taking place in different subcellular 
components as well as between different cell-types. The present work describes the 
compatibility of the use of hIPSC cell lines with the MFC system, however primary 
human DRG neurons could also be used to evaluate whether mechanisms of 
nociceptor sensitisation in these are comparable to results observed using rodent 
and IPSC-derived DRG axons. Elucidating peripherally restricted mechanisms in 
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human DRG neurons could provide useful information for future drug therapies 
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